var title_f3_9_3216="ACL full thickness tear";
var content_f3_9_3216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Full thickness tear of the anterior cruciate ligament",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This sagittal proton density magnetic resonance image of the knee demonstrates complete discontinuity of the proximal fibers of the anterior cruciate ligament (arrow) consistent with a full thickness tear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3216=[""].join("\n");
var outline_f3_9_3216=null;
var title_f3_9_3217="Acute cholangitis ERCP 2";
var content_f3_9_3217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute cholangitis ERCP 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography (ERCP) showing multiple filling defects that were noted in the common bile duct, cystic duct, and gallbladder (arrows), corresponding to stones seen on MRCP.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3217=[""].join("\n");
var outline_f3_9_3217=null;
var title_f3_9_3218="Patient information: Psoriasis (The Basics)";
var content_f3_9_3218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15495\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/13/39135\">",
"         Plaque type psoriasis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/35/13886\">",
"          Psoriasis of the nails",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/30/6626\">",
"         Patient information: Eczema (atopic dermatitis) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/52/835\">",
"         Patient information: Psoriatic arthritis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/6/7267\">",
"         Patient information: Psoriatic arthritis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/11/3252\">",
"         Patient information: Psoriasis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/36/36419\">",
"         Patient information: Psoriatic arthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Psoriasis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/psoriasis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H542578186\">",
"      <span class=\"h1\">",
"       What is psoriasis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Psoriasis is a skin condition that makes your skin thick and red. It also often causes silver or white scales to form on the skin. Doctors do not know what causes psoriasis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542578193\">",
"      <span class=\"h1\">",
"       What are the symptoms of psoriasis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of psoriasis can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Areas of skin that are dry or red, and that are usually covered with silvery or white scales (",
"        <a class=\"graphic graphic_picture graphicRef74211 \" href=\"UTD.htm?38/13/39135\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Rashes on the scalp, genitals, or in skin folds (like the folds you have at the elbow)",
"       </li>",
"       <li>",
"        Itching",
"       </li>",
"       <li>",
"        Nail changes that make the fingernails or toenails look pitted, crumbly, or different in color (",
"        <a class=\"graphic graphic_picture graphicRef71998 \" href=\"UTD.htm?13/35/13886\">",
"         picture 2",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Psoriasis has an emotional effect, too. People with the condition often feel embarrassed by their skin, and some get depressed or anxious. If you have these problems, mention them to your doctor or nurse. You might feel better with counseling or another type of mental health treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542578200\">",
"      <span class=\"h1\">",
"       Is there a test for psoriasis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no test. But your doctor or nurse should be able to tell if you have psoriasis by looking at your skin and by asking you questions. In rare cases, doctors take a small sample of skin to check if psoriasis is the problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542578207\">",
"      <span class=\"h1\">",
"       What can I do to reduce my symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Use unscented thick moisturizing creams and ointments to keep the skin from getting too dry.",
"      <strong>",
"      </strong>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542578214\">",
"      <span class=\"h1\">",
"       How is psoriasis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are treatments that can relieve the symptoms of psoriasis. But the condition cannot be cured.",
"     </p>",
"     <p>",
"      Treatments for psoriasis come in creams and ointments, pills, or shots. There is also a form of light therapy that can help with psoriasis. All treatments for psoriasis work by slowing the growth of skin, controlling the immune response that causes psoriasis, or both. Most people need to try different treatments or combinations of treatments before they figure out what works best. The medicines that are used most often are called steroids. These medicines are applied to the skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542578221\">",
"      <span class=\"h1\">",
"       What is psoriatic arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Psoriatic arthritis is a form of arthritis that can affect some people with psoriasis. It causes pain and swelling in the joints.",
"     </p>",
"     <p>",
"      People with psoriatic arthritis can take medicines to reduce pain and swelling. Exercise and physical therapy can also help. Plus, some of the same medicines that help with the skin problems caused by psoriasis also help with psoriatic arthritis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H542578228\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/30/6626?source=see_link\">",
"       Patient information: Eczema (atopic dermatitis) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/52/835?source=see_link\">",
"       Patient information: Psoriatic arthritis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/6/7267?source=see_link\">",
"       Patient information: Psoriatic arthritis in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/11/3252?source=see_link\">",
"       Patient information: Psoriasis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=see_link\">",
"       Patient information: Psoriatic arthritis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/9/3218?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15495 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3218=[""].join("\n");
var outline_f3_9_3218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542578186\">",
"      What is psoriasis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542578193\">",
"      What are the symptoms of psoriasis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542578200\">",
"      Is there a test for psoriasis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542578207\">",
"      What can I do to reduce my symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542578214\">",
"      How is psoriasis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542578221\">",
"      What is psoriatic arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542578228\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/13/39135\">",
"      Plaque type psoriasis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/35/13886\">",
"       Psoriasis of the nails",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/30/6626?source=related_link\">",
"      Patient information: Eczema (atopic dermatitis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/11/3252?source=related_link\">",
"      Patient information: Psoriasis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=related_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/52/835?source=related_link\">",
"      Patient information: Psoriatic arthritis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/6/7267?source=related_link\">",
"      Patient information: Psoriatic arthritis in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_9_3219="Plaque formation PI";
var content_f3_9_3219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Plaque formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3219=[""].join("\n");
var outline_f3_9_3219=null;
var title_f3_9_3220="AIP duct sclerosis Light HP";
var content_f3_9_3220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEOAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDtbuznknnwqJuZirMvueevNYMWma5YX6zXixXMX/PJgVVh7EdK3Zb1Z5rqESKfnYFZATnDHpUU1/PLKv2i4yyrtO5SABXSk0rfodMea5FrzrNIF0sJanCkoVPBxzzUkbs0EcSWwmmGFZwvJqWdv3IZ2QR4zuGMce9Vri4knsSumMVicZMyHDN9D6Ukr6dCrJLzHXwltEEsyCNXBUDGTgdaxZrK5k8RQxnThPCVDNOXZR+QNRW8V7EyOwmOHyVZst+ta+v+JH02xja7TOfkWOMAH/gRA/SnyXdo6ju4rVFyazTYPKjjVVO0lehNQxxxwsokG5j91QM5qvDdS6jZR3NzH9ljRCQPRQPvYqrYa/D/AGpb2ulafdX3nr81y7fdHqPQVHs+3Q09pZWtqP1vUbW2YRX8iwSTkKsa/eHp06VZgsktbXHmMV6jJLEj1yan07RLJLx5ZYxd3CymRi/IVvTNUdc1tnXUFjCmaAAAHAX6Cq5ObSJCqJdilbaq91etHBbgwI235uv1q3erEbeR5gwUD5tpI49q4qK8X7U0UKSQahLgNJuyFb+6PStbSLTVZNSjub6UtHgxGFmyWPpitZQitdhczZo6ZPG0bLbIyKDzk5J/HrUF9rRitJZUg+0CJtriNvmHvWhNLp2mXX2S4uY4JnO3ylQswJ9ccD8at6LbadBqFxHb2sqREbvtTfxt6BalpLVofPpoUrFbnU9PSXJ0/eMhGYAkeuOta1pYvEiFpWkbHV0xu+lZqeF9OfXJNRaae6uwd4FxINsf4f0ravJI4cG6upMnoIxy3sPSk7PREJ9WNmsxG6z3ckcRPQSyBAfoM026jLOuGgGeDtBP61zkMsK6qoktGQOcNJdSbio/EcmurjsZ5AGFs+3ru25BH1pTShuVD3tys9kTj96SCPTirEunRwyiD7WpuRjMYjJA/GrH2d1cs1xFbheAXcA4+lMkFvCn+jzxSynqwQlifqeKi99h8thkdnpsUSPqDTeY/SNTg49cVdaTTbS03QPZ3SZyFaMrJjPT371R8kygi5uFRsdX9PwFMWXRLWYJNe28sn91CMfiT/Ki1+lyJQT3YXMsd2+6G3htogMBRyfqTVV7MsvMxxnstXI7qGaXy0ESRr1kijOW+lWPKNySLW1uTEB950zn6Yo2LVorYx5bRbZC0ckkjHorkY/lVa61TSrNYn1OHUrdiOWgj81frxW0YlsxvvXjj54hkbDN+A5pt3d6SctaQ3oc/wAAA2/me1NeaFJq9o/hqTWukxX9pDc6Lfm5jcZKSqEYfgeaY+iyQSKs4miY/MWRNy/jWdF5cvzLFIGGec9Pxq1BdTR4Ec91GBnIV2wPcUra6MHCSX9L+vuK+t6P9rhfyUlt32lPMUsVPHUdwa4waZq2kaZPFG8k8jSZEhJYgY6c9K9GTVr2IeWbnzFYcrOvB9ucfpTJNRKPH9r0uFiB8hjLKSPTjqKpSlHYlJ21R5ro+oa2l15U6tPGUcZlGApx8pz35rT019ZOk3L38G+TcBEwIBI79K7QjTLtS32Wa2kP8IAYfnkGs2SwZLhmhuXSA9Y3jzj8Qf6VftL7pAkulziNQu5NJ3Q20jXNy4JljLljH/sgVf1HUZtL0q322soa4jJeVn/1RwOMdzWqPC9qdW+2w7jPndt3YyT1OKuaxpUV7eQMyzIsP3UHcen51XPHTQfLc5vTrLVJokOogtbTKGibOMnsa0hbSwx7Z33Kg3Kitggdveo59Lv59VtrjzZEhhzuiJOPyotvDcw1a41D7YHkkz8jHAGaTlF63KUGtLF21vYnsfLusRM7fKGPJ/rUEl1ctfiP7Mkdmg253c4/xqW78Pm/MZmGHjIxscVSutF1qbUg0UimHOAikHihOBLjqXljtkmxas+8+zYH51qpBAwjklYgk4fZxj0NZNy+px6iIH09oSi7fMl/i4/QVELHUbmaR53WBjgB0PXH0pOMXuwTa1R040uGTzmguk2xrvG8/e/CqLWauCrjB6hkbI/Ss06ddEAC6eOfH30OAfwqzaR6hEXW6jXay7fOiGCR7+lZWj3NEpb6MoJM8F1NDcSJJGGwmRg/nWgiQuAcujdjuyDUF/ZxwzCacywyAABm6frwaihn8t41uLmHc5/dsqkAj0Paq5eZXiUpW0kW3h2spPHPytnr+Ioq46IsY3zbN3cLkN+IorSlC66mFWauQ6it3/ajCyICCR9+B33c5NUfFW6XTVtkuWgurpDBGxOV3A5GR79M1b8QXdxp8spsxvd5XJAXnqe3ek+yJfR6fd3kTC5jBwn8IOOppJ2sx2Mjwpo93p1lLaalKriY+ZKS52xjv+ddWy2Wm2K3FxLHHZgfIpPG3/PauR8fma4sYLO2lVFdwZ5Aeg7Crk2mvf2VityxSKFdqrjqOmfrik4pJOTHzSqSfKLq+rapcX9jJocETWLZM0kiDIA7AepFbKXtvJDGbi3DTEgiIrk57D/69Qi2Fjp2Avl8YQuOFHr7mufi8SaXNcPp2mTXM98ykeci8Ie+M/zppc6vbT+txNKL5Vqzc1c2ttcDVdUumEGPKWGPlcn1FXbC+sX0qe7slNrYxcABAGY+rf4VW0nQ9P0uwkid5QJju/fYJLevt9atQ2sA06Wz8vfbScsOpY+uan3XqKSeyItM1zT7zSrue1nnZbNS0q7QDz6AU2xtLTW9N+22cSESsUlVgAxI4wR3rOs9Os/DDTSWiSySzj7ioXwvp6CtewlS4jDLHIrd8gLt/KiTXQcYPe5Hp3hSzF1JKgtoH43MzZb8B0ravZre0gS10l188j559u5h9PQ1SnYQwt5VoZcc/M3U/wBPxrmdSuddtHSKO2kUyjeVtAJAF93JwKUYuT1YpNX12NOy0TTrC5eZSv2tmL8/vHyfrmtUmSTcoikJIxnPzY/DpWPpep2NlbATK0t4PmkVD5pU/wC90q4PFcDSBbczMfRMcfUin7N3uDqOWhnr4LhjlDyW9zu5IV5TzWolisCRK8SLgcK0gI/KnLcLN++MjEHju2amS3S6wHDTZ427QB9KTcn8TLehFDHbw3BeWUzRYI8hT8v8uaydS025Zw1pqU1hbE8xrnYB7ZxXRGwks5gzzmFQMgJsJX2wOaikufMBEzRMM5DMu40KVtUyI67ao4/QtXj/ALYeyW4vdQkyVaX7LhRj/azXWtZBTjcVI/hOBTkeIhtiSOM9eEX9KjJZj+7SCNPUMAfx70OXM7lpNaEVxZQPE6NK5VxhtjFapWWj6dYyM9rZxNK3O6Qb2H0z0rVCKke+3uoDKD0XlvwzVPUrB7u0eOPUmsZmIPnBQ5980K+z2JckWopJoQcWnBPJA25P1AzRLdicFHiZmH/TVgc+9UNP0+5sLVozqi6jOzZEky4Cj0wMVNPYwSgG4srRpccurn/2U07JE7u9ieG6ntwPJsElGCT5gMmfxpo8QzwyEQW9pb4+9HgAD3+amf6S0EcNrdGNYuVCknb+ec1Um0tLvB1JhM5OQxTGf06UrRe5VnfVGoviN5yPLnsImPBRQMN9fWrbXtzcbYmlhDDlXGI1z7cViNothKqqwiQA53iNWI9ualltIVZEW9lPoFTP4dOKOWJLSvoP13QBqt0tzeXECbeSqzDB49BTlvr61s4bayjt0SMnDytvzn8P85phFvEQEfe2MHdwar3eqw2uDPepCW5w0Tfzximk3puDStqTRNeyXQVbdWdgF2RZCn860TLBCwS6gvUl7kOHX8R6Vnx6hJLbo8Gp3ALj5cFSG/H0qo0N/HIWjn8xhgMkyDBHsRzSsnu7F2l2F1SwkMn2qynNmVOZI5HBib/gJOV/A1bi1BrlFTyLZ1X/AJaQnLD8c1U1DWdFsSF1LRbyUsNsgRxIF+g6/hV1o9Li8oaWWh8wA5mjCjnse4ou7aitqlYonULsaosNzYv5DZ23cTAqB6MvWtMrKi5kAAbo2QRTrjS7uG3M/kLMi9Wt5MgfhnNU1LiTaI2WXusi4J/xpaPVDjJdGOlibaSTvHqvP6VHHEREroYmQHHy5BBqvc3l5A2H02XH96NsfoaltJI50YkyQuP4ZBg/4U+XQrnNO8N7d2ivZxiV1Xayv+8x79c1ALe5WLzBG+MZcLyFPf8AyabFEyHdbMwb/pkwqN1VW/0lbiMt0mGSTU26Cj7r02FeUKQSgYj+NDyPqDV2HxFPEPLntLeWLG3I+Q/jVUafLKPNt2SeIcZDYP0I7VQ1cX0aA2djaSFPvxTBgx98g0XT0f4hKEJa7+hoPfGSIrEpSDGDDIBIv4HtWS7W1im97X90T/yzXdtPrjr+lRWV3JNbs82ntazAZKwyeYp+nemz6hZC0STUSkUUmQPMO08e1Uo67fcFlHZ29S1b3tnfsfsdxAzjkxk7GH4HFFZf9k2t40dza3DNHkMpb519evUfnRW8Ixezt9/6GE3PrqdpfpZQQlNOyLkyl5GJLYyTkDNZcxlmRl6Y4IzyfrTtasBdySF5WhEcjMpjbB+9/OkiPl4cEuTwmeST61gtjWCsrlO30aC3k+0XLefIT8qnpn0rSulntbM3EEAu7vOREO2Palgla0QSqEMnQNJzs/3R6+9ST3Fy6ptVU3DjJ+Z/c0Pe7DVqyMfxBplxrUFpfa5fPZOqgm3Q8fgO1N0l7G1k2aJZY3H57jaMsf61LqVvG9xv1K5Uwp/dJwx9BWtaRotsjW0Yt0bgAnaceuOoqpapJ6/kTFco3y4IZPNvWDynkIW5P170arrkllpZu4bLdFj5VQcv6fgK0IXis0U2dn58oOTNOMKvuBXLa3pl1rOqfa9Q1mSC0RdggiGDIe4HtUK17yGlz6W0/roJa6rLrNwr6hFdCM8vsGQPYY4rUR0t1+WABmPyIDuPt8tQ22mxRTwzrqDxWka7Vtg4cH3OO/1NX5bqC0k3Knyg5WMdWPYsR/Lim9dkU3b0GRRMilwhBwXbzGwEB6k+grm7uKy8RNILTXXfYSsgj5RR6L2rb1eKbxFavaXcbbJQN/73y1AHQcdqox6Ho+nwi3aWNVHWKI7Uz79yapO3qQld6md4Z0jSNGa7t4DNfvMQHb7+4e4HArpYrK2dQkdrHFEOCSMD6elV0hvpI1TTUitLMcFgu3P4mpsKNour9XVBgty3+H9KmTvqWl/X/AJZESODEe0Rg4wBwaaks90SqB3Poi8AfhTUubOTHkKZlHRz8+PoB8o/WrQuJEiO26FlH/dRd0h+vp+dS1YpN7JGHfXsdpObdYLy4uQM+XFGW/UDH61OrJBbR3GqRy2hkGRAV3zfiueKtxy3FwfLsVldO7Z5P5cCrVlo81yxK7s5+aQ/cHrzTckN8y+J2KMEsVwgaC3lVOxnIQ/lmnuy9DDk+gOc/U1auLG3Mpitrt7pl+8VTAB/3qh+zZYrCHeTHQSbuPwo5hJJ9Su6wrH5013bQR56EkD86jjnsrklba8jmfrxG20j2Yir09lMtoJZrdZVC71gYqHYeoB5qhBdX08yiOxt7O1B58xuT9AM/qaFqrhfWyYPFgAheD1f5tv4cCq9m+pR3Wwxw7M/KQSDj6EVvpNKpG2eTaB0UfoM/wA6pyzBN4kmmVx/CDgmhMd31Lwm1IBDNCj4wVCRZPH0qtMuoySBsbYwc+VJGY1/WoEljUDbfMrHn5mPH5Gq+oxX7FPspeZ2YAtvJIX6GhKzI5UPvZdUtuf7NkliP/PJwcfT1/CmRXmYvNEM8AbqrQnNPSUaewN9eQRBmCqHGwg+nHX8q0xcuAVW88xMDaXzs/IZxTe235krTRDbO9WKLLy29xCefLdRn9RkGo7i4s5ceXZmLI5ZmygP0xUzwWJYGS5tRMxxhQ2FPueKcuh35U+ThQecrICD+Rpe6tyL9W7FYzJdIkUn9n5XpIg2t+nFDyRQyeW0PnNjHz854xxjtWF4gmvtMnjEkEyxNwZltxJtPvgg1qQW08kMTPPb3GQNzo+MfVTyKpxVrjUraFeXVNKitntLyxdFJ+Uyo4C49Cen4Gq8OiXlx8+k3fnQ4z5dyyuD7A5zWs8V1CyxXBKjsGAZD9DTZ1iSMsYfLfoJI23KD6EDmi/8v+Y7WZDZQahaSFo4ZIXA+YK+5T61PPd39ywW5ZCg/gkjxj8eKgjuPte2GJoGlHUSGRPz/wAauTxXsS4mhkRGGGMNwZEX6gik9Nxt8ztbUp3E9naQGW6nniiz1iDSAfUDtTrK70u/j32WrQSKBgpKDvB+nWkOfNSPfbMyrkboyvH+8OaSzhjmaQy6eAQpBEDhsn1PejR7/wBfeGqJUuIVciWEOh/5aRHBHuD/AI1JHcXDylEl81X6AkBsfjxmqM+lRXGGMUbKpyWaXYwH4GqEf2B7xre1e7Dhto35aNvxI4/OmkmFjbTS5btnaEIZlGWAIDg+44/Ss521q1vYYZNJvZot3y3MeGUfXvViS28tRJJKqKoI8xXNMgju5B5lrf3JixkNHIWVvbnODQF30ZLOtrNk3VtJDMDhjD8nPY4PSs+90C+u5P3NzLdWvUwzgScex61duhNKq/aJRNkAq3Uj2PpSWsDTEiyuHjnH8DNjd9DU7FJXV+xm3UN5pdoiWdmpXeqsv3QATyaK2xbxTbhcyy212BnZOSQ+PQ0V1Yd07PnV/v8A8zKrK7JLiIPNPIu9v3jAtIeByf0qmt3brcGOyV7mcDG5Rkfn2FaV3ZTXbFLgCONnYpGOMruPzH29zVaX7NY27yyssdpEM7Y1xvA7/T3rmVrabmid92SNA1uvmzKkk/X5hkJ74pVuBHlogbq6fIL4+UelYGja/ceJLrbp9iY9NViTczDap+g71uanqMNgsdtbRSTXTDqBgj/ChR1t1Cb0VzPfS7661J57s4SHG+4kYDB/uov9a2YWFvEGZm3KoGWJZzVO3N20YeXb5i9j91Pc+poRfNLO7eYi9ZHYgE+wHWhu+4lBklyPOi8yaQxxDlmY9PwrKls7C6uFmN3I0UanJJ+VvfFSLpsuoTG4klItVPEtwcRj/cXua0ohbiB4LICO3xulnkGC/uf8KE1fQp8yVr/L/Mx9N1Swvbj7JpFvLKsHAmK4V27hAOOPWt7QVshfyWs8iS3wjMskZbKxD3PrUMVq0thILESW1q6srTqNrMT/AHSaytG0e10NLgW4kknmIM00rbmPoKPdd7f16smTlJcpHc2dzNqBmNwzKXJSBE7f4Vuxabb2kS3OpzKkzEERKoZ/y6D9arQO80rR24y6KWkYHCoPc1N9lnMata+XJM/SSYkIq92J6miUr7jasrbDZ1vdRYiFXEI4G48D6n+grOuNF0+BDNqVw0zqwGxAXGfT0/StO1MVrMwuL2S9n7BU2Rj/AHV/qeacGkaWO7VFXys7WkOVU+oHc0m2gi+iMi8u76K8hsdO0ye3RgQ08ifdGOME8D8BWvDZ/wCgI2pXbPHHwsMTcMf9o9h+tQSX0RukS4nMt1NkIZSSSO5C9hWcusxPNMZ47lLJTsS42AJK4/hRep+tPlb6DvpqzXR18oRwSGZmOTtykSD0yetZ08N/PM5l1mWaFc/uYQUjUenvVyziVLCS4mR1Rl3L5hxn0XGf500TX3ki5hsreeMcfZg20gHvngUlpsN2662J2FvbIPtFxFHGFy3V2P4D/Gq8Gpm/LLp7ThOgJTy949hU+n3EbiR7zRY4ZScLGZ8hR6sScVYEkAB8xooIm4SO2jL7vUbs0bCvfWxWNvNcXu+eKac9WUqVJOPU/wBKpatogknSdJb23RcKkbPlR+GOara+2pwwn+zZ7S3sUPzTyLls+/H6VcsNOudW0+KfTNcs5JYgokUMArnuc44qrNLmuJyS3JowyKFAVmbu7fKff3pmni+VpFvtQgvXcgIiRrGsa+gPJ/Grlxpty+nTxard26wyKQGinyU45KnisDT/AAzZ2S2xtNUvvKjcuSZPM83PY+1SrW/4Acyky1dafqR1mGeG8WK23DMJhSZWUHkBhzmtRtpSRYcRMTnMgx8vqO2aY939js2a4V7m1jO8gL82efx/nTLPZqmnC8idWtwxXCq24f8AATzinq0TonqZl096HuP7bNjeaUD+6EiDcoHqetFpc2VvBizt2ggPIRJd4IP93OePxrUnsYLywNsZYVtpkO9bkZXH5f1qhpOmyaXJbIYdHurKFSkEkTlSg/PnnNCaasytFsJpmr2+qTz2tvHJHNDy0cqhXI9R6imw2Wpw6xJNJewvpsg+VAnzI3HAYfjnNSeIbXUBC13opglkjK70WMO6qepVu4p+hahc6lbE3cHkTZIBK7N+3AyAePwNPpeIr9zm9Z1nVdK8TeXaX8csEm0pb3kGEb2D46102nakJxvubQ2EzHDKGyp/wok1m0mmNnNc2YmL4UP8qswPqeAavTxmHywIztPzH585/pQ27aoElsx4ZlXbBOPLJwdpBC+hxUNxaaik6q379BjDFcp/312qK4VQA0tnFz91lBQn3ypqS1kuJN0UMl3Ht/5Zu+8H+XFRdlOK3KmpWsUx866lvrdskrLE4ZFPTP09qo6NNqDaxcxx6ha3NiFURSxShSp/iDjt6+lX9S1+O0urTT79nt7icfuiyExv2wT0zTxpl5A5uLW3ghdjkyCMFJD/ALXUfyq0+Va9SLc3YseZcQvvWWFiM4kXDD35BqjeazFE6y3NsDIRgyW6kZHvjio9V1K7tDan+xo5rmSQR3CKQqAf3/arF9H5EwWS3aHIBAPOR9aT0s7DpxvuVItXt3udkVt5kUgA+0YJKk9mUdB71qJLqEVuENw0aBsHYFdT/ketVrWbJ8uOCCcseQ4w2PqOaSMLFcMGha3BbpMgkAP0703bYLMsSLJLdCOymtnXHMbRmM57kg5BqC8tTDE8EkQiDjEqICg/3gecfUVI0UTOBqS8n7k1su3j6dCKWVZ1kAhvBfxdonUnA9Ce1JCb2TK+l2FrZWaxzXEroA0nnSTeYQo9+hxRLaSXCLPp6peQP8yyxyZBHqMd/ao5JH87Edi0S5yfKlG0H/daqWnaYNNupLqwzGJGBaAkouc9QBwDVdbsEn0NGdJRDlZPNtxxiTqh/oaKtPFbXEsktzPNazsudjruVvoRRWlGVk7uxFSaIby/aW/nhV2kZXbcB91QCcbj/Snjc0LNLmSN+OTgt/gKlSzjElyVVViWZmc+p3fqabf6zbR6g/mBZLg/djQDZEP9o9M1itdka82lixaSQ2aJ5ka7AMBUBGOOigdT71ChNxKz4EMRJOT2+p6moreJp7lmeRlA/wCWuOB7AVZTHzM4JRT8vHBPrRp0E1Z36jGAuCEwxhHVEBy1VtSvneaKxtIEkZcbLaP7ufV2qVxJL5gi3LCuGkYnAx6D601pYdFspZjJGLqX5Rs5KA9h/tH1paX0V2XZ21ZDLZYZZdWu/PnXGQvypH/sqP8A61N0zwvJfavHd6vdlbRF3rCp2oi9snuas20lvbxxz3cDz3wG5IHbKxj+8w/xqvqKy6pCJbydlt2J+UDHmH6dgKabfWy/rYhp6RiaGo6jZTXHk6Nl4EG0vk7S3t64qm0c1xKLO1Vmduu0ZIp8dqLC0iMMGDMdkQfjPuB6VcN42gadM8DK946kvI38PqfoKnV6RLsqcbrUleKPTyba5iVYlwVtIm3Fv9qQ9yf0rI1m81PVHFvYsIfMbDOBwijsv+ccVk2ElxqdvLJcSywiZg/mA4lkHr/sg1uQTPcxOYEaGHIDSsMmTHYVSXLtuLl6yDTrO2sbZXdjcTY2iR2zn1JPf8OKr32pyi9t0Nt58YTcZCdsUIBwBjqT7CjXtUtdIjUzHcZMhUU5kkwO3oBSXdrDKLUapcxWYcbliMnzSk9FA6miztfcIuLfvOyICbO7uDLDEDcZA+0sDnA7D2pPGGt2mj2SPNLN9pI2wgJvbPqo6AGrD3US3Bs9Ls3nCcSM+AkZ9z3PfAq1p2o22s3t5LZIly1mmZrhITsXGcgE9TjpihX3kgnKP2dDmLm51gaLY6np2mXWoXVyeY7qQKYV9dvQVbvodQ1PUfsOuadLbWOE8u8hlOMkcggcYHNTjxbbvpk2p3Md1Z20TiFSIPMdyeRz6VYtdWubi/e1Y3LLsDswtyyjIzgk1b5lrYhbl7TNLsrWz8pGhniVzHicbcnrkEnNX3vJYlaOGSHzGGAY02gDsOOKotYqdQjvZljuHUYAdgQM+3Y1jN4s8O3uvzaLbW8kV3IWiaRFZRuxg4ye1SouXmKTuy60fiP7NdrDPbgOu2Hcp2A+/wD9esG1g8T2tiI7ixsNzTZbYqKCvc5XkVqaDosekSSCK7vp0kGC11JvC47gGtWOS4iDfbJ41iJ+TaQn0BJ6mjmtorfcWlbVmT4n1TSdLWK1ubee9nniyIEG4sPSqmlS6k2lB9P8ORWMO7I+0FuffPeto6rbrq9xZXuk3m+CISpO6rIHU9SrDpz2rIl8TatqQa48MLbzWq5SVb0MhiPoO1NXta34k6vU6DQLtNSneC5vbCPbhfLWMgqx9dwB/HNaV/ZrYzr58kMkBz80LbWXHrjt0rJWKS7s/MumhW4KnMqNhd+OD6kfWqmiWWsWhuH1C5gfK7Y0VsknPXgdMVLSeqYKL5tWXp4RfW80Elopt5BtIkYyK31+tJYWUdpbCysrVIEQ7Y1iZgM9TjOcilnjlaS8mtzJcO0ZUROTs+hx3PrmotFnlv0jV0e2lj+UiTnGO+fT60rablbvQv3FpHfQkB5LKZVKxyWzlTnH8QHesrw3dxapFcWmo3UN1e2x2xOqFXbH94HqeKoz6b4hk1RJXZNN8mY+TIj74blM5wwzw3f0rZ1O0t4phcm3ihllwGnh5+f+6fSq0ta//AM1uZh8L6LJLFdTWk7TrId6PIVUH24/Q1flJtpmh2F4mP3VG7FWPtDtZyQCPzHZlUl+do9fb61FZ63p0dxfWt1Lve0/4+Y2Uh1GPvq3t7VPvPzNb8urQ1dQS3Vi+xYlyQW5Cjv15/Wp2cSEsZUhC4Kyr90/iOlYd1pqOv27Q7+W7syCdjndlT3I7/hWlYCQ2hYAb9uZB/Envim0lqhXTK15c3tyVmsjb38SPuMeQzMQeqn+8MdK0mmgvIjMIntZHxuCuVwfdT0NUbbQtMfUlvbO2azuJMo4t5NsUjeuzsfpUrN9lmaG8AWRGKgzrgOPRjTunoiLdS2JXWJoLi0a4Kf8tGPzD60xtWews3dDE8UKlgrx+ZtUcnHf8Kgu0uJLEpaXRtpsgwtvztP93P8AEppYDNPaRtd2w+1AESxbdp3D0x+dDSsSitYeIrfxJCZbbyW8o4JCFCvt04qeXX3sw0WozZhZeDND1H+9iljuUjt3ISK2aM4IkACj6itAedeaaHRLWaVeSAuVZccYpe7vbT+vIqS5dGU7RxdQF9Pv4lP93dgMO3TpVSb7ciGW2tkZ1OGKTbcjvxnrUltbCFDKLe2LN/rEjYfKfQf/AF6lidiw+yIYiOcFM89/8im1Z3QRl03M9L8XRCXUdzFKeP3seV/77HFXG8yBR/q5Ie5Vw2PrUsl/Im5vs5kB6+WFfn3Xjj86o2uq2t8ryWKWR2sUcxjaUPocGk097FxbtykgmsLtNsbL5i9dkm8ZH06UUySx0mOZblo5FnYffQg8/kM0V1UXJL3TKd+rNS9JlnkWZtsKO2ERuep/KufSwa+1NIfI2WwbcsS/ek929q2tRLR3MkGACzszY64yTVy3eLTrN9gLXUo+dwM7B2WuVXS0LcrIimk8lRCgG48cGkPlR28KynNySSFPGfcCqGlO2q3ha3DPBC+M4wJW9M/X+Vat8kNpNLEkySXTAm6uSMlRj/Vp6elK2tmVKXLZR6kBkMcB+UjncGkyVHoT9KxZEtv7Ttpr+4lV52KWvyZJI6vj+Ee9aax3kujGWPZHApJjEx+Xd6n1xWV4etbI3F3di4mu72QYkupuAq+i/wB0DBqls2K2pdljWaR0XfFp4fEjZ+eYj1PXFb2j6d9tU3+oJ5WnwruSLoXx3PoP51W0q0h1i+gkZiulwDbGOnmN1J49+TTvE2oqZJtOtGVoxhZHHT/dJ9qh3ejE5cz5Ib9yC51L7XqEl/INsagpbr6e+KwdaE3nRSPbPePgGGzUYUn+/KegHoKm0WRpIptSnOyyUFIFxyVHV/x7e1P8Oa6daiaW1hkWBmKKsgHzkfxH2/lVJOOppo/dQ9bWLTorm9vrgRRnEk00h4UD+FR6egFX7BzqFuLvZKunY3xIAdxHYH3PWrGo2dtM0Vs6xiMgbjL8245zkj+QpmoT7LR1j2xWMAUYk43uccAdaXl1J5nPU5HxnbWVnqlr4j1a5Hl2yCKG2VeTJuJyR6AH9K17TSYb6e21zU4CdRljzbmWTChexCk8E1o3DadqF0mmXEdkziRZjHMoIUj+ID+lcj4wstZtbyW8tkGrX0lxthVhlYFxwSPXsB0FaJ82l7ELQ6DWNXn0/VrG1tNIlube5yZ7gkBI88YHt3qd7iW10+WKDMdnEGbyrVArMPQD196drFvdnTINk1taTCBVkmmbbFHkcnPfvxTtKYSWaQ2tx9oaJdpuVGDKfUAdqjSyY466GT4c1PVtZngurXS3tNGDuss16538AYKj+Ik+1dJqFpfJpjztdi1cRkxvMQfLP97b6CszxL4iGiyQ2lvZyX+osMrv3BEA9DXMQ6FdeJNROs63dvamYtbG2dyF2FcEL6Dmq5b+89ER7z2Ok0C6hFjBb3OtWd3dzbh5iN8rnPU9xWha2FraTPc2q2bXTNl5IUDNnvkkcVxEvh3T/DOu2IshPOsMLvEoQ7pmAJznFdHb3V3qOnNcx28lveYKiN0wrcZBB4onFPVbFLY0dXNvPDPBezr5Tp5bbAQD7A8VhXPg6w1DTIrCVrqa3iIeHc7Bh7Z6Adar2uialqsjDxA8KxhcokROVPuR2610FxPaaNpStfXPloRhCc8n0+uBRtpF6jSstTG8UDxGY1PhwW4RIFiRWILAqMH7386j1G91a28N6ZHeQQNdzRsbvjKq46Lhe5GDVye61E2Vpd2a72fhfMGQ6nkcdf171sS6wLBYoJbZZpLhMykqNq4IB6noO9GqtZJg1bUxfDuqTS6BNealZTQxoQsXlqT5qj0zyKsWHiGxv/3JjkgJ+6koxg9uvepdd1TULPSzLplvu2K3+2Q3oBVPwjc6hr1tH/b2hlp3l2RypCU2+7HtRZNOTX4ibtuWTHqa6gjxXSfZepEgwyewPeob7WbzSLu1jayvblrvj7TDH8ijPR/51q6hc2ul3Pk3UPkPu2oo+Zd3Hc8DPp3qtrOqQ6fGbm5im8kjmQAsd3Ybc+lSm3bS5ektir4uhs7jTFjvJZreKT/U3CKW8pv9rBwKsabp15plpbWb/wCmKoLmUcmUdsDocfnTr7VrCOyQzqJYb4YD47fStK3QMg+wxhiigOoIHHbGeQaG2o2ZN7anP3LnRG/tNbrzNPZsG2dstCx7jPb2NTB7G7t21WzRWvRGVlR48Myeh/Co/EAsIXnk12IzwXAQLctw0eP4XA44PcU/SNLsre9ivbXUZnhZNsSLhkP1b+VN2auxruReF4bfSrf7Rp4uLeObLiAncF9tp6CtPVrVQrzxFoI5gUYxnBjJHUHtUsyCSUCZIpHyTvIAIA57Viy6dqEviCO4huibGaIpLCPm3/3SMehqb3d7lWuU9GvNRs3ksdXkUXCMPLnbgTKejD3rrrma31Gyaz1m3M4wAssa5b8R3rlPEGlvqtoqLcvHdWyFVAYYZc9CexrT0Uvd2Fuka7XVAJC7hhkDvj6daqSUlzEW1szK1jwxbSaOLGK7naGObzopI85jI4xyK3pLh9ImtlubqPziivBvJ+ftkHpnFNg1fT7ZttxdNDP/AAgn5gPXHcVLrlrYasrR6i7PbJhk24Xk8blNDctpbA2r6IZqBAUxzTWymU7kDqXDZHPJ6/rWfodgmn3zva3DQrtxLCGJjJ/vDHQVPdWrtFa20xnurVR/o0yD5kwOFf0PvV4QO6o7xxxug/1udobPVWHTmhO2lxO1imtqF1GWUWo3lsnYCG9e3UVpWlm86vc2cmGHBSRuMH61mPdz2CGSO5dLXo0J+YJ9M9vbtXLeIZbvUI3ga9bccNFtGFx6cUr9GzSNGVTWKOzuLZw5VrRI2jH3gpP6k8/hVQSaVptyts2l2kFzdvvBiJQysPz5rnbW8nS0itnnDGNQMjlh6nJ6fWtswxX0ltMNSKpEB+5yp3H1PGR+dEXFvcKlGdNXki++mvJEZYIJkH8aSEED6EGigpGXZVmjkkAJ3oTz6iiumi7J6nPOTJEjxPd3c/35ZWjjz6Bjk/pVbU1kUBQSd5yQO5NaNw/2m4wF2xRFhz6Bjz+JqpdTbQLgDcFBIHsK5FdbbnTG0neSJrZWsEt7SxT97tLkLwsa4+9+VP060SWSFp4y4X5zAjbjK/v7etOs4RbafJPfZ+3XiElDkhU6846Vf8Pj7FD/AGvcCJIShU4/hGeAB78VO6v/AEyJz5bpbnN+MtaktNXs9H2eZNcOfkHzKo75x/kU29ie8uDYWkYgsYVBuQvV2/hjB+uM1ZlEb3D3pjH2pt824jkAngD8hV37RFY21tZQRrJdu3nzMBnDZ4Un1yc4rW+1v68ybNKzL9zdQaBp8djYRob0oBJJgYDH+tc/BAZI3VRvJHzHrx3/ABNWxbF2LzHdI8gUMersep+gFW44IoMgSYQsAzE4Az796haFxSgvNkNxhLf7MygowBIHoO30qS1gSxjSMII3J3sAfuqO3pzTYzH5m8Nu8lSXbHU5GOvpxxWD44XUbjSTBo+xZrplhYyHG5T1wfXpTjG7SYm7bFq6110mnuLWeFoIGH2u9cblUk8Rp/ebt7Va1yF5o7ecOi2EA82SMMSXbPyjPeuZvvCeoSado2lS3MaxWkgkuBH/ABN6nHGa76dY5rcN8sFjDhn3dXIHQU5NK3KJaWbOetbFIp5NSmjVb66jyzvksi4GAq9iQKvq8ka2rmJ4ZVLGMyKRgf3jnqfenwbZrt2WQxlFaYruzIqDqT7npVe616CPTmupF86CFvlmVCzfNxtH48UJNhKWuhna7YWmuWM0eumZUEqkL5m3vxznvmodb0e8Gipa+EpjYokqYkY/dQfeBPXH86hvIL7V57qC+gjlsJPmRlXDxnjAPOc1p20Vvo+hyNp0dwwRSViMpbzGx8wOfwq9Vaz/AMhdDUhinWCQXZjmWIDymEhPzEcE+g74rkteDa/IEgLzWtqxHnRzZIfHI5H0o8Ma5q+qXMklzANNs8bdzAkE/j6AfnWh4tvdItLeN7W7lu953yMGUKD3JA7mhJxlZbjW+pPZ38cKwwzTCWOIBYccyJ2OWrQQ5iTz76RFkDNAHHDgH7ufrXl+q6klwjf2aJorjO4DH8I64qxY6jd6hpvlyTSRSxgoGU4I7kj603T6mnKnsej6xf2baYNO0yNLXU9oKGQ7vr7nvUkGht4h0yKLULaG4ii5LMxQO3RtvfFeSaRf+W08WrztO0Uii3eQZyB716l4d1pRpSri4eK3V1WVEDuoPJ/TPNTOLgvdMpQajeJfSSMSxiNI2S3PyIrdMccVna5HDcRzIjmaSMtME2kFmPbPp7VnaTawWFy0lpfyPbM27ZJHux6c/r0rcvpNP+0xyG4eQjlTHyPoR0pNWegJNHP+CLyPS7pI7m3mkuppCyqqlmUY+84zwM/nW9ffEiIeJJtEa0uLbzwBbXLDGXxzx9arpLo1vFstrK7W4kcbpFcY65PU9O1N1prO4vDJYJ9m8sAoWXcykjnr/Sh2lK8kS6am9TR8QaTJNbMlwFKzRswfOdrfwsB3OeazPDtne2+ltba/Pb3hzgFF5K443A9x/WrVtqLR2sUEztLGpwNx+6OvWnSXSapZLb29wDJjdFdKAd46EZHX6UtbWZUU46MjXRbDUryGxutqsiF43zwrcEDFU/GEepaHNbz2jCee3iKTKg4libpuHqD0rT3KkELMwMiBg79wB/kVBYata6rb3UySfaXVdqZypVgehHUikuZO/Qtq71ItQu7O+0zThcxLsv4zC6MPl345U+hPBrjfFNtD4Xig0S7eWHR2UP56fNKkhOc5/wBnjj0ru5VtlhuFvoIZ7KQibeTtKuuTkcdetY1pe6Z4osGlAM9kCyPHOvI29znp+FVFtapaEpX0ZPpEmqW8dvALlr6BFVRdbcSAHoSe496vvEZoZYLhWiZzvSaNsYYdx2B46d6I20/UrG70/TpWt7mCALsToUxw6Hvg/pVXQ9TuI4hp15dwz3ttj7Qq5LMpPysPcDFS76scXzaJFO8WWze2u7FEuFlbc7AcScYI/HvTfB+ktpJvppWItZ5825RuIh6N+n5U9Yn0g3F5CGGlyOQ8bZKxSdx9DzXQTskjWb264glhVjGWAXB/hHt6VXM7WWzFK19TJ8Q232u1MktqLy5iLMOiMRjkZx6c1k+HbS7sliihuGuLGQbl84AlT2U/jXVutsJJoZ1ZUdceYv3g3Yn9Aa5bwVc237+xJu7i5tZXMgZNp5Oc4oi/dYX1L+sLJa38d9HfnTwjYMT8Kx9xWqiHy9khj8x/m+bIDg9CD3PNQauhv4njHlXEBxHIkh4cdvcfXsasXiP/AGRdafsS3uDE215G3NCeNhHbHapb0QbPQ5TWr3zZWEDEKnG3b+Z//XXFDXYZrqWykjlilGQCwwG+la17K+miJb6dHmdtpZBgFvf0qF4zcsxYorrnrx+AFYSevc9mlBKCtoZcd05Eq3MbwFeUl3ZBFbmh3rQ3RLkGN1H3eRn1zXP6jbNKYGgvWt27qcHPtg9a0lM0Vq7QW3nSbcBDwD+NNS1HKN4tM7OOSK3uCYo3ZpQGMhbAP0orlrDU9TgitpYoGltpJVjeCaI74ST7dveivWw0E07tfeeFWspbHo+ov5MU7khRLceWoJwev61S07Ujdatc232NoLOyfYjt/wAtSOWJ/IVF4j3XWo2nBK28zH053Vdud04is7MgeaN08v8AdTPIyf51wNJJFwu0LMJGtftEshklnBYk9varyWs2uxpablSwtCN5B2s4x/kZqpKklxdxWY+USTLEi+3c1otcz297q9paIFRSsYOMt0qZXYc1ttzK1u8t7Sylu5I/LhLhFUdwBhVX19zTNHtRDDFsLO7/AL+Vz6t/QVk+I5U1bWtP0JZ8PZRtM8IH3u/J6dK1dWvH0nQxOFDzzuscY9vu5/M1bWiiuv8AS/AIvS7LtmouNTjLzFLZM5YHB285/PH6ijUQLlm2IAGkCxRnoirnBOKs6epi0u9uDIiNEmCcck9hj6j9a53VtSlt9S0mziiYS3Dh2AOQFA+Y/if5UkrvQW8rdjZRfKjMTZKu4dyByR1wfTk1mx3F/ceLbLTpYgbBLdpy+MYY5Oc+3FVvHUeonQraPQhMbm4uELlD91Rk5Y+mcV1eixj+0bOKZg0z25klIPRQo4/Ok3aN+4SlZN/1sYOuLHongW6ls5NzzT+V5xO7GDyfzzTdQ1l9O8KRXrxCeS2t2kZSCA8uAEz6560/TIZZ/D2hxuu/aZ52BHDLvO0n61fuLrSWul0yaSJrtV8+SI8gYH3vwx09TVdbPWzZN/d16metneyxQ6yFWC7fThFLBKMgEncSfx4rI8QWVt4f+F1vb3949s91deaXhG9jnJC4oufE8qaVNqV7HLJE0pjVIjklAQBn+tdCkVl4g0N7EWn2qGZBNEJQG8t8evpindxactrg4NrQ5DwXp9vDBa6rpOq3c0W1kbem07schhn8q1ZryfW7SWwWXypJdyQyBgWVhyc+hx2rTsNX8NaXeR+HZ1h8kkIHi5xJjnp0GTUtvoKDXJwJIogjYErnAbPQj3octby+RSa6kU+irZeDrM3eotcBF2kMeXyO1ed6vcK0r29vGkdohwFKZL+5r0fWWE1xDZyoBHartABB3Oepz6Vz9/FbWvDrCCeB5p4/xp03bcuKaV2cxaWKGITWkecHDg5yPoatvbtHcC4gUbT1GcfhU2nxXzNiz6bjl0YeWPr7e2M1vS2ZZfNeMCDO07cZBx3qpOzNIyORms7S6uixiCv1IJxz9Kn0RbjSpbgW9w+GBwB2FX9ct4be1SSOMzbjgZ4x+NZ9v5v2cTRq2w/KVY8gj0NO7aK02MbUNZvEvhHaPOgj5CA4yfpXQaZ4hnn1OZLiyMEHkhkJBwzdCRVWcwvdxzNDtkC46YP41ehjjuowhbDR5ILHsewobTWwrdRmp3lxDq6SNMyxMV8s7sLjjIIq3rU07SCRZf3XAIz6CszULJr8RMxb5CFyO4FS3KvLcJE3yxbssx6CnfYnlNXS9TN9GbSbbGZZVjB7bcY5rY8OjT9LBsolMYRzKS38Oev4VwVxcvZyLcIFWESAIewPbNdTpdxHexG+uQftMylDt4U9t2PfFKa0v0IsdQvlqcMQ0M2c4Gcn2qLS9FgsLW4ubedApkXe8i7Se/QdeKy/DE7kXdqwUGFw8e9sKRznr64/Wuhs72DyLidARFPC6pkcBs9v5VhJON0Jyb23Oe1HxFDJ4tGgyWxVDbeaJ2c/NkZ4Hf3rWVbVtOSGytLZfOlYN5cZRipyOfQk561R8V6IZp7TUbCPzb/Tpfsx2H5th5Xd9CTS6fqFk+vy6Pvd7wRiZm6AZU9B65NOyaTiJcttSWztYNIsyYMstkhZWY5dwDlgP14pi2FreeIbfWbAsk3ljJ/gZDyMioNP3adq2ovfuEtCqTwySn93Hu5Iz6Zzx71P4u1V9E8KzalbN5SSuI1KIDgcYx7UO7at1/UadtSnp1wmu3/iLTridTbibzo153+W2CRnpw314qTR5LqHeuowBLK32rAcH94ntVe61m50f+zL6zsI5oLokOwHIQ45B/E9adrWqSaTdtLaSLdLbTeRKuThQRkAjt1qrN6IEknZl27njt9Hv5oppNSMYkXyHj2HbjOOvIx3rK8E6tBrejLc2VqI7hW2SYJ81D7n+Ja6KFY2to7yEAIw3FG5wMdQfQ5rK0rSk0O61K7gaUwXu1I7bHCY6nd/F1qU1Z3C3Y1POjgtYVhTKyZDArzkdc5pt5MbmzkllAEsShNwHUZ44/rVEQX6xy/aZ0lEj77bAwwx1RvfjrWXo2raj4mj1q0gtFsJIRsinkB+duRkj1zQ1dXQKyd2cf4isrma7hLLF9jJ3vkkNuzwRUN/cRwSRxuWjnlOFjPIJHpXY/2WsmmJZpfJqF7BlbiRMfK2emBWPNojTygpCzSod4Vhkggcn2rnkuV2Z61KrGceZM5w24uZA0ylpEBAweVz3FbGnyrptg6rMV3rsRpW53Z6ZPU017E/aJApZWA52jmuitfCkl1pcR1BMwbwyM6k/N2xjmlBPrsXWqQir31LmgSo8UiSsofu+N24dsj1zRTbDw/YaPemf7YI55wQBK+3PsFPJ/KivRoPlWn+X6M8PET5p3idHexBobmTjImbbwcnk0kEixafK6xje77WY9Nox8o/Goor9Hj16AjDQ3IVSf4s5Jx9KivJY7ewRpWPlySKQB06An+lc6TLTVmi7AWt7yCWIK06vhV7Jx3/ADzTZLqSe6uZrmYRbm2vKo25C8cCs3RVIghnV2BeR5GPqM4qt4guHSS0hT5IRMPMx1OTT5VewJXfMJ4c0mQeIr3VJ4fLMx+zwEA7mjxz+gFal5aR3uoWe8u0ED7yB/CBnA+ueauYkj0/TLi5c5eVgkYPyqB3+vFV7KTM9wHUtuUsH64Gcipbv739dhx7di2XCxuXBMRJlKY64B7VwV74jfVdA1XXILY293ajyIBu6pkc+x5/Wu8EDLPGCAV2ZcN3yOtYVjpunSaE2nRLJJa3EpdnJG4gHsfbH5VcJJa27EuOugy98WCxsfDKTwKx1B0jkYHGRx/U1sQ3j22sbceXLeJKmGH3Tjp9cVT1jRbXWbazilQxm1dTGEPIZf8A61ahjBvDcXKgsWLA5yU55+nSo0shtLVdxLiWKGcMZ0t7a2iW1hHdpAOhHpXI2egX/wDwsjVNTlhcWvkMqkdDlePw4JrodUsYtUubRmDCO2kMygcZJzkt+AqW5u722srldKjSUthjFL8u9cAYB+mTmmm7WXUm3L6nnr6Rq8H9jxwyedD5byMYhhNzOTgg9RjFdxFqmnWdnI9yHhRSEdIo8nOMAL7UmuSy6MumW0ECTW88uXYkkRrgYA9PX8Kp3fh97PV5SJBJFJubywh+YNzjP8Q9KttTs5DT00H20enahbTXnh2KGHUJXws0qLuVvoen4U3XdAu9TstNstSvx5sEwlkKNgyAdcY/rXM6loV7Y2TXNxhN8oRFXO1R13HHQ11uhxxLp1vcz+abzbgM7ZLAEjd7DHrVP3dYsSR0GtPpgtreG2g2umCxznIHqa4zXIIdSukuIFS22DYc5ZW9xXZ2cMdwrB5Y0iWMv5hGRj39a5PUrywtby1MwIgmkKK6nEZYHgZ7Z9azhpsVFpaMgg0xraxeWwvo1mVwXicbfO+gq08moPewC1t4DbSKPtLFzkEcYAHfFT2GtXeoXM1nf2VvFBGCAsUWNmO2ev45pYkivtHuUjl+zxTIyiUMF2Y6n39KvXqF9LlExxpKyqGdCxGHII+mPWoL2ZbYjEQckZwOAKn0aHSNO077P9rku5G+d5k6Bu2fQdam1K1L2Q+zeWzudgY8hSO5p9dSlLQz4XhvI2SRU5yNjHnPtWbcabdWu42z+dIB8sUhxn8afZpDBd5urqLdHyhjUsoPTk1tW8DFXeSXzXb+LsPpTatsVGRa+Heg/wDCSWkl1ePLapE5je2PD5Hf6Va8c2GkaPJbWVp/x9f6x9xydvQVpeBJZLPVJfLjeYyKFdYxzjP3vw/rWp8QfBtl4jUXC3AtdVjTEUu4AMPRh3Fc7napq9DmlUcavvPQ8juEBgkGRgggF8YFUvCqzx6i8Cu0m4YBOSg96tXMdzpMzWeq27K6HDcZH19x71m6lNsuYmtrxoV7KOBXTHXQ62tLnY3mqW+l6tYC6wbJiROUXlmBAyT6f411C2by+NdRkDxLYzonkqOgwoJOK4axksJ7PZqSiVUO4Mx6k9eRXU+H9TW+1ScBQ8dvg4XnAAx0/rWU07aGThaXMN8Kytp3jq9u4ZWudP1V/NdgCVViADj6GufTU/L+MQs4raLasZDTYy5XG7r6dBXT6raCw0/SZrDNtG1y/mKnuev04pttpQi8Q3WpusavJFsPygnKgk8/lSut/KxCj1QnivTYda0aGwmMkcMYMryL1PPQdsfWl1vS0Xwd9gusmzSBZ0JOSecfyIrYZfMlu7OVmMX2c5I7HaDgnsM1TYDUNKtoo3Etum+IYO4Fduce+CDUJvboU7GfeaeF0O2sY5TFABGNw5YKQCB6dsVVt9GLa1q1yXaWG/jDSRhOAyH72fcVo+K7f7RptxHZzsj7Y/LKnblsjP4YqR5LrT4rKa2tHukZVjulDYO08bvwwapN233BvS5XQalHr89ovlx6NHYq8ZUjJcfeA/HioZ7rbaRQrcTWl1cloVZfvB+xA6ZpviC1u4NesfsDTXNiyEShF5CscjI9u9SXMAeeFwsbz2zCRFB43A9QTR2YRs09SpLaahd+HLqLWtVhQpzHeoQhTB4L+hzV2wCSFLPzkLuoDMWHzjb976VX8SW51nR9Qs7n7LCL+EiFywQvLkEADvjAyay/Cvhu30WeDVNRaSTUXj8pwr8RgADiqWqdyeaz0NO20O0t/ED6jZ3BsrrG+SEYCSt0Jz0/CtGw1qxnu51014biTBaWILs4HUqx7VPcC3uIg6SBCBn94mT7HjqKqXVvDo+iyyzWMMcChnkMSAtIPT8fSlfT3iL3ZaW2sZm89xCJiQRE0w3N9BWfp8WqNfGe7u3W1Dcxo2/nOBhfSsbwxBo3iHW31KG1ltr+2wMjIiBxxu454rtdTtrCba8OyPUN337VyQcdSR0otyOwSm78rMvWIIrm6SbTJbO5lg4czKDIg747iim/YYWklZxFHL1eQLsc4orooOysvyuRIdc+St7c+YQGDMwBXO47sfyqC9tBeWG2bI8t+B749KrahdSjxFL5b7c7wAPZua0IZmNpbO4yJJWyx65JFct+Vnao3gmkQ6bE6wQq3GFOfxNS3NnFPE7SqGEcuST64qw22IkKNoRtoH406BftEEgZdqndIzgnrjgYpt6k7Ruie5EiadpMdzHyoc7T6Z4OPpVeJXBleJdnyAH29f0NVdVuXbSDIgxLFGypjrn1qgGvT4j0DZI3lPCyyr2b5c5NJR90S0bZvTMRapK77Wji2g5429a5uLUGfwXFe6Xcr50L+epQEb1VvmH5E1qXepW/9mXU9qVm+z5jkUfhuH1xmkgtraxs4rXTreNLYR5CkcFCM5+pzVbWv3JScrpG1GkFucSzYa5cSQ4IO7oQD371yfhrXX1zR9cupnAntJJY4YyvU8kc0/UrhY9XsI7KDz7qyMSys5ysatlnbjuOBVjSbfS9A8TDTYLdwt+73hGcphSFYc84O4H8KSVo+e4n6j/B95d6loFhd3wzdGPB3DO/GQMjuSK1QyDVTCwMMezOGOcKeoHp/wDXrH8T6RLrqWq2M4s/IuY5w6tjhSQVGP0rS1F1u7lxCEE7QlkDnA3cj+eKLJ/1sDeo+5givtMkKurCJSY1HDBh/Q1m2OrT6jZSxQTvZ3+NkUsqldo9QD+HSq76hqF34eg1PTYUhvQRHNG3OSvykfTv+NQ64ja9okX2y1ktr6JvMQg5DdjkdQKpK24km9C/pdp4gulaPUo4p2YYWdTg5HGSDwfyq3dNZ6K6W1zP596ybT8vI46sPqelc58P9F1/w9JdT6g8v2aVWnQh8oqLyTu7EjHHtWqsmn64ItW0+L7ZbXhImmdjlSOMY7E+nah7+XkJO73NzRbiO1uttwFa3kBikyf4T3rD0jwva3nh7U9NZv7QSO9eSNG7R4BBPPB5/Gtm9jtbzw7JanyoJtpUSrwAuMZP+NZXw30t9AtbsS3E120xVxNbuGAjXgZ5+tTeybT1FLuihrGsmCyW2eY21sAUCsfmJ9a0ZtOjtdMt457eaeOGNSvlNtZGPJY8e9N8ceFv7VWPU7J1RFy7KzcYOOvvxVHT9t54yjv1uHniPE9vG24gBSCBjr19atWcboq6aukSaXp02ofaUKy28eSxuXOxdp9B6nHTtk0mpymVWSAEQqdqKOoGAOvc8Vo6vO80xAWSOzB/cxO2QAOM1g6ldXKRqmnLudurADA9qa1dy4rqypHowFtIyl+Puxvj8s0tt9pEgDztGo4wPSrtrHPGoe+mUkjvzWnpFpbX143mkLaQr5txKfTsv1NNztuVayuzotCddB8MNqGAbq7IEYb0/h/qa5m5kN7NJcTP5twx+YkdPbHYVZ1jV31G6Rh8ltGNsMQ7L3P1rMS9trbVRZzLtVhs87sCeRn9OazjF6vqZxXL7z3ZDqFmZ4VU7mA4ALZ2/SuO1u0e2hLGHzVDc46gV1Wr3F5azrLb8wnhhjPI9ag1HfHarNDDvEijcG5wa0V1qap9DM0mKKe3SN02RlNw3V2mh2EVh4H8Q6nprxNqEkTCJnbAXbyOfxrmfCYiu/FFpFdqVtxnzYz0xitTxahubQ6fpCbNPdy21DjIHT+tTPV8pFS8vdRo+FJ7vWPCtu2pBEvFIZlBBznPP+fWtVpnjtp1aHdFEpZmyAFB6jPfpXP3SXPhmy8LWkNrvnvpT56qMlEA4Ge3vW4+4288c7r9mf5vm6Aj+I+3+FZS3uupUWmjE8PeIItd0rxAzR+UsYd5WDff+U4zVzwW8UfhGzgjRlkctIXJwI8Aj+f865m2vpIob/w/p9iBbvbiYXaKQ1yzY5+mOAPaut8NRrYWUdpMRMYLVvMjIweRnH1rSasmZ2Tu7GLqemXui/DR7i4bzXhlIf5skfPnIP1qzBC2qXmlayt7KmIQPs6thZtwHLe45rRivo9Z8K2ptpMWUj+ZuYfMTyMYPHXJNSWlmxs+W814gTuOAAoA7ClzPW+9wW3vEtvJNNIj28IiJlaIANjGR1J+lPntlt7xWlIMjR48tRxx1/MVj+IIbyeXRGtZGgghlkMqpnEgZcDP0qj4UF1baXB9sSZ5zJIkaHrt6AH8eaSjpe43vsYHxG06S61hb2a6YW0Plxxrgts9xjpXVWR12JJpNPurSZTGF/fYcOewq7d6I+keHNVuZbV7q7uWaVLYSAO/TBB56e1cbp2uaWb2y07VLK+sLm4ZfkZ9wibPGe/P04rWL5o8q1sZOSd2dS9vfzeM7T7OiuFib7UIfljB6Ee3NLqHia1sNdt9KdnkkmfaBjIBPTP1rRvtaGn5ndtvnrtXaPmwOrewrjvEtnZaNdHxHILi/hLDZEijcpI+8SenftUx1aUhWvqaGt69aXkd1pGm3uNQWcK9uAEDAHkK3GTVHwrqupXE19pFrALdrVcNd54D5zg/QVt+HPCGi6sltqNrZmSbAm8yaQqxzz+OK17Kyt/tWxmSKF5MSNt4dvT1o5lFONv+HC8WZWgwatcS3cmv3SSW8cZ2xs/mFj2I9KK6fWNNuBo8kkOW+fO0gcpn9MCitaKVS7bsZ3T1TOP8TQvDqi3MKsR5zbto6ZPNbFuyi3ZWO9AVfBH+FOv9rG5ZhkKzcfUkUrw/ZrReDltjZ9Fxkj865272R2Q+AW8VYrmcN1O0gH1IqfT4ZbOyuJJijeYvyc4JwecVSvYWub5NgwjnnJwOnrU6szaD+9LK8MhRg3JI4z9Klq7QXahYyrq78q906HdtFxNgsRkd6u6jZS3V7pU0coj8kSFmAx7AVl+J7WSe50lYEMjxXQjO0cgg5H6Vc1+5urKyxpg8y7VjDjG7ALDLY9q03asS/hujE8E+TZQ32k3Uga5F55s6kcAMDzk/lWzpWpCx1640RrcuRp8dxHPnP8WNuPpioNDsI7jWJZ7maN76e3McoUg8rhlyB34rXtbRvthl3hvNiMR9Ux0wfoc1M2m2O2ljLub+Kz15LeG3jhW8VpJ5QclwBgcH6HNabQ295qcM6jN5ZxNa7ifuqQCRx+FUGs7bSNLtFeBrsxOIPMf7w3HIOfQmnaM5urK4u5HEP2onds4KSAbGx7Z2mhq+otNh97cCz8QaZZ78QXJKlcc7ioIwfxq1aKqXwgRpWmbc6O65U9W2/wCfahdJOqatps83W3zFJ6nCkKw9wQDUrbkSFo5is6YO4DO7sRx9KTa2XYV3s90UdH1W31SSeS2CyQI7CUqu0xyA4YEe4xWhdslvd/Z0QSltskTKuBtznOao2FvZWMN02mxw77iQNNtYbtxH8Q7GtCC4kgLquHTYVUlQGA7/AKmh76Dt1RckuWH2qziO+MnaY2wUkU8/yNchdvpvgjTI7W0s5GWScsFacLtLd+evatk/bN220W3IyTJ5hKlT9RkdutQ61o1trMS2+v26TGMgpIV+Ze+ARz0pxsnrsRy2K/iBNGvLIaXf3KW5vACIC5Vn542kVp6PYwaTpAsbVBHBtCBmy2FHv+ZrlPGd9oOh6lpsmoWM11eIoFvt/gA6f/qroo4l1S0hu9T3WFpGAZCWKtnPQAVTTSXYLrqRajcadPbnShqXlROwEiK+0sPTPat3SF0jTbe8tdKt1jjkjIGDkrxjJPU5rjNQttBvI7uTw/HcahewYJBJAHPXBHOK37J77StA8/WjbI1yj4jKqGKfw/MOhpSWgpWehj2mlTWE+orcT/aVMYMUaD5SepPsaztY1C7tEspfsomt3b9/tIXyU7YA/UmtHwP4klur28XUdIEMlqdvzZYHd/EOMcD+dR3+k7tQu3tWJLoQhJ+XB4yR6Yq72l7xpG+xUtGjuC3O51bG0HOPrWpI4t7TyRtEbP5jc/ePQfkK56dX0XyobV1MjDfI7DO7tgVYudUWCztpDEW87quenrTcb7F8xegkjLsRIrtGSDjnGe1R3mni/JlglCTJhJFIyGHYj0NYaRtYXMrDhJvmDZ6gnOavaSLu18QNFLuIYEsecEYyDTtbVMT10G6nc3en6lMhlPl7iUDDIZfSlRb0XEckUbtC+GbPKFT1ra1Oe3hBmuIBOCdoUjOMDrVqyVXUCMAIvzZbnA9CKXNZbBYzZRb6ZfQFUH2y4/dxpjOCe59gK02vbHRPKluMllkVYExnnPeooZNOn1qGV4Wlu1DCNiewPJA/PnFZxuZr3W7tJLVJ3tVZ4ouBvYc4J/KotfcOhvSXF7qGowyyovlouxpV4KnPTH9aZc3Vsbk6czYlkhL7G5GORjNS2c8yaYbq+WMXZVdwjHyR+34VT1ttO0+4TUbgSMwSO1hZf+WhPzZx+NSldivbRE9ppMQ1D7dHJ96JYBB02YGD+gqj4EudTuLy8udcCwl53jQEYwB6+3OK0Li9j022dP3rSiP7WEA5IH+NTaK7yWS3OoQLbSNAJZIycBR1Uc85JxQ78ruJ2MfUrS/8LeGUSzjg1WeGVF8qJflXeSSfpik01Ly08X3E1zMDazwjEIbscdvajSIJLJTYTgStdLJdtK0nIPROOvQDmq2j2VxLewy3U8RmjiKTKHG5ATwcfjWi6kLVamvZaTfLr99cyXqvpkkcey3AP7tgO31FbFnqC2kWo3Q2RSRrhAFB5JzwPXmq0kD2UxSaUOyDCk5G/wCormvBl3dT2epX0g82WMtIgc8fL6elZ25k2EveiR2GsP40t7u6V5Ip4HKfvDjK+vHSr99oVvpOuWF5dG4vrpwpUKmY0fGN2epNYmh3GmW/iRr6NmW4uo/KkjP+rBHJA9/Wqui+Mr2w8VJbatLLNZyHa0APypk8YHpW3K7+6RK6XkbfjG4jhvrVDAPJALBB8pPJJzWb4q0/VNWa0sYLk2lkQHjkUccepz1zxir3iq0mu9cileMtl8KFPCgHp+IrU8Hw3F5Zf8TpUne0uZTvI6dlHYetRG0UpFylol2Fj8SQaFqljYRSySMIhFMW+5uPp79Kp2+qx699r0PT9y3WSscrfMD7+1Zvjzwy9/qP9r6YGWYMP3YOF4GA31qx4D0STQpxf3UaPN91gW3deScdqaUXHme/6mbsldGzaDU9J0H7JPqKyXe/b5ckhG4Z5AJ/GiofHuiJr9/aanDPA8tuykQQucqM5y3vRXVheWUXKTSZD2VkaMpLPdA8lnZfyY1FfXsUcKfaWITKx9OlPUgXcinPNwwP0LVVuLH+0Li60zGZpyWibsCK4YWe51z90sStutpSMnYePcU8lFt78mQOJyjFt2djAdz2qh4fEkcElvcD978qcnJBHB/lVC71GG1f+zJZUiTUE2j5cbZFOVbPcHoRT5dxX7HRxOwkj+RS4YyNg4JJAApujLatFeTXAZJ3Tam7jHzdKLcmaxtNREq3Ak3CRwNpVlOMfhUFokhfUYpGEcbzrNCW6YcHcP8AvoVC1Q5LSyMvw1ZrJdXlwoME0QbzDn7rqe3sa323TWvmKQrS5U7fUYI/nis6ytXt9QW+W4ZQwaG4ix8rnoCw9uOauxXBiM0DkbZAPLOOA3v+Zq5au5N3exleLdcuNN0ZrizsZJwXiV+dzBM9QB3GK0INNUo6XbvHDdnzkI42lhzgdv4TVMtNoVnLMkpMEtxEfmGdqsTuUfiCfxrQ1JUTbFlwspDAuwwcZB5+hFLZaFPexbkkEN32mRXVldOQwzg/0rI00TxXmoRXAK+VO8sb4+8jDcoHv1FTandixt7ZpSVhd1t946KTyGP1OBWhcGeNX8xs+WdkjAZYY6ED8c0ltYnZ3MPT9JtbLxZc6kbnyxdwFLm3PQn+FgOxBxXQ2piWTbIGWIxlWkbggjoQO4NZ+s2KQMuoLGQrwg/LyHI6/Q9qxdU8R6kbzSl0i2t7zTHBhlYghoySD65BH9KdnPUd106kfifV73wvPb3X2aWaxZzHOY+gHTd711Qnma5UW7O8E8QKzKRyccj2qa2ntbm5TSbo+fczZmiywBjwMEEdeoP1rEvPtmh+J0/taNR4aVGJuAQPLYfxfjkCle/TX8yXJXtI15Y2MSblSWSI/ut6gnOOuT1rmtEl8SX32i11m004QOxhARysiDOCw6g8496lSxm/4Sw6hp9019pV3AGV0kyiAdGA6c9PWrfiO01G50pX0zUmtri2bzdgGI5sHlG5qlbYWm5b0Cxj8PoxiET3MpAlYoMsw7kZq9c273xkuZmRwUCttGUUem3nFcYvjA3mr21vLLGYJh5EfkoR5LnufXmjw358c2pabcXkbX6uJFTzhgY427c5yc5ocGtXuPrd7m/Hd3GnuTZXdpcQ5P2iCORXfYeuB7UkFxpdzYTNYXCtbwHmWbhouehGf0rMGgiw1u1vY7tLVAf9Vj5m7Mq9m684qTxZY6JoF7cXN1KUg1EfNGuSrOOc8dD0P407K9kK6uY1zqWnSTzxXHkyQKwMdw3CsSP0/rUmoWX2rSP9HjR2DB0zzx7fhW74a+xw6cs8VpAyXK5kE6iVVUDjnFRaRd3V9cXCzWkcNovEYCbTj0H4enSm5dV0NE+jMbS7Bn05DfpmRJC0Y749DWvaq89wGjRncegp90+X8iKOKG5I3CEvlgmeWAraupUhDvbqILZFAXyxgscd++amUrjuULuyEFsXu2jztLLERvy2OPy71T8HaaLiW7W3uRO64M7jlU9B7mpjbLqKtG/mvGOCFOCx/wAKntd2mQyaZoN0tveynDLEA7jA7jHGBSu+VombcdtxGfRLC+eytJUOpCMs0IhZTt/3sfTisLw3azyQzXZkeGQSP5z4zkY4zn05NR6dLbW+qMLK7uNW1CTIuLxyNibc5A65+vSjxfb3muaLYWdn9otLyeXzSVJx8vA3EfXNUlZ27gpe7dlLRre91O91hYZJYbJIDBAST87nA4Hc5ySfeuyls9K0qz0rSbxzPNEoYng/N3xnv2FZx1qDS9Q0zSGwdQuFCoyJ94gfM49s5xnvUMmhs3iR9TvSXulXy4Ig2VTjGc92P9aUnfV6IN2bqRm51eW9uEjVDGS4HVI1GQo/Dt71m6VNdXdrfalqa+THdvkLL0iiA+X8uTWH4NttRv5LrWtcDpK0pjtbc5wq9Dmur1W1N/pkWnvIIDLBIHGMdScH8uaT93Qlq70MjTLvSNRN1rtjKXMSmFh6Kg7DtkCuV8JWU2p+JH1qCZxGQVdexJwAPoK6Wx0+18M+ELgQwGaIb5JQR/rR938uaZ4b1fT38P6guiWUqsqeZ5Zwo3KpIHP860Ttdx9A2L82opqeo3tuGJubCYJKcYGCOo9axfBWt2c+q3mnWMbm2jUxKrjadxJXPXkda2rQ2tlHFPdQIt5coWmZCPnfyweT+lZvgIWl95+p6fG0Mkzuu08BXA/iI6ikkkn2Jb0MTVNT07TvEsNpPpIuYRcC3aYycZb5S2B/niugguPD11r8Mc9onmW0n+jSggb2XjBxzj0zSx3miljHqdur75d89zDCAm/s3qcUy2+H1jbaxbav9ukuUZy8EAx+846k+gzmquvtaEy03HeKr4bYZo/kzMX/AHTY4HYYrQ0K0tbCS5WN3SO7fz5Qz7lZzznHpik1PRYm0vyoo2iUHOW6luchfYc/nXOaFcvFeJBccq6srg5O3HT8cHpUpJxaRad0dpdTxyQtPbFPKBwoQfKB2PvXH+KLrUrma0i0MmWTeRchSMgds57e9augWsunrf2UyBod6mIg8L+Hvwax1vJdP+Ii2/2GQW0rN5bKCQcrzkjtmnFLmsiNk2Q+D/Cl3bXAvEea3I3GYSNjzOvBor0WC7tb+xltrspDKpaSFCQCVHRh/hRWtOble5lKV3qYepK0V5IUJGZG498nFS2k5W4EyH98pBT8eP50y8vLW31FLW8kRZbqZ0hVjgs2T0qDy9l3ID0Bzx6H/wCvXLsrM7laaCCSGC7MDtiYDcxzznPXH41zHiazOpJYzpE3nW14Y2YHOBnOT7Vf1rQpbvxM+vR3OyPySkkZByTggYPSqnge4e4n1CzvAdsimQYJ+bjFarRcyIT79DS8KzS2kd1BcEzWNyPORgMeTKO30Nbd/dLbQwTFNyyZjx3QnkN+lZOjfYrKxudIuJtt+fngVjxJH149+1a1zDHqOjfupQhSMEZGSHHY+nSsvtalytq0W53DXofYqRzRiNyDxnHDD07VleItPOo6Xd2YdopJo/KLdNrdj+dW9Ku4LtZVztlgjXeh64Pt6Uya/wBoa5mjWSOJDHN/tDsapXT0M7FfSop5/D1vp2uqk0kaAOynO/GQc+4Pena/pEWseH1gkcl4dkeenzAH5h/I/Sr0Eok/eJIsuQXjbHXjp+I/WpxmKyXEqoT8zHGd4PGMe1SnZ3Q2tDPsYYjok2la0WnMEKLLtOCSOVI9+1YumeJ49StRJZO9oLF2W8hvRltvQEnua6Vkt5kjZAVlVSr7m5Izn9D0+tY+raB/aWopOLqMq8eySIDG84x1x/P0qouPUTV9TS8Lyah/ZdzaSrHL5cm6KQn5ZYWGVYZ9M4NTW1tFYTyzWyIUlkBlQchWHcenesNLpotM+zaNN5N7ZsrBlOSE5yv610jzJNA8lwhWRow8hXqCMg4HftUv8wcXCRzGuWFrfa5p8qX9xYajbOfugYk6HGSc10GrQNrmhXGm6zcpIWO8OnDADkH0zkfjWXquj2HiLT7WeRgzFS0FwoySR/D+la1hcWlxaRSWkq3F/YBFkIZXHHBV8c8jjn0pt6JroJ2MLR7K08PWkGmw30r+eS6JKoBznsufWugSaFrpoJZTDcklkVxlHPofrWXr8+gxapZGR4UvrhiLaKYEFGHOzjoD29zUMjT/APCalHi8/TJrcToxPzxP3GB2zxTeuor3RU1exh07W7a6k00R2katJJLFEWMbDOCO2O/0zVrTl0PU7lfENhaI+okMm6MMrg4/iGcdO/pW7A4uoNtpcCe3Klg6EMjDOCoPt71TtbW2i2DT44oURss2MB/wHtxRzaeY0k9Rt1pi6mdN1BpplNnKZowq4IPGQe3btTNCtNQtrC5t/ESW+qiaUvGJYvurn5RzitB0aEgROGMueIsnvwAPbpXPaX4eFlrM91LrV3JFcPl4ZXDBeecYOfxpX0s2HLcu3Ml1bT2sdrB5UIYrII0CrGBnse3bisC08Ra9LeTPBprOkJOIHjyjIOBlj3roPEml6vcyW95omqCSFdoJmYAp7N61bmlS2jjllmWFUCl5FPAbOMDvyad1ba4RakZGioLjUUv9W023sdWWNlYW25iiZ4ViTjPtWtdRu7JIjoIlByCTwSMjp61Q1jWYNNkjis7ObUL2RgSqDCgZy3PrWvp0Wp36rK9lb2EjnhBNufb9D396UtPeYXSJWa+NnNbabJHAwT95dLDygxnoen481yGh7dQ0LUrfRppYpZ3CS3kjZlmU53fTPt7VtXMU1xqkklzPIunoHhhtUJG7IwSx9ffmqdlY38erhYJrKz0GKLDR7MAt/eLHnjtjrQtExKPVk2laRY+FLBLe2iaaeQiIBGztJ65P4kk9KpaZrj3eu3EEbh4I3MchIK7Gx05/Sr+l6zaauk76Us91FHIYckbVb1Of7veq+pLBZyxSQxLLcTTLDaQZGZJCO5HYZHPpT1vaW5ata5paRYWS3c+sXEJnvwhS2yMNEo9PRahs7i4vNblitlR7K3jVzLF8xnlboAemBz0p+uLcjRToocbrg+Xc3MZ29ucZ64PYVm694enstD07S9Ou20+2Rg8zMSJDEPp0ycmkrPdkLc1PFF21tFHpeh4u9VjBlmYcxwk/dBPTPfHtTrCAm3ha5lWZki/0i4kOCWIO4j61ZSxkitIXQRwfaP8AVKfvBccyP74/nVHxNoa3c2kxXM08KWBM4iEg2vxj58f55NJW0iCdttWUrAajfa9qkmqTJ/ZFxshtYF6RxdOeO/8AOrEWgJDYz2mmxNieN9jM4JfB5/QYrQlmS3sJ5JSQ+AyoF/hUZrK0DVz4j0yG5EM1kkTcK/VwD97j1zVa20DbYp6tpd1d2umwoxiVIf3jk/dOB/QVY8MRWFtaWltpiE21xMzyZ43dmY+lZLafqFvq2t6ze3vmQyRm3hhjYkLuPQ+mBWloduulaWs9zuaVlKpH1wG55H61bfu7itcq654Zayhumtb17mFCxWER/MwHbPrWfb3txNqOnefa3VvJId7Kn3U7DAP05rfuPEVrpz2bQyhvmLEw4baffPX6VrLeyX774nE8rfMCqgBlNLmcVdheT0ZaRpHtlgWMlt3Du+AoxznP86871W6j1HWY9Ot9PlluI5w+9G2bip5OR2+tRS+N9YfTjbjTnnnnuZI1j2lSsCkc+vX+Vddp9pZ29w08aeTcTr8xHJUeme1NLkfMyY6Jo574haxf6PEZrRkiG4EuqnI9jn6V13grVINe0S11GWMQ3mBtLHClx396zdL1z/hIlu4p9LhFvCcYkw4II4B9+KpatdPZ2UVho9qxuXU7WA+RPoMdutS1ePI1qDXMUbvQdVm1e+vdbmIcyARJA2AoDZ5x2orZ8OTJZW00Gp6g9xqEibTjkZx70V2YefKmrXJkmx+oWNreais1yhaa0uHkhburZP5iryYL7xhigwfdTWJdi9vprpLab7LPHcuNxTII3Gkt9X+wX0Om6nhLqfLQSoPkkHcexz2rhcW0dUWk9Ops6XMpSePdmNi0Lj0I6U+G0QXUUUUaGYrsXAx3rLt4WXXb+JWwsyrOBjjOMGptLvnmu4r3ZzBIUkTPIxxmhrdonVDrPQ7a71e6lniC3trEWQOeUZeRj65xTvBfia31+SWCZI4LiEMkgjXC4IIDDvwaJ5PO1ua7ZnRXIX/cGKpL4XtNIv5tXsZSI7xDnbxtbPzA0NJpp79Au3a/Uv6fZLp96t4y7pJgbaUjsQeD/I59DVy3VGW5Mw2ITsk749iPQ9QaIljYJCWZmkx82M846iogk9qG8yT/AGZB/fTPB/Cp3Kl1YxIEs5Ps8bKLY8xMp4APYH681atyFdTKvmQSccHkN1z/AI1HNGLizWNQI/LJQAtwQe/tzUKuESTKHI+WSL+JCP41/qKbVwi+hZu4ZBHMyRZEkZ8ts557An2PHNcX8KHQwahZRIy3tvP5hTzCyoejAdh09a7myufJLI3z+auQ6/3uuf8APrUVo1pbQ+ZAFjgnkPnxRqFZWzyfU07+60S7plaaxthqv2i1UxzyYYqeAfbPerlwjLcAr1ABKn068+1QatpRm0+eG3UlHVjA3m7ec/dJHY/1rnPh74hPiBr2zvrdY9QsyELBThk5GD7ii3u3Qc19WTX9zceFbaa+s7WS80uSUG4tlYExA9WXvjp9KsXbR6RFJregxLG1wqvclRiR4zyMj2OMj3zW35EyPKsTDKMVRyMBvbPrUnnPNH5skS/KNrZUYx7Uc3f/AIcGuq2Mq/t7DxPZWN49i8dyo3I4j5ibGdwPof8A9VRaedP1XbbzT3sV9YuEjuFG1j649c9wa0wyRqtxGzBCpBKcggdMCs3T/EFjqEU8emxKt8qny43BQNJ2OP8AA07u2glGxBcSWvhHRNmmaZe3dq05eRIxkgt1b6HjipNSn1W9msLjR7ayNiyhpo7glZFB/kR6Vf8ADV5qTWY+228VrqDOVkWGUlCPXHSpdSmtrS1a71G6hgQEb3f5cHoBSvr5hZLUsRy3DSHy3VU+42B2x374+lczbQafqviV7W7sruzvYgWhmDZjk7gCuiiJksGvtMMd4dheNIWz5gArI0nxCdS0x7/VdPNpFC7IyTpt27ccg8dzRFtJ2B2bL2vXMWj2j3EyEhMfKg/ImrujzaPrVgs9pqaRSYG+O5i2kN/X9araZqVjqtkt1p89tPbliv7wNyR1BBFZWs6Ve6hf/abfUY7W3jXAgRDGo+hzzSstnowabsdFPY28TxyW8sDzr8qsm4gdTkds+9cNp3gue38TRardazNdSxH5FbLEt259PatGxN5BqZ06LVbiRcB2Z4TIoHoHPA+lams2+pXWnxW+iTS2kjsWnl2fNt7KGHQdfrVJuOl9xWNBEMd2EmjmcdGZVO4LjqPT2qjqUttcGO0+zXLKrBiozke79qpxahqNlbxaLC93qDRgbxGPMYZ5w7Dp9Ca0rlLrT9Pa91SNrdD/AHsFsnsF6k4qdmU7LdkiQFIGgs7ZYoHYhUBwG56YHP8A9fioZdNe21izvrtMTwxkW1seWDMfvgewp+nyKxtr5LdlnZcRiRfmA/3fT61ZnmmluxNeXGJj8uxRwg+vr7UtUxO79DGn0S3bxONd1m+MVhpyhEiLbVD55OT69K3WvrabVLjU7qMyKuCkWMjI6En0FZniHQ7TVrq3GoKzW1md8UKynYWPdscE1MTDHbl710gs0bGTkBie2epPoBTfvJEpdWRHxBNqaXj2dq8l4ThJJG2xxqOgA9B1yaTR4biGESanI08skm+aV8Yzjt6AYxV37dA8kFkwW1hKkIhIMj47kZ/xrC8Zahq9ne2n/CN6d9ojlTZI0oyIRnuPUjvTir+6hN20sS6NqF3rur3ix27RWQO6OX1I4xz2xVjU47iKwuINICfaHwuS2AvbNW4S0MSrJIERid57+uB6D2pdKvI3uzIke6OHlWYdT7UPukVdq5X0axFpp8VjbjzDCpkf5up9cmuRim1OHVdXTWjHFaTPtt3Z/m5549sV263AjuRhN88m5yv3Qa53xQfD2o39na6pcvDeDBUI+fPPtnoO1VF+9qGpl2FjH591ps+nsoWLImHILHsv51teGQ0KCyidvtMIBZU5YBicD6+1aqpEI0li3CTpt9qxbm+FnrsFppttKbi+I8yRDggeuad+bQG+xe8RSxaL4c1ObMlzesNm4oPkPYZ9zyaoeHtJupbW11qW5jnZo0R1hOcSYwc9vwqx4me4s9IuYljMkroIl77Sepx3PWneEPPsLIRsPKVUIbaeh7nnj8aSbUWyeXsT6T9giv72wtLmDzwfMlhVvmBPbHTNUNe0e8uLj7Rpl5tYoY5YGbHH95fWqBs5bDVxPotriyYGa61Ac7m5+UU+DVJby5UHKeZJtV0GAxHJANOzvdDS8yz4e0uV7WW41BEgvUOMO4ZpAPSio3a81K4lFvIQI3G/AByAaK6KWt3J2Im0nY1rtN08+04fzXBx3G4/rUN1aQXSwG9QSNBIGjk6FT2P+NKL2yv9QuYYrlBIszgqDhshj2p03mRyGOTkMOorkW5unpYkQss4fGHQYz6is+EG11qVohm0vBvXjG1+4NWzNsjjBbDE7Sf5GqtjcGaSazvVxLE/BPf0IprRMHq0a1xH50kiqwAMY254we4NPN091bvYmTaij5Wx3B7/AMvpTkUyEhQp2gnJPYHj+lYPh46h9mkk1ZFFwkzqCMYZf4T+VTZMEn9xsW1ncQI84nEjNkhSclCvUH8Ks6be293aAFw04OOuQwNMSfEiHozj/OfWsq++wwlHth9lZSXeFVOSc/wnt9OlK2g7uctTWMRt2ITDIwJUHkHHUVDdyKkkLyOkcLkFZX7egY/1qpa3011ftZTERTxgMmVwXHY/X2q1PZwYey1FhHBjLnqoz+oFVfuTy8r3Jf3ImkSPggk4xwCfT2NUtTaexjM8Ufmxry8WRmVfr2IqraWl5ZMYZn+126D9xcA8lO2fXFaVteGKRFIDI2dyN91/8DSskVdtXI7TU5prd7izjE9oApMYI3Ffb0PqO9Vj4f0x9WXVLf7Ul1JwUiPyyE8Zbv8AhVy3iSGSLyXMKhvugfKM9fz9KZqsbzw+UsjWrq6yLJG+0eoOeg9xTvZ6C5eo/VPsuiaZJM9z5oMgULNPt2kcAAnuaLOf+0bPz1WaI8ArP8pI9+fyI4NYtiX8XQXula5pC/bLSQGVMsAw52up9OvSsyPWdT0jWvsOrIqaUI8RogyNg6bT1p8l9OqFFtdTt7SciLy/LVbfdzt4kRj3GevQcVSuNDtJr7zgXjuyeQilAx/vU8TLeQiQmOS2nXfDMvDMPRge/GOKdptnf+aD54lsuHjS4BLIPRe5Ht7VK06jk+qNNdPuJSht7UpuYB3kcFTj0Y881Q1nTFvopbDV4GMcoIaJgD+KkfnWJ4802e+3HTdXuGhijxPbCYLtfqHAqh4R1fWUuILe5lku7F0Km5kJLkjpjP5VSi7cyZnFtoQ20nhbVtPSzn1SPTI02eRFD5iPknqc5zXWahfyx6PqE5i8+ONNxgEYbcD1OD1qQSQzeXEm9SW+fypMFvw6VzeveNI/DWtSrNp5ms4CisBIRJyM5H50az6ah5Ffwbqc91Hus/s8FqG3G2No0Z98MvGa6w6jGL1bZbuCCVhlbeS5Bdvfae9QX+saDE9lN/arJaXAVvs4YbxkZAOfu1W1HSLPUpjqWh6laWSRDY8lx5cik+jAcg475pNqTu9CebyLWta62mWsb6juUekcOSM/TvTLCx0XVLVNWuNe1CNQ27ymbYvH+xySKntYJDp8cpeK7ckAy2g3BvYAcj8aDGkzAeZEkgzkP8hHt/8ArpXsrIrlTWjsRab4glW4mi0K2a103cf9IkVVMzf3wmM1PcXM17fIkjtdOg3mQ/djGf8A61VLu5tLRkE0yIX+VASMn2GetV4rSzbxKb2GG4F5IgX5+I4wBjgfhRZPUpRUdbEN/LdwauZ42m+z4EUcEbbmc45ZuyjPr2rViJ3o7CEyEg7C/Cfj6D1PWiKBI2mMUEUEjnezsR87DueKfaPJd25EbW1xPg5eEZXPsKbsK7sWr21i0+JfMuLaQMdz/P8AMfoPQe9ZrWcl3JHqGoSrdrA2YIY1/dxnPoOp96zNc0m4vrdY7cPA6tubb6+9RQaTdafZORqDQzBQPMkY4UeuM8/ShKy3Go+Yms+D/tGtXmsXk+yViGg85woUgcAAdAKzbpPGV1qUEthcwyQYAbyW+Qjvg+la0FhNrukNBc3zXBRgrSx5UEjtz29q1tOto/D9n9msd+QCF2sDuJ6lveq53Fa6iSu7IwvHeoXuk21rEkSy3krrCUHQnGSfpWjZ6pGzrbW8SsyJklVyqnuPc1bubGK6UpeFXcgHhslf8DWTpN7Yxa3PpenwuZbYrvJB2725Az1JxSTTjbqVYx/DF/N4q1K7M26ztrZxiUvjdyfkJ7dP1rQ8Y6ZaW1xBr32X7TeWqKEVSemTztHXFdFefLHIINkLyHLYUEnnuKqqglUocuw+UZP3vw9KHPW60QopyOd1HxNNp2pWz3EBtbC4hVokEe6ViQCcjsBWjpFtI+tf2tLMWikQJDHtwFHc/XNaV0qSyo7wozBRhyu4gYxSXxmj0yR7eFwqIQhUcn3o5lskPlstS5qWnXrRPPYqJ7spmFJiAntn8a5HXrPxrBpdqt0tkt42/wAyC3AO9e31rS8Lya9rYKaku+IKEi3Aqf8A6+PWt+W61HR4Lixt/Iub8ofJd2yobGBnPP4UneDto2Ze90Zl6DZXieE1tbuQO6/NIsa4UEnp9ahUafoCSTX1xFCH+RWlbcwz1CL2J9aj0W+1PQ9IkuPF9/FeNJL5gjjA6/3f51D4fh0LxhOl7e6bdWpicmJJZt6ZHr7e1Vq23062Buy1M7SvEb3fiGaHRYYotMKkSSYw5Y+poroLgxzag4t7WBI4hjdFGEXjp060VtSlG3YUl3OW1bRUvdWupdNuBbzR3Dtz1zuOeRXaiN5bZPNKtIqjJzzn+tcrPbzafrN3JDhg07kgdCCxrSsdRMlx5W0rtGck1lNNo3hpaxoCCNnZJfuMcrnsfSs3WbKRr6G6tmxJHhXUHBYVvFFngchTgfe9M1SYiTY3Ilj4Yn+IdjWalbUq13ZE+ny7t6Njc4yCP1qvPFcNdt5YxGMCQHrz0IpNwiKk468e1TvfnYoPBDDk+np+FFuqFezsRhftUkccswVo8jd0xnvVufw4NRsz502WV1DGNthBzwQex6VT1bTpPtS3FrLsK4LDPysD3Bq1BfXNneApGDBIuJR2J9D/AEp+cWRJuxn6nr9iviaXS7218nV7aLcJZBxIuOSrDkGtYgyRK20SydcnrID1BqjrOj2+q3EN7JGHubb54ZMHO3urH07UumL5Gm332icx2tuQylufLDdv8KNLKwkrLUh0rSrkamDpcpSwkDF7aRv9QfRTU2s2lzFAZUiEro3zJnAkX29/Q1Lb28019Bf2V6BHjbIq/Mky+o9GHr+FV9Za/cLdaNdrJcRfM8Eg+SeM8fnmmndhdoLK8huv+PBy8oH7y3nGHX/PrVm6up7nTJxYGGS8ZMfZbhAI5+xAPrUMKQXUHmTWxinAG8L96M45ANc3dWuo+HZzPaKL/RicmLqU9fdT70KKvoXL3l7xueD7+SOI3USzxLE2w2k2fMhYHmPJ+8npWtcpZ3V6zJGjo4MgicAvE3UgZ7VF5ny+ZwXdRgSDJKkAgOPXpzUayiScPGgt7tOSjj5WHqp7ioeruJR6liBjLC6wBUmjKgbgFjx6AdqxPHd3qOj2lgPPNnC8uZplJLMMcBT0x24q5da5pltqtlYXheGa6BMKNH8uR23dKNEvb7UJdSs9X06NbK3fcGchkdB/EB27dKaVnzNaCb7HOeBtIIub28ecvbXHMZOSXHXuOvauxlZf7PHl2vmFAVSJcK0nBPB9e34VFbyxPG8dtHKNrYCsABsxwR6jpU8izPGsymFWc8xMGOHH3enQH/GiTbldlfZMfQ9PfyvtjWjWM7syqfM349DjvUmuQaTdXlvZ6nc2t1qBXKLMq7yB6DvT7W3e+uoLu5iktnh3K0Q6dc5xnp71Hrmn2155h02NYNRZNtvezbXMTH8OPSqvruS0UYfA9uNUmudQl+2DI8pcbQe4JPcjpioV8NW93aXVobQaOXnWQyxHzDN16j0q5pmm6tb+HJLG9vw+pMSpuiuPLGc9MfrWloFlfWVhJbXeoRzT7y6vMu7aMf3vw4+tPnfcTXUp2+oaZ4KtEsrWa+muLltxZEyzcEZA6KOe/NUdE8NWdle/2i91dTMSXKynOT6/Wukuby3hQST/AGaMk4MjPhM+2f8APNRS3Vt9nM5kBTBbMO0nA9h1pcz6bsIrqxj6bptzNDLdRJI8PzREL36/zxVuFJy7OCq7jkliBmsrQdfs9eWeO1hvo2iAXbcR+UG/3SfpTtMnuri8u49Qs4rW1jciCUSszSj1wOBUvm2fQasX7++As3bV9QigslGw9F3DpjPHNZdj4fubLS7iLwyotnnYOt1cksCfbOM8d8VH4h0wa3BBHBBDPLaOHhE5woPqVHWtlFu5EjF9crKFVQdrEoreoHTr+NF7LQHC3kZ1613YaGLNdaSbV9uz7RKMKpPU4HXHaqFtoLT29rBrWqXV+27AVSFEjHnn2ArentrZ5FlMcBlUYVpE5zVzarKZmKxxoMmSRsDHf/Ip81tUTsivGlvbxC2soIYLWPOAWOB9T3/Cs6V7976J9NeNIUbEgK4yPX6VSuNStbq9KwNPJGvUxrwO/et2ELJb7xbxQADKuzZdwaTutWWkktDn9J0qew1e8uri/a5SZgVjYZCdc1rW9olizNaL+8mkZsjkknuTVLUr9LKFZmyUYhVReQfrVG78Wta6bFeXNncXAdvKWKBdzDH8qfvS1Rcko6M2Io5pLR3kjxlyqMOjAeprL0aPUkknlvZokQsdkacAD1zT73xXplrBY21/I9mJhujinyAv1xwOtaUuXnCl1C4GVx0B6Yo1W6Ji7oqXl+lqHuLy+jitCAuD1z6k+n0qWwvLm7vGeGVZNOaPdG3K4+meD9Kje00/VTJbTtFLauTG5U5Kn8Kj0vS201Ht2lzaJxDFG3KqDwST3pJ6ajkk3oatvcSFxI0cyFFIZ1O0MexP4VXtLg2kY+zv5kvPmSSjcQPQGm3yh2EZnZ4F+4npUtvpc85VivlwqMkngY9TSv3Eowtd6CeXHNbokkQkGC+Hxt3ds+1ZWhQXtkLlbm7W68xmbhQqKD2UUX2s6ZB5I06Q6tIZPLeO3bhPc+orWjguCxnllt44AMlnwMH+dVdxXqTZSK6GPzZYkkSSVR+8iVxuiB6EjrRVPTotJa4uru0nVpJSQzRDBc+5PaitIehM1Yy/El42nrdzqhlYTsCM9tx5NL4f1D+0beOZYhG0nHI6YqJrq4j1zVTcCJ40llKqBn+I9qSC4d54TCAquR3wQc+gpNWVuptF31OqsL54JyhAaIna9WLiMBy6Dj27isq5lWLVNiA7X6/WrljPIl5NbzNvjI3IR1A9DWT7gmlqVJpY4Z1t7p1VZBhGJ70rKUby5OD/AAk96frNjFeRKrk5UnB6YNECNJYRRyOS6DAb6U7j0auSRXIFobacMjZ3IezDuKtmBtwMTebGY/MVx1K/T27iokngEgt7qNntn/u43K3ZhUkn/EvvHiRjIkZ43ccEfpR6GTlrZjrG6jhnDSMwjUEnH6j6YrN1u1guphCJJPssjBgFOAQOzD2rSlETYkiUpnt6VWKocuMhhz9aL9UVBpO7Mnwzpur6PdMtxPFPpUzsUIYBo2HT/wDVXQ3yxyxjdEsboSGCD8mpo2B1QFxFJ8wUdjVuZQs25ZH3yYViygjPY4zS5ru7FJroVbd1Ecazl0kP3HAyuc9aoazJqFglrJp9oswb/XxhwOPUds+1XGEBz5YkjAyXizuQkHnHcVT1jUJdJmtjbqHt5gNys2GH0qlq9BJ6lpZVdRvZk3985x7H0IqW1LIrB40lCj7ynIIPfI6GmGZ2jVsKwIPyt3HXr/Wqyj5mlUkbugBwQD70r9y7LoWJAPPjmVPOtwV/dyLnae/0/SptkZZlYhYpCNqsMlfx7iq8LPbXEW9ss/3ZEGDj0YdDVTVIrhbhpLC9ltZT1TaHib6qen4UaehLdn3L8rR6dGPtqoYT8/mCQLgcjv8A1qWD95+8s5TImMqWIBI9sHms5JY72xms9atIblCCJEUnGfVSeRUmlaZb6fYmz03KRQnKJL82ATnhs5oaS3BSuX7mefawZ3ZW7FuuPcfyqi/iGxhna2u3ntlIChigG7/gXQfXNWndkCiZI2OByox2ohgjvU2IAAv9/wCYdaWi3HdOOo6KOLGG2RDGd5lycepxkZpYVZCGLRyJnAKEH8M1bbQ8KfLnAYjoY+P51nXMZtpfLZv3hGMqBg/hikn2FzRns9RLqysJ9n2q2t2kQ9DyR+Yp8Nt5C58kCHPAjiwQfpwKZF58QwsxUMecKCf/AK1QfZrm9umFvqdxDGFJIMYOOeSOad+lx8qW5e8qXoItxBOAAM+/PSo5vtBgaKCS2BwQXLAGP6A1Ss3ltWEL3LXK87meMIW/KtCWVtySrGmzoQSS350mPyMjR49Rs94vdXjvju5bysY9uBiteO3/AHqyyyKi7vnOCWI78YHNMlvfORgIto74kIPPoQM9qi0nTrV7yWSJXSedeZXdnIHpgnpTb6sTdtS0JbYuy+dJCm09E3OTnJ5HSmzBNUlmSONmhEeFjH8XHOSagkNrFeOjJKSnYMMf41H5x8hI4hsBJI/w/WkmDinqijodjcIk5uxHFCh2RrHhsH147VozozbIyjsi8AKM1jaEmpsbxtYmt5YzJuhSEEbBnoTx7VuG3jjjia3aRN5+ZScjjtTqaS1KhK63KN/GXs5JEthIi8rGxwGPYU3Q3Y6ck97am2klHNvGckHPrXPeIfEeo6dAGggtW81iFDM2FC9zxyea27e5v7j7I8QtljkgWYo2eCRyB7Zq+SVtULninuW7y1tNQjKX9rHKi/MqSIDtb16U4wmVpA+8rjaWzgkVZEyQ28TSRBpX++M5X8KhWYSMQqhQRn15qH2YRkrtozdL0e30tGhtC7/MXLM2SSa1RAw4OxSeMls/r60+yEMc7NKrFlPy7fX3rI020bTHvNtzLMs8m7D9qOa922N9FEsy3EOlQLcyRFwX2g4zlqjGqS6km+V5DGcgJ90fl6U+5iE0QaUlk4+WiN0GCiAEDGaLr5gordlawsrawdntraKJm5+UYqjJ9kv9YgeOKWW5gzwjHYPcjvXT2Fkk4d53IReyis9bzDvBpsa2sKnJkABkc+h9BVRlrqZzkn8IyC3Fop8qGOJm68ZIFFXbKGS882V5m3J7daKuFTlM6klc/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power (200x) view of a pancreas biopsy in a patient with autoimmune pancreatitis showing a small pancreatic duct with a lymphoplasmacytic infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Russell Dorer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3220=[""].join("\n");
var outline_f3_9_3220=null;
var title_f3_9_3221="Carbidopa: Drug information";
var content_f3_9_3221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbidopa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/27/10676?source=see_link\">",
"    see \"Carbidopa: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lodosyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F146022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, Decarboxylase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F146017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Optimal daily dosage determined by careful titration; generally if carbidopa is &ge;70 mg/day, a 1:10 proportion of carbidopa:levodopa provides the most patient response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Carbidopa augmentation in patients receiving carbidopa-levodopa:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients receiving Sinemet&reg; 10/100: 25 mg carbidopa daily with first daily dose of Sinemet&reg; 10/100; if necessary, 12.5-25 carbidopa mg may be given with each subsequent dose of Sinemet&reg; 10/100; maximum: 200 mg carbidopa/day (including carbidopa from Sinemet&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Patients receiving Sinemet&reg; 25/250 or Sinemet&reg; 25/100: 25 mg carbidopa with any dose of Sinemet&reg; 25/250 or Sinemet&reg; 25/100 throughout the day; maximum: 200 mg carbidopa/day (including carbidopa from Sinemet&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Individual titration of carbidopa and levodopa:",
"     </i>",
"     Initial: 25 mg carbidopa 3-4 times/day; administer at the same time as levodopa, initial dose of levodopa should be 20% to 25% of the previous levodopa dose in carbidopa-naive patients; first dose of carbidopa should be taken &ge;12 hours after the last dose of levodopa in carbidopa-naive patients; increase or decrease dose by",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     or 1 tablet/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F146018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lodosyn&reg;: 25 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F146004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals to decrease GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F146003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Given with carbidopa-levodopa in the treatment of parkinsonism to enable a lower dosage of levodopa to be used and a more rapid response to be obtained and to decrease side effects; use with carbidopa-levodopa in patients requiring additional carbidopa; has no effect without levodopa",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3245270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lodosyn [U.S.]  may be confused with Lidosen brand name for lidocaine [Italy]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F146020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions are associated with concomitant administration with levodopa.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, chest pain, edema, flushing, hypotension, hypertension, MI, orthostatic hypotension, palpitation, phlebitis, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delusions, dementia, depression (with or without suicidal tendencies), disorientation, dizziness, dreams abnormal, EPS, euphoria, faintness, falling, fatigue, gait abnormalities, headache, hallucinations, impulse control symptoms, insomnia, malaise, memory impairment, mental acuity decreased, nervousness, neuroleptic malignant syndrome, nightmares, on-off phenomena, paranoid ideation, pathological gambling, psychosis, seizure (causal relationship not established), somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, malignant melanoma, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes, hyperglycemia, hypokalemia, libido increased (including hypersexuality), uric acid increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, abdominal distress, anorexia, bruxism, constipation, diarrhea, discoloration of saliva, duodenal ulcer, dyspepsia, dysphagia, flatulence, GI bleeding, heartburn, nausea, sialorrhea, taste alterations, tongue burning sensation, weight gain/loss, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine, glycosuria, urinary frequency, priapism, proteinuria, urinary incontinence, urinary retention, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, Coombs&rsquo; test abnormal, hematocrit decreased, hemoglobin decreased, hemolytic anemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase abnormal, ALT abnormal, AST abnormal, bilirubin abnormal, LDH abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, dyskinesias (including choreiform, dystonic and other involuntary movements), leg pain, muscle cramps, muscle twitching, numbness, paresthesia, peripheral neuropathy, shoulder pain, tremor increased, trismus, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blepharospasm, blurred vision, diplopia, Horner&rsquo;s syndrome reactivation, mydriasis, oculogyric crises (may be associated with acute dystonic reactions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, hoarseness, pharyngeal pain, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Discoloration of sweat, diaphoresis increased, hiccups, hypersensitivity reactions (including angioedema, pruritus, urticaria, bullous lesions [including pemphigus-like reactions], Henoch-Sch&ouml;nlein purpura)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F146007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carbidopa or any component of the formulation; use of nonselective MAO inhibitor therapy with or within prior 14 days (however, may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B); narrow-angle glaucoma; history of melanoma or undiagnosed skin lesions",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F145994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyskinesias: May occur at lower levodopa dosages than with monotherapy (levodopa dosage may need to be reduced).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including a history of myocardial infarction and arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endocrine disease: Use with caution in patients with endocrine disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with wide-angle glaucoma; monitor IOP carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychotic disorders: Use with extreme caution in patients with psychotic disorders; observe patients closely for development of depression with concomitant suicidal tendencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease (such as asthma).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiparkinsonian activity: Has no antiparkinsonian activity when administered alone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal or significant dosage reduction after long-term use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13276948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Carbidopa has been found to cross the human placenta; absorption in fetal tissue was minimal.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13276949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F146009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals to decrease GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F146008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lodosyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $454.45",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13457241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of Parkinson's disease; CBC, liver function tests, renal function; blood pressure, mental status; signs and symptoms of neuroleptic malignant syndrome if abrupt discontinuation required (as with surgery); periodic intraocular pressure (in patients with wide-angle glaucoma)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F146010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Duellin [+ Levodopa] (PL);",
"     </li>",
"     <li>",
"      Nakom [+ Levodopa] (PL);",
"     </li>",
"     <li>",
"      Pardopa [+ Levidopa] (PL);",
"     </li>",
"     <li>",
"      Poldomet [+ Levidopa] (PL);",
"     </li>",
"     <li>",
"      Sinemet [+ Levodopa] (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F145993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carbidopa is a peripheral decarboxylase inhibitor with little or no pharmacological activity when given alone in usual doses. It inhibits the peripheral decarboxylation of levodopa to dopamine; and as it does not cross the blood-brain barrier, unlike levodopa, effective brain concentrations of dopamine are produced with lower doses of levodopa. At the same time, reduced peripheral formation of dopamine reduces peripheral side-effects, notably nausea and vomiting, and cardiac arrhythmias, although the dyskinesias and adverse mental effects associated with levodopa therapy tend to develop earlier.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F146006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Distribution: Does not cross the blood-brain barrier",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9200 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3221=[""].join("\n");
var outline_f3_9_3221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146016\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146022\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146017\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146018\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146002\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145990\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146004\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146003\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3245270\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146020\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146007\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145994\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298969\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145998\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145999\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276948\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276949\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146009\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146008\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13457241\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146010\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145993\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146006\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9200|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/27/10676?source=related_link\">",
"      Carbidopa: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_9_3222="Brompheniramine, pseudoephedrine, and dextromethorphan: Drug information";
var content_f3_9_3222=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brompheniramine, pseudoephedrine, and dextromethorphan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/8/10373?source=see_link\">",
"    see \"Brompheniramine, pseudoephedrine, and dextromethorphan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anaplex&reg; DM;",
"     </li>",
"     <li>",
"      Bromaline&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Bromdex D;",
"     </li>",
"     <li>",
"      Bromfed&reg; DM;",
"     </li>",
"     <li>",
"      Bromphenex&trade; DM [OTC];",
"     </li>",
"     <li>",
"      Brotapp-DM;",
"     </li>",
"     <li>",
"      LoHist PSB DM [OTC];",
"     </li>",
"     <li>",
"      Myphetane DX [DSC];",
"     </li>",
"     <li>",
"      Neo DM;",
"     </li>",
"     <li>",
"      PediaHist DM;",
"     </li>",
"     <li>",
"      Q-Tapp Cold &amp; Cough [OTC];",
"     </li>",
"     <li>",
"      Resperal-DM",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F553981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Cough and upper respiratory symptoms associated with common cold:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anaplex&reg; DM: 5 mL every 4-6 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bromaline&reg; DM: 20 mL every 4-6 hours (maximum: 4 doses/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F142731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Cough and upper respiratory symptoms:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2-6 years (Anaplex&reg; DM): 1.25 mL every 4-6 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     6-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anaplex&reg; DM: 2.5 mL every 4-6 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bromaline&reg; DM: 10 mL every 4-6 hours (maximum: 4 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bromaline&reg; DM: Brompheniramine maleate 1 mg, pseudoephedrine hydrochloride 15 mg, and dextromethorphan hydrobromide 5 mg per 5 mL (120 mL [DSC], 480 mL) [ethanol free; contains sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bromphenex&trade; DM: Brompheniramine maleate 4 mg, pseudoephedrine hydrochloride 60 mg, and dextromethorphan hydrobromide 30 mg per 5 mL (480 mL) [contains propylene glycol; ethanol free, dye free, sugar free; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brotapp-DM: Brompheniramine maleate 1 mg, pseudoephedrine hydrochloride 15 mg, and dextromethorphan hydrobromide 5 mg per 5 mL (120 mL, 240 mL) [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LoHist PSB DM: Brompheniramine maleate 4 mg, pseudoephedrine hydrochloride 20 mg, and dextromethorphan hydrobromide 20 mg per 5 mL (473 mL) [dye free, ethanol free, sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Tapp Cold &amp; Cough: Brompheniramine maleate 1 mg, pseudoephedrine hydrochloride 15 mg, and dextromethorphan hydrobromide 5 mg per 5 mL (118 mL) [ethanol free; contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PediaHist DM: Brompheniramine maleate 1 mg, pseudoephedrine hydrochloride 15 mg, and dextromethorphan hydrobromide 4 mg per 1 mL (30 mL) [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Resperal-DM: Brompheniramine maleate 1 mg, pseudoephedrine hydrochloride 12 mg, and dextromethorphan hydrobromide 5 mg per 1 mL (30 mL) [dye free, ethanol free, gluten free; contains proplylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: Brompheniramine maleate 4 mg, pseudoephedrine hydrochloride 60 mg, and dextromethorphan hydrobromide 30 mg per 5 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anaplex&reg; DM: Brompheniramine maleate 4 mg, pseudoephedrine hydrochloride 60 mg, and dextromethorphan hydrobromide 30 mg per 5 mL (480 mL) [ethanol free, dye free, sugar free; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bromdex D: Brompheniramine maleate 3 mg, pseudoephedrine hydrochloride 50 mg, and dextromethorphan hydrobromide 30 mg per 5 mL (480 mL) [ethanol free, sugar free;  contains sodium benzoate; berry-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bromfed&reg; DM: Brompheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg, and dextromethorphan hydrobromide 10 mg per 5 mL (473 mL) [contains ethanol 0.95%, propylene glycol, sodium benzoate; butterscotch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myphetane DX: Brompheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg, and dextromethorphan hydrobromide 10 mg per 5 mL (480 mL) [contains ethanol &lt;1%; butterscotch flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neo DM: Brompheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg, and dextromethorphan hydrobromide 10 mg per 5 mL (473 mL) [contains propylene glycol; berry-vailla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sildec-DM: Brompheniramine maleate 4 mg, pseudoephedrine hydrochloride 45 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (480 mL) [grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of cough and upper respiratory symptoms (including nasal congestion) associated with allergy or the common cold",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, flushing, hypertension, pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Convulsions, CNS stimulation, dizziness, drowsiness, excitability (children; rare), giddiness, hallucinations, headache, insomnia, irritability, lassitude, nervousness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dyspepsia, GI upset, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular skeletal: Tremors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Dysuria, polyuria, urinary retention (with BPH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory difficulty",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to brompheniramine, pseudoephedrine, dextromethorphan or any component of the formulation; severe hypertension or coronary artery disease; MAO inhibitor therapy; GI or GU obstruction; peptic ulcer disease; narrow-angle glaucoma; acute asthma attack",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in sedated, debilitated patients confined to supine position.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children. Use with caution in atopic children.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F142732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F142723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effect.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Brompheniramine maleate is an antihistamine with H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor activity; pseudoephedrine, a sympathomimetic amine and isomer of ephedrine, acts as a decongestant in respiratory tract mucous membranes with less vasoconstrictor action than ephedrine in normotensive individuals; dextromethorphan, a non-narcotic antitussive, increases cough threshold by its activity on the medulla oblongata.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8698 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3222=[""].join("\n");
var outline_f3_9_3222=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142725\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F553981\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142726\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142731\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062968\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142716\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142703\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142717\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142733\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142719\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142707\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142732\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142711\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142723\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142706\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8698\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8698|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/8/10373?source=related_link\">",
"      Brompheniramine, pseudoephedrine, and dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_9_3223="Alfentanil: Drug information";
var content_f3_9_3223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alfentanil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/41/41620?source=see_link\">",
"    see \"Alfentanil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2903?source=see_link\">",
"    see \"Alfentanil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alfenta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alfentanil Injection, USP;",
"     </li>",
"     <li>",
"      Alfenta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Anilidopiperidine Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated to appropriate effects; wide range of doses is dependent upon desired degree of analgesia/anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anesthesia:",
"     </b>",
"     I.V.: Dose should be based on ideal body weight as follows (see table).",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Alfentanil",
"     </caption>",
"     <col align=\"center\" width=\"77\">",
"     </col>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"64\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"69\">",
"     </col>",
"     <col align=\"left\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Indication",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approx Duration of Anesthesia (min)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Induction Period (Initial Dose) (mcg/kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Maintenance Period (Increments/ Infusion)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Total Dose (mcg/kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Effects",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Incremental injection",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &le;30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-5 mcg/kg or 0.5-1 mcg/kg/min",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8-40",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Spontaneously breathing or assisted ventilation when required.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20-50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-15 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Up to 75",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Assisted or controlled ventilation required. Attenuation of response to laryngoscopy and intubation.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Continuous infusion",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-3 mcg/kg/min; average infusion rate 1-1.5 mcg/kg/min",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dependent on duration of procedure",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Assisted or controlled ventilation required. Some attenuation of response to intubation and incision, with intraoperative stability.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Anesthetic induction",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130-245",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-1.5 mcg/kg/min or general anesthetic",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dependent on duration of procedure",
"        </p>",
"       </td>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Assisted or controlled ventilation required. Administer slowly (over 3 minutes). Concentration of inhalation agents reduced by 30% to 50% for initial hour.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F131484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2903?source=see_link\">",
"      see \"Alfentanil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;12 years: Dose has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 500 mcg/mL (2 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alfenta&reg;: 500 mcg/mL (2 mL, 5 mL, 10 mL [DSC], 20 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F131505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F131455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. slowly over 3-5 minutes or by I.V. continuous infusion.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10 mg in 250 mL (total volume) (concentration: 40",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F131510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Bivalirudin, cisatracurium, dexmedetomidine, etomidate, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, propofol, remifentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, thiopental.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atracurium, midazolam, morphine, ondansetron.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesic adjunct  for the induction and maintenance of general anesthesia; analgesic component for monitored anesthesia care (MAC)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alfentanil may be confused with Anafranil&reg;, fentanyl, remifentanil, sufentanil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alfenta&reg; may be confused with Sufenta&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, peripheral vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness, sedation, intracranial pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Antidiuretic hormone release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia, orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Confusion, CNS depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Convulsions, mental depression, paradoxical CNS excitation or delirium, dizziness, dysesthesia, rash, urticaria, itching, biliary tract spasm, urinary tract spasm, respiratory depression, bronchospasm, laryngospasm, physical and psychological dependence with prolonged use; cold, clammy skin",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alfentanil hydrochloride, to narcotics, or any component of the formulation; increased intracranial pressure, severe respiratory depression",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opioid agonist toxicities: Shares the toxic potentials of opiate agonists, and precautions of opiate agonist therapy should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradyarrhythmias: Use with caution when administering to patients with bradyarrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: Hypotension has occurred in neonates with respiratory distress syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years old.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid infusion: Inject slowly over 3-5 minutes; rapid I.V. infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest; nondepolarizing skeletal muscle relaxant may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained individuals: Due to the high incidence of apnea, hypotension, tachycardia and muscle rigidity; it should be administered by individuals specifically trained in the use of anesthetic agents and should not be used in diagnostic or therapeutic procedures outside the monitored anesthesia setting; resuscitative and intubation equipment should be readily available.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F131499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Anilidopiperidine Opioids may enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Anilidopiperidine Opioids may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Alfentanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of Alfentanil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Alfentanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Alfentanil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fospropofol: Alfentanil may enhance the adverse/toxic effect of Fospropofol. Specifically, the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or grand mal seizures.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Alfentanil.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Anilidopiperidine Opioids may enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.  Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propofol: Alfentanil may enhance the adverse/toxic effect of Propofol. Specifically the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or grand mal seizures.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Alfentanil. Management: Monitor closely for decreased alfentanil effectiveness.  Increased alfentanil doses will likely be needed.  Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10112601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alfentanil is known to cross the placenta, which may result in respiratory or CNS depression in the newborn. Use during  labor and delivery is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Alfenta Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/mL (2 mL): $10.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection",
"     </b>",
"     (Alfentanil Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/mL (2 mL): $4.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F131448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F131452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     100-340 ng/mL (depending upon procedure)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alfast (BR);",
"     </li>",
"     <li>",
"      Alfenil (KP);",
"     </li>",
"     <li>",
"      Brevafen (AR);",
"     </li>",
"     <li>",
"      Fanaxal (ES);",
"     </li>",
"     <li>",
"      Fentalim (IT);",
"     </li>",
"     <li>",
"      Rapifen (AE, AT, AU, BE, BG, BH, BR, CH, CN, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MT, NL, NO, NZ, OM, PL, PT, PY, QA, RU, SA, SE, SG, SK, SY, TR, TW, UY, VE, YE, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds with stereospecific receptors at many sites within the CNS, increases pain threshold, alters pain perception, inhibits ascending pain pathways; is an ultra short-acting narcotic",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F131457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (dose dependent): 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Newborns, premature: 1 L/kg; Children: 0.163-0.48 L/kg; Adults: 0.46 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Newborns, premature: 5.33-8.75 hours; Children: 40-60 minutes; Adults: 83-97 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bartkowski RR and McDonnell TE, &ldquo;Prolonged Alfentanil Effect Following Erythromycin Administration,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1990, 73(3):566-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/9/3223/abstract-text/2203286/pubmed\" id=\"2203286\" target=\"_blank\">",
"        2203286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartkowski RR, Goldberg ME, Larijani GE, et al, &ldquo;Inhibition of Alfentanil Metabolism by Erythromycin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1989, 46(1):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/9/3223/abstract-text/2501060/pubmed\" id=\"2501060\" target=\"_blank\">",
"        2501060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bodenham A and Park GR, &ldquo;Alfentanil Infusions in Patients Requiring Intensive Care,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1988, 15(4):216-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/9/3223/abstract-text/3142717/pubmed\" id=\"3142717\" target=\"_blank\">",
"        3142717",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis PJ, Killian A, Stiller RL, et al, &ldquo;Pharmacokinetics of Alfentanil in Newborn Premature Infants and Older Children,&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1989, 13(1):21-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/9/3223/abstract-text/2505988/pubmed\" id=\"2505988\" target=\"_blank\">",
"        2505988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkham SR and Pugh R, &ldquo;Opioid Analgesia in Uraemic Patients,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8958):1185.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marlow N, Weindling AM, Van Peer A, et al, &ldquo;Alfentanil Pharmacokinetics in Preterm Infants,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1990, 65(4 Spec No):349-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/9/3223/abstract-text/2337359/pubmed\" id=\"2337359\" target=\"_blank\">",
"        2337359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meistelman C, Saint-Maurice C, Lepaul M, et al, &ldquo;A Comparison of Alfentanil Pharmacokinetics in Children and Adults,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1987, 66(1):13-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/9/3223/abstract-text/3099603/pubmed\" id=\"3099603\" target=\"_blank\">",
"        3099603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/9/3223/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pokela ML, Ryhanen PT, Koivisto ME, et al, &ldquo;Alfentanil-Induced Rigidity in Newborn Infants,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1992, 75(2):252-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/9/3223/abstract-text/1632539/pubmed\" id=\"1632539\" target=\"_blank\">",
"        1632539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scholz J, Steinfath M, and Schulz M, &ldquo;Clinical Pharmacokinetics of Alfentanil, Fentanyl, and Sufentanil. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1996, 31(4):275-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/9/3223/abstract-text/8896944/pubmed\" id=\"8896944\" target=\"_blank\">",
"        8896944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9347 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-41.78.124.10-CD13024F2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3223=[""].join("\n");
var outline_f3_9_3223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131467\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131468\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131503\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131470\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131484\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131471\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671392\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671393\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131451\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131436\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131505\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131455\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471261\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131510\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131454\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131512\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131501\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131458\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131440\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131499\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131445\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131447\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10112601\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322969\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131448\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131452\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038321\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131439\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131457\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9347\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9347|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/41/41620?source=related_link\">",
"      Alfentanil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/53/2903?source=related_link\">",
"      Alfentanil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_9_3224="Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families";
var content_f3_9_3224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/9/3224/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/9/3224/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/9/3224/contributors\">",
"     Dennis J Ahnen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/9/3224/contributors\">",
"     Lisen Axell, MS, CGC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/9/3224/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/9/3224/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/9/3224/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/9/3224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/9/3224/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/9/3224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16735291\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features that raise the suspicion of a familial form of cancer susceptibility in a patient diagnosed with any type of malignancy include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A cancer that occurs at an unusually young age compared with its usual presentation",
"     </li>",
"     <li>",
"      The development of multiple tumors in a single organ, or bilateral development of tumors in paired organs",
"     </li>",
"     <li>",
"      The development of more than one primary tumor of any type",
"     </li>",
"     <li>",
"      A family history of cancer of the same type or related type in one or more first degree relatives",
"     </li>",
"     <li>",
"      A high rate of cancer occurrence in the family",
"     </li>",
"     <li>",
"      Cancer occurring in an individual or within a family with congenital anomalies or birth defects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The genetics underlying an inherited predisposition to cancer are rapidly being uncovered, and have led to the routine use of molecular tools to diagnose many of these disorders, and to interventions to prevent the development of cancer. A searchable online catalog of cancer family syndromes published through the National Center for Biotechnology Information is available online at:",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim\">",
"     www.ncbi.nlm.nih.gov/omim",
"    </a>",
"    . A concise handbook has also been published [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the multiple cancer family syndromes, several are known to be associated with the development of colon cancer, including adenomatous and hamartomatous polyposis syndromes (eg, familial adenomatous polyposis, MUTYH associated polyposis, Peutz-Jeghers syndrome, juvenile polyposis) and Lynch syndrome. These disorders may be diagnosed during evaluation of an individual patient or during screening of family members who are known to be at risk. Although the effectiveness of screening and surveillance strategies is unproven in controlled clinical trials, the high cancer risk in these syndromes warrants screening, and reasonable recommendations can be made. For those disorders for which genetic tests are available, a list of testing laboratories can be obtained through the Genetic Testing Resource (",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ). A listing of national genetic counselors is available at:",
"    <a class=\"external\" href=\"file://www.nsgc.org/\">",
"     www.nsgc.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    This topic review will discuss the recommendations for screening and surveillance of index patients and their families with Peutz-Jeghers syndrome (PJS) and juvenile polyposis. The diagnosis of PJS, the management of patients and families with other hereditary colon cancer syndromes, screening strategies in patients with a family history of colorectal cancer or colonic polyps who are not known to have one of the above conditions, and screening strategies in patients at average risk for colorectal cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other genetic syndromes are associated with gastrointestinal polyposis. The risk of colon cancer in these diseases is uncertain, and may not be increased. Examples include Cowden and Bannayan-Riley-Ruvalcaba syndromes (both part of the spectrum of PTEN hamartoma tumor syndromes), intestinal ganglioneuromatosis, Devon family syndrome, and Cronkhite-Canada syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    .) These rare disorders will not be discussed in this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21759646\">",
"    <span class=\"h1\">",
"     PEUTZ-JEGHERS SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peutz-Jeghers syndrome (PJS) is an autosomal dominant disease that in most families has been mapped to a gene on chromosome 19p13.3, close to marker D19S886 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The defect in these families involves mutations in a gene encoding a serine threonine kinase (STK11); the germline mutations of this gene, perhaps in combination with acquired genetic defects of the second allele in somatic cells, are thought to be responsible for the clinical manifestations of PJS. Mutations in the STK11 gene are found in 80 to 90 percent of individuals with clinical features of PJS.",
"   </p>",
"   <p>",
"    PJS is characterized by the presence of numerous pigmented spots on the lips and the buccal mucosa (",
"    <a class=\"graphic graphic_picture graphicRef80815 \" href=\"UTD.htm?5/20/5455\">",
"     picture 1",
"    </a>",
"    ) and multiple gastrointestinal hamartomatous polyps (",
"    <a class=\"graphic graphic_picture graphicRef67988 \" href=\"UTD.htm?0/22/354\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef81889 graphicRef69268 \" href=\"UTD.htm?40/43/41658\">",
"     picture 3A-B",
"    </a>",
"    ). The lip pigmentation usually appears by age two, but may fade with age. In contrast, buccal mucosal pigmentation usually persists into adulthood. Hamartomas occur most commonly in the small intestine (65 to 95 percent), but can also occur in the colon (60 percent) and the stomach (50 percent). Patients with PJS tend to develop recurrent bouts of small bowel intussusception, obstruction, and bleeding, often requiring recurrent bowel resections. The mean age of onset of symptoms is young adulthood (early 20s); however, symptoms can occur in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A clinical diagnosis of Peutz-Jeghers syndrome may be made when any",
"    <strong>",
"     one",
"    </strong>",
"    of the following is present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Two or more histologically confirmed Peutz-Jeghers polyps",
"     </li>",
"     <li>",
"      Any number of Peutz-Jeghers polyps detected in an individual who has a family history of PJS in a close relative",
"     </li>",
"     <li>",
"      Characteristic mucocutaneous pigmentation in an individual who has a family history of PJS in a close relative",
"     </li>",
"     <li>",
"      Any number of Peutz-Jeghers polyps in an individual who also has characteristic mucocutaneous pigmentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall cancer risk in patients with PJS is markedly increased for both gastrointestinal and nongastrointestinal sites. It is estimated that the relative risk of any cancer is up to 15-fold higher than the general population. In a meta-analysis that included 210 individuals, the cumulative risk for all cancer was 93 percent from age 15 to 64 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/5\">",
"     5",
"    </a>",
"    ]. Markedly increased lifetime risks of cancer were observed for cancers of the stomach (29 percent), small intestine (13 percent), colon (39 percent), pancreas (36 percent), and breast (54 percent). There were also significantly increased estimates of lifetime risk of cancer of the esophagus (0.5 percent), lung (15 percent), uterus (9 percent), and ovary (21 percent).",
"   </p>",
"   <p>",
"    The risk of gastric, small intestinal, and colorectal cancer is thought to occur via dysplastic change within the hamartomas. Dysplastic changes have been found in 3 to 6 percent of hamartomas removed from patients with PJS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21759653\">",
"    <span class=\"h2\">",
"     Screening and surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the risk of complications related to polyps and the risk of malignancy, screening is recommended for individuals with clinical features of PJS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with an STK11 mutation. None of the screening recommendations for this disease have been validated in clinical trials, but multiple groups of experts have proposed surveillance recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. A group of European experts on inherited colon cancer syndromes met in 2007 and conducted a review of all the current literature on PJS clinical features, management, and genotype-phenotype studies. The group proposed guidelines for the surveillance and management of individuals with PJS which are summarized below [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21759660\">",
"    <span class=\"h3\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual complete blood count, liver function tests, and annual clinical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21762797\">",
"    <span class=\"h3\">",
"     Polyp detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic polypectomy should be performed for polyps &gt;1 cm; large polyps in the small bowel may require surgery, although endoscopic approaches may be feasible (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=see_link&amp;anchor=H388475172#H388475172\">",
"     \"Overview of deep small bowel enteroscopy\", section on 'Therapeutic applications'",
"    </a>",
"    ). In addition, clearing the small bowel of polyps at laparotomy reduces the need for recurrent small bowel surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopic surveillance should include [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline upper gastrointestinal endoscopy and colonoscopy at age eight years. If polyps are detected, the examinations should be repeated every three years until the age of 50 years. If no polyps are detected, the examinations should be repeated at age 18 years, or sooner if symptoms arise, then every three until the age of 50 years.",
"     </li>",
"     <li>",
"      Colonoscopy every one to two years after age 50 years because of the rapid increase in cancer risk after this age.",
"     </li>",
"     <li>",
"      Small bowel screening with video capsule endoscopy starting at age eight years. The examination is repeated every three years if polyps are found at the initial examination or earlier if the patient is symptomatic. If few or no polyps are found at the initial examination, the examination should be repeated at age 18 years, or sooner if symptoms arise, and then every three years.",
"      <br/>",
"      <br/>",
"      Small bowel imaging with magnetic resonance enterography or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      follow-through is a reasonable alternative. However, barium follow-through is not favored in children due to the radiation exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations differ from others in that they recommend a baseline gastrointestinal tract assessment at a younger age than recommended by other groups. The rationale for starting earlier is so that those with polyps are picked up at a young age to prevent problems in late",
"    <span class=\"nowrap\">",
"     childhood/early",
"    </span>",
"    adolescence, which is when most obstructions occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21759668\">",
"    <span class=\"h3\">",
"     Genital tract malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PJS are at increased risk of Sertoli cell tumors, with a mean age at diagnosis of nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/10\">",
"     10",
"    </a>",
"    ]. According to the European guidelines, males should have annual examinations with testicular examinations from birth until 12 years of age. If abnormalities are detected on testicular examination, a testicular ultrasound should be obtained. However, testicular cancer has been reported in patients older than 12 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/11\">",
"     11",
"    </a>",
"    ], so continuing exams beyond this age is justifiable.",
"   </p>",
"   <p>",
"    As is recommended for all women, screening for cervical cancer should start at the age of 21 years. Screening should be done using liquid-based cytology and should be repeated every two to three years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine surveillance for ovarian and endometrial cancer is not recommended in the European guidelines. The ovarian tumors seen in PJS are typically sex cord ovarian tumors with annular tubules (SCTAT) and are very rarely epithelial in nature. SCTAT in PJS are typically benign, multifocal, bilateral, very small, and calcified. The authors expressed concern that screening for ovarian cancers in PJS would lead to unnecessary surgeries for benign tumors in a younger cohort of PJS patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other groups, however, have suggested ovarian cancer screening using CA-125, a tumor marker for epithelial ovarian cancer, plus transvaginal ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/8\">",
"     8",
"    </a>",
"    ]. Using CA-125 and transvaginal ultrasound is controversial, even for epithelial ovarian cancer, since there is a high rate of both false positives and false negatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21759683\">",
"    <span class=\"h3\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monthly breast self-examinations are recommended for women starting at age 18 years. Annual breast MRIs are recommended between the ages of 25 and 50 years, followed by annual mammography after the age of 50 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21759690\">",
"    <span class=\"h3\">",
"     Pancreatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is an increased risk for pancreatic cancer with PJS, no recommendations were made for pancreatic screening because screening for pancreatic cancer is difficult and has not been demonstrated to be useful, even in patients at higher risk of developing pancreatic cancer. At present, pancreatic cancer screening is recommended only in the setting of a clinical research study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/7\">",
"     7",
"    </a>",
"    ]. However, other groups have recommended endoscopic ultrasound of the pancreas with or without a CT scan, as well as CA19-9 blood tests every one to two years starting at age 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/8,12\">",
"     8,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21759697\">",
"    <span class=\"h3\">",
"     Screening of first degree relatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;First degree relatives of patients with PJS should be screened beginning at birth with an annual history, physical examination, evaluation for melanotic spots, and evaluation for precocious puberty. In addition, male patients should be examined for testicular tumors. Predictive genetic testing can be offered at around age eight years (in at-risk individuals in whom the diagnosis is not already clinically apparent). The implications of genetic testing at such an early age are incompletely understood but may be justified by prevention of morbidity associated with emergency complications (such as small bowel obstruction), which occur in up to 30 to 40 percent of patients by age 10 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21759704\">",
"    <span class=\"h1\">",
"     JUVENILE POLYPOSIS SYNDROME AND FAMILIAL JUVENILE POLYPOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated juvenile polyps (hamartomas) of the colon are common (occurring in 1 to 2 percent of children), usually solitary, and are not associated with an increased cancer risk (",
"    <a class=\"graphic graphic_picture graphicRef72376 \" href=\"UTD.htm?37/2/37928\">",
"     picture 4",
"    </a>",
"    ). By contrast, juvenile polyposis syndrome (JPS) is often defined as the occurrence of 10 or more juvenile polyps. Approximately one-third of cases of JPS have a history of similar lesions in at least one first degree relative, and are called familial juvenile polyposis (FJP). FJP is a rare (&lt;1 out of 100,000 live births) autosomal dominant disease with high penetrance.",
"   </p>",
"   <p>",
"    JPS has been convincingly shown to be associated with germline mutations in three genes (SMAD4, BMPR1A, and ENG), all of which are related to the transforming growth factor-beta (TGF-beta) signaling pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. About 20 percent of JPS patients have germline mutations in SMAD4. The SMAD4 gene is located on chromosome 18q21.1 and encodes for a cytoplasmic mediator in the TGF-beta signaling pathway. Another 20 percent of JPS patients have germline mutations in the bone morphogenetic protein receptor type 1A (BMPR1A) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/15\">",
"     15",
"    </a>",
"    ]. The BMPR1A gene is located on chromosome 10q22-23 and encodes for a",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinase receptor protein that is also involved in the TGF-beta signaling pathway upstream of SMAD4.",
"   </p>",
"   <p>",
"    An association between JPS due to SMAD4 mutations and hereditary hemorrhagic telangiectasia (HHT) has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/16\">",
"     16",
"    </a>",
"    ]. The association was unexpected from a genetic basis since HHT is caused by mutations in the ENG or ACVRL1 genes and had not been known previously to have an association with SMAD4. However, germline mutations in ENG have been shown to be present in two patients with JPS [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/17\">",
"     17",
"    </a>",
"    ]. The ENG gene, located on chromosome 9q34.1, encodes for the protein endoglin, which is an accessory protein of TGF-beta signaling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role, if any, of the PTEN gene in JPS is debatable. It is currently thought that patients with hamartomatous polyposis and germline PTEN mutations probably have Cowden or Bannayan-Riley-Ruvalcaba (also called Ruvalcaba-Myhre-Smith) syndrome but have not yet expressed the non-intestinal defining features of these syndromes. The mechanism by which any of the known JPS mutations cause hamartomas is not understood, but genetic testing is now commonly available for these syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462459902#H462459902\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Cowden syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462460023#H462460023\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Bannayan-Riley-Ruvalcaba syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462460007#H462460007\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Genetic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with JPS typically develop symptoms between the ages of 4 and 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/18\">",
"     18",
"    </a>",
"    ]. The disease usually presents with rectal bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia (75 percent of cases). Less common presentations include rectal prolapse of polyps, abdominal pain, or intestinal obstruction.",
"   </p>",
"   <p>",
"    JPS is associated with an increased risk for the development of colorectal cancer. Cancer is thought to arise from dysplastic change within the hamartomas, which has been found in approximately 8 to 47 percent of hamartomas from subjects with JPS. The risk of colon carcinoma in affected patients is unknown, but may be as high as 20 percent. In one review of 60 patients with juvenile polyps, 10 had dysplastic epithelium within one or more juvenile polyps, including three with adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/19\">",
"     19",
"    </a>",
"    ]. The average age of diagnosis of dysplasia or adenocarcinoma in this series was 37 years. The risk of developing dysplasia or adenocarcinoma was greatest in patients who had at least three juvenile polyps or a family history of juvenile polyps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21759711\">",
"    <span class=\"h2\">",
"     Screening and surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;No consensus has been established for optimal screening of asymptomatic individuals at risk for FJP or for the surveillance and clinical management of patients with known juvenile polyposis.",
"   </p>",
"   <p>",
"    Asymptomatic first degree relatives of patients with FJP are at risk for juvenile polyposis and colorectal cancer and should be screened for the disease. If the gene responsible for FJP in the family is known or can be identified, genetic screening of at-risk relatives can be done and endoscopic screening reserved for gene carriers. If the gene is not known or genetic testing is negative, endoscopic screening for family members is warranted. As an example, in one kindred of 34 patients of whom 15 family members were investigated, juvenile polyps were found in 11 (73 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/20\">",
"     20",
"    </a>",
"    ]. In another kindred of 118 family members, four died of colonic malignancy between the ages of 30 and 55 years, and another five had juvenile polyps throughout the colon that included large lobulated polyps containing dysplastic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/21\">",
"     21",
"    </a>",
"    ]. One reasonable screening strategy includes annual fecal occult blood testing and flexible sigmoidoscopy or colonoscopy every three to five years beginning at age 12 and continuing until approximately age 40. Symptomatic patients should be evaluated regardless of age.",
"   </p>",
"   <p>",
"    A guideline issued by the British Society of Gastroenterology recommends screening at-risk individuals with colonoscopy every one to two years beginning at age 15 to 18 years (or earlier in patients who present with symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/22\">",
"     22",
"    </a>",
"    ]. Screening intervals can be extended at age 35 years.",
"   </p>",
"   <p>",
"    By contrast, documented gene carriers or affected patients should undergo surveillance until age 70 years. Colonoscopic polypectomy with regular surveillance every one to three years, depending on the presence and number of polyps, is probably adequate therapy if only a small number of polyps are present [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/18\">",
"     18",
"    </a>",
"    ]. Prophylactic surgery can be considered for those [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      With a large number of polyps",
"     </li>",
"     <li>",
"      With multiple polyps that have adenomatous change and high-grade dysplasia",
"     </li>",
"     <li>",
"      In whom polyps cannot be removed endoscopically",
"     </li>",
"     <li>",
"      In whom complications (such as bleeding) are not easily controlled",
"     </li>",
"     <li>",
"      Who have a family history of colorectal cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Upper gastrointestinal surveillance has been recommended every one to two years beginning at age 25 by upper",
"    <span class=\"nowrap\">",
"     endoscopy/enteroscopy,",
"    </span>",
"    upper gastrointestinal series, or small bowel follow-through [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/22\">",
"     22",
"    </a>",
"    ]. The usefulness of video capsule endoscopy for identification of intestinal polyps is not yet defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"     \"Wireless video capsule endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, screening patients with known mutations in SMAD4 or ENG for concomitant HHT is warranted. In the absence of genetic testing, the diagnosis of HHT is established by the presence of at least three of the following criteria: epistaxis, telangiectasias, visceral lesions, or an appropriate family history [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3224/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       \"Patient information: Colonoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"       \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21762689\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peutz-Jeghers syndrome (PJS) is an autosomal dominant disease characterized by the presence of numerous pigmented spots on the lips and the buccal mucosa (",
"      <a class=\"graphic graphic_picture graphicRef80815 \" href=\"UTD.htm?5/20/5455\">",
"       picture 1",
"      </a>",
"      ) and multiple gastrointestinal hamartomatous polyps. (See",
"      <a class=\"local\" href=\"#H21759646\">",
"       'Peutz-Jeghers syndrome'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because of the risk of complications related to polyps and the risk of malignancy, we suggest the following approach for individuals with clinical features of PJS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with an STK11 mutation (see",
"      <a class=\"local\" href=\"#H21759653\">",
"       'Screening and surveillance'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Endoscopic polypectomy for polyps &gt;1 cm; large polyps in the small bowel may require surgery, although endoscopic approaches may be feasible. (See",
"      <a class=\"local\" href=\"#H21762797\">",
"       'Polyp detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men should have annual examinations with testicular examinations from birth until at least 12 years of age. If abnormalities are detected on testicular examination, a testicular ultrasound should be obtained. (See",
"      <a class=\"local\" href=\"#H21759668\">",
"       'Genital tract malignancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As is recommended for all women, screening for cervical cancer should start at the age of 21 years. Recommendations vary with regard to screening for ovarian cancer. (See",
"      <a class=\"local\" href=\"#H21759668\">",
"       'Genital tract malignancies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monthly breast self-examinations are recommended for women starting at age 18 years. Annual breast MRIs are recommended between the ages of 25 and 50 years, followed by annual mammography after the age of 50 years. (See",
"      <a class=\"local\" href=\"#H21759683\">",
"       'Breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Juvenile polyposis syndrome (JPS) is often defined as the occurrence of 10 or more juvenile polyps. Approximately one-third of cases of JPS have a history of similar lesions in at least one first degree relative, and are called familial juvenile polyposis (FJP). (See",
"      <a class=\"local\" href=\"#H21759704\">",
"       'Juvenile polyposis syndrome and familial juvenile polyposis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FJP is associated with an increased risk for the development of colorectal cancer; the risk may be as high as 20 percent. (See",
"      <a class=\"local\" href=\"#H21759704\">",
"       'Juvenile polyposis syndrome and familial juvenile polyposis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No consensus has been established for optimal screening of asymptomatic individuals at risk for FJP or for the surveillance and clinical management of patients with known juvenile polyposis.",
"      <br/>",
"      <br/>",
"      We suggest the following approach in patients with juvenile polyposis (see",
"      <a class=\"local\" href=\"#H21759711\">",
"       'Screening and surveillance'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Colonoscopy every one to two years beginning at age 15 to 18 years (or earlier in patients who present with symptoms). Screening intervals can be extended at age 35 years if no polyps are found.",
"     </li>",
"     <li>",
"      Documented gene carriers or affected patients should undergo colonoscopic surveillance with removal of all colonic polyps until around age 70 years.",
"     </li>",
"     <li>",
"      Upper gastrointestinal surveillance every one to two years beginning at age 25 years by upper",
"      <span class=\"nowrap\">",
"       endoscopy/enteroscopy,",
"      </span>",
"      upper gastrointestinal series, or small bowel follow-through.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/1\">",
"      Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998; 90:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/2\">",
"      Olschwang S, Markie D, Seal S, et al. Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet 1998; 35:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/3\">",
"      Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/4\">",
"      Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/5\">",
"      Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/6\">",
"      Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998; 128:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/7\">",
"      Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010; 59:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/8\">",
"      van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010; 105:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/9\">",
"      Hinds R, Philp C, Hyer W, Fell JM. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr 2004; 39:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/10\">",
"      Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006; 4:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/11\">",
"      Dreyer L, Jacyk WK, du Plessis DJ. Bilateral large-cell calcifying Sertoli cell tumor of the testes with Peutz-Jeghers syndrome: a case report. Pediatr Dermatol 1994; 11:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/12\">",
"      Edwards DP, Khosraviani K, Stafferton R, Phillips RK. Long-term results of polyp clearance by intraoperative enteroscopy in the Peutz-Jeghers syndrome. Dis Colon Rectum 2003; 46:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/13\">",
"      Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998; 280:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/14\">",
"      Fogt F, Brown CA, Badizadegan K, et al. Low prevalence of loss of heterozygosity and SMAD4 mutations in sporadic and familial juvenile polyposis syndrome-associated juvenile polyps. Am J Gastroenterol 2004; 99:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/15\">",
"      Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001; 28:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/16\">",
"      Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/17\">",
"      Howe JR, Haidle JL, Lal G, et al. ENG mutations in MADH4/BMPR1A mutation negative patients with juvenile polyposis. Clin Genet 2007; 71:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/18\">",
"      Grotsky HW, Rickert RR, Smith WD, Newsome JF. Familial juvenile polyposis coli. A clinical and pathologic study of a large kindred. Gastroenterology 1982; 82:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/19\">",
"      Giardiello FM, Hamilton SR, Kern SE, et al. Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Child 1991; 66:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/20\">",
"      Scott-Conner CE, Hausmann M, Hall TJ, et al. Familial juvenile polyposis: patterns of recurrence and implications for surgical management. J Am Coll Surg 1995; 181:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/21\">",
"      Sharma AK, Sharma SS, Mathur P. Familial juvenile polyposis with adenomatous-carcinomatous change. J Gastroenterol Hepatol 1995; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/22\">",
"      Dunlop MG, British Society for Gastroenterology, Association of Coloproctology for Great Britain and Ireland. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 2002; 51 Suppl 5:V21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/23\">",
"      J&auml;rvinen H, Franssila KO. Familial juvenile polyposis coli; increased risk of colorectal cancer. Gut 1984; 25:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3224/abstract/24\">",
"      Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91:66.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15805 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3224=[""].join("\n");
var outline_f3_9_3224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21762689\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16735291\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21759646\">",
"      PEUTZ-JEGHERS SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21759653\">",
"      Screening and surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21759660\">",
"      - General",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21762797\">",
"      - Polyp detection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21759668\">",
"      - Genital tract malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21759683\">",
"      - Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21759690\">",
"      - Pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21759697\">",
"      - Screening of first degree relatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21759704\">",
"      JUVENILE POLYPOSIS SYNDROME AND FAMILIAL JUVENILE POLYPOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21759711\">",
"      Screening and surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21762689\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/15805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/15805|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/20/5455\" title=\"picture 1\">",
"      Peutz Jeghers oral lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/22/354\" title=\"picture 2\">",
"      Peutz Jeghers colonic polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/48/16137\" title=\"picture 3A\">",
"      PJS duodenal polyp Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/63/35833\" title=\"picture 3B\">",
"      PJS colonic polyp Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/2/37928\" title=\"picture 4\">",
"      Juvenile colonic polyp Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=related_link\">",
"      Overview of deep small bowel enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=related_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_9_3225="Staphylococcal scalded skin syndrome close view";
var content_f3_9_3225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80198%7EDERM%2F72261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80198%7EDERM%2F72261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Staphylococcal scalded skin syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A wrinkled appearance to the skin, bullae, and desquamation are present in this patient with staphylococcal scalded skin syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staphylococcal scalded skin syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse erythema and desqaumation are present in this child with staphylococcal scalded skin syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3225=[""].join("\n");
var outline_f3_9_3225=null;
var title_f3_9_3226="Febrile seizures";
var content_f3_9_3226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Febrile seizures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/9/3226/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/9/3226/contributors\">",
"     Marvin A Fishman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/9/3226/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/9/3226/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/9/3226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/9/3226/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/9/3226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Febrile seizures are a common cause of convulsions in young children. They occur in 2 to 4 percent of children younger than five years of age, but the incidence is as high as 15 percent in some populations. This incidence has been attributed to closer living arrangements among family members making detection more likely, but racial and geographic variations may also be important.",
"   </p>",
"   <p>",
"    The generally accepted criteria for febrile seizures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A convulsion associated with an elevated temperature greater than 38&deg;C",
"     </li>",
"     <li>",
"      A child younger than six years of age",
"     </li>",
"     <li>",
"      No central nervous system infection or inflammation",
"     </li>",
"     <li>",
"      No acute systemic metabolic abnormality that may produce convulsions",
"     </li>",
"     <li>",
"      No history of previous afebrile seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Febrile convulsions are divided into two categories, simple (benign), or complex, based upon clinical features. Simple febrile seizures are the most common and are characterized by seizures that last less than 15 minutes, have no focal features, and, if they occur in a series, the total duration is less than 30 minutes. Complex febrile seizures are characterized by episodes that last more than 15 minutes, have focal features or postictal paresis, and occur in a series with a total duration greater than 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known how or why seizures are generated in response to fever; it may be that fever-induced factors (eg, interleukin-1beta) are proconvulsant in individuals who are susceptible based upon the stage of brain development and genetic susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Certain ion channels in the brain are temperature sensitive and may generate fever-associated synchronized neuronal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. There is also evidence to suggest that hyperthermia-induced hyperventilation and alkalosis may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Febrile seizures can occur during both viral and bacterial infections. In one hospital based study, the incidence of febrile seizures was similar with influenza, adenovirus, and parainfluenza infections (6 to 18 percent), and somewhat less common with respiratory syncytial virus and rotavirus (4 to 5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/8\">",
"     8",
"    </a>",
"    ]. No specific virus was associated with risk of complex febrile seizures or later recurrence. Other studies have reported higher rates of febrile seizures (up to 36 percent in the 12 to 15 month age group) in primary human herpesvirus (HHV)-6 infections and also a higher rate of complex features, recurrence, and febrile status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=see_link&amp;anchor=H4#H4\">",
"     \"Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment\", section on 'Acute febrile illness'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Febrile status epilepticus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of febrile seizures is increased after administration of diphtheria, tetanus toxoid, and whole-cell pertussis (DTP) and measles, mumps, and rubella (MMR) vaccine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .) In a large cohort study, febrile seizures were significantly increased on the day of DTP vaccination and 8 to 14 days following MMR vaccination (adjusted relative risks 5.7 and 2.83, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/12\">",
"     12",
"    </a>",
"    ]. The risk for subsequent seizures or neurodevelopmental disabilities was comparable in children with febrile seizures whether or not they were associated with vaccination; however, because immunization and the clinical onset of neurodevelopmental syndromes occur in early childhood, there may be a perception that the vaccination is causative [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility to febrile seizures has been linked with abnormalities in neurotransmitters. However, whether observed abnormalities were primary events or were secondary to the convulsions is unclear. As an example, the cerebrospinal fluid (CSF) concentration of gamma-aminobutyric acid (GABA), an inhibitory transmitter, was reduced in one series of children who were studied after their first or second febrile seizure; the samples were obtained after the convulsion and, thus, may be the effect rather than the cause of the seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/14\">",
"     14",
"    </a>",
"    ]. Furthermore, low CSF GABA was not confirmed in other studies of children with febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSF neopterin concentrations may be elevated in children with febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/16\">",
"     16",
"    </a>",
"    ]. Because neopterin is secreted by activated macrophages, this observation suggests immune activation within the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron insufficiency may play a role in pathogenesis. In a prospective study of 150 children, mean ferritin levels were significantly lower in children with a first febrile seizure than in matched controls with febrile illness but no convulsions (29.5 versus 53.3",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/17\">",
"     17",
"    </a>",
"    ]. Plasma ferritin levels &le;30",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    occurred in a significantly greater proportion of children with seizures than controls (65 versus 32 percent). Further studies will be required to confirm this preliminary finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic and familial factors appear to be important factors in the expression of febrile convulsions and the subsequent development of epilepsy in some children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. Among first-degree relatives of children with febrile seizures, 10 to 20 percent of parents and siblings also have had or will have febrile seizures. In addition, monozygotic twins have a much higher concordance rate than do dizygotic twins, in whom the rate is similar to that of other siblings.",
"   </p>",
"   <p>",
"    Susceptibility to febrile seizures has been linked to several genetic loci in different families, including the long arm of chromosome 8q13-21 (FEB1) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/19\">",
"     19",
"    </a>",
"    ], chromosome 19p (FEB2) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], chromosome 2q23-24 (FEB3) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/22\">",
"     22",
"    </a>",
"    ], chromosome 5q14-15 (FEB4) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], chromosome 6q22-q24 (FEB5) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/25\">",
"     25",
"    </a>",
"    ], chromosome 6q16.3-22.31 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/26\">",
"     26",
"    </a>",
"    ], chromosome 21q22 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/27\">",
"     27",
"    </a>",
"    ], and perhaps chromosome 18p11.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/28\">",
"     28",
"    </a>",
"    ]. The trait is transmitted in an autosomal dominant fashion. However, susceptibility genes have not been identified in most patients with febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic factors are also believed to be important in nonmendelian forms of febrile seizures. One study suggests that common polymorphism in a sodium channel gene (splice site variant SCN1A) is a common risk factor for febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/29\">",
"     29",
"    </a>",
"    ]. However, this finding was not replicated in a follow-up study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A syndrome of generalized epilepsy with febrile seizures plus (GEFS+) also has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The most common phenotype consists of children who had seizures with fever in early childhood that, unlike typical febrile seizures, continued beyond six years of age or were associated with afebrile tonic clonic seizures as well as other seizure types. The epilepsy typically remits by mid-adolescence, but can persist into adulthood. This disorder is usually autosomal dominantly inherited. Family members who inherit the mutation may only have nonfebrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among different families with GEFS+, a variety of gene loci and mutations have been identified, including chromosome 19q with mutations in the beta-1-subunit of the neuronal sodium channel [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/31,32,34,35\">",
"     31,32,34,35",
"    </a>",
"    ], chromosome 2q with mutations in the alpha-1-subunit of the neuronal sodium channel [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/28,36-40\">",
"     28,36-40",
"    </a>",
"    ], chromosome 8p23-p21 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/41\">",
"     41",
"    </a>",
"    ] and a mutation in the gamma-2 subunit of the GABA-A receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. A mutation in the last gene has also been identified in a family with febrile seizures without associated epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations link febrile seizures with afebrile seizures in some families in an autosomal dominant fashion. In addition, previous studies have shown that siblings and parents of patients with febrile seizures have a 4 to 10 percent incidence of epilepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hippocampal lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach linking febrile seizures and epilepsy was suggested from an evaluation of two families with familial febrile convulsions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/46\">",
"     46",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) was performed in family members who had no seizures, febrile convulsions only, and febrile convulsions with the subsequent development of temporal lobe epilepsy. All subjects with febrile convulsions who did not develop epilepsy and six clinically unaffected relatives showed asymmetry in the size of the hippocampi. In addition to a difference in the size between the right and left hippocampi were changes in the internal architecture of the hippocampal bodies. The authors concluded that a subtle preexisting hippocampal malformation that was present may facilitate febrile convulsions and contribute to the development of subsequent hippocampal sclerosis, which was seen in the patients who developed temporal lobe epilepsy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Subsequent temporal lobe epilepsy'",
"    </a>",
"    below.) Furthermore, the hippocampal malformation did not appear to be a consequence of the febrile convulsions and, therefore, may have been a predisposing factor associated with the development of epilepsy. Developmental abnormalities of the hippocampus, including hippocampal malrotation, have also been reported in 10.5 percent of children presenting with febrile status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Febrile status epilepticus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In another study, the effect of prolonged febrile seizures was evaluated in the immature rat [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/48\">",
"     48",
"    </a>",
"    ]. Prolonged hyperthermia-induced seizures did not lead to spontaneous seizures in adult rats. However, the experimental animals, but not control animals, developed hippocampal seizures after systemic administration of a low dose of kainate, a chemical convulsant, indicative of a reduced seizure threshold. An analogous situation may exist in humans. Individuals predisposed to developing epilepsy, by a variety of factors, may become symptomatic in later years after having their thresholds modified by febrile seizures in infancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Febrile seizures occur in children between the ages of six months and six years, with the majority occurring in children between 12 to 18 months of age. Febrile seizures have been reported in children over six years of age, but in older children, febrile seizures should be considered a diagnosis of exclusion, as they are more likely than younger children with febrile seizures to have subsequent afebrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simple febrile seizures are the most common type encountered in children. Generalized seizures are mainly clonic, but other forms include atonic and tonic spells. The facial and respiratory muscles are commonly involved.",
"   </p>",
"   <p>",
"    Complex febrile seizures (focal features, longer than 15 minutes or multiple episodes within 24 hours) are unusual; prolonged convulsions occur in fewer than 10 percent and focal features in fewer than 5 percent of children with febrile seizures. An initial simple febrile seizure may be followed by complex seizures, but the majority of children who develop complex febrile seizures do so with their first seizure. However, an initial complex febrile seizure does not necessarily indicate that all subsequent seizures will be complex. In one study of 158 children with a first febrile seizure, prolonged seizures (&gt;10 minutes) occurred in 18 percent and were associated with developmental delay and younger age at first seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/50\">",
"     50",
"    </a>",
"    ]. The findings of this study suggest that 10 rather than 15 minutes might be a more appropriate criterion for complex febrile seizure, particularly for purposes of prognosis.",
"   </p>",
"   <p>",
"    Some patients present in febrile status epilepticus, ie, continuous seizures or intermittent seizures without neurologic recovery, either lasting for a period of 30 minutes or longer. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Febrile status epilepticus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The majority of children have their febrile seizures on the first day of illness and, in some cases, it is the first manifestation that the child is ill. The degree of fever associated with febrile convulsions is variable, and approximately 25 percent of events occur when the temperature is between 38&ordm;C and 39&ordm;C. They are often seen as the temperature is increasing rapidly but may develop as the fever is declining. Recurrent febrile seizures do not necessarily occur with the same degree of fever as the first episode and do not occur every time the child has a fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involuntary movements can occur in sick children and be confused with seizures. Shaking chills are usually readily distinguished from seizures. Chills are common and are characterized by fine rhythmic oscillatory movements about a joint. They rarely involve facial or respiratory muscles, which frequently occur during febrile seizures. In addition, chills usually involve both sides of the body simultaneously and are not associated with loss of consciousness, in contrast to children with generalized seizures. Thus, bilateral manifestations without apparent unconsciousness strongly suggest that the movements are not convulsive.",
"   </p>",
"   <p>",
"    An underlying metabolic disorder presenting as a seizure in a febrile child is rare. In such children, the history and physical examination yield clues of an underlying problem. Infants with a history of vomiting, diarrhea, and altered fluid intake may have electrolyte abnormalities (eg, hypernatremia, hyponatremia) that can lead to seizures.",
"   </p>",
"   <p>",
"    Meningitis and encephalitis are the main concerns in a child presenting with fever and seizures. A thorough evaluation by an experienced clinician almost always will detect the child with meningitis. Although as many as 40 percent, particularly younger infants, who have seizures as an initial manifestation of meningitis do not have meningeal signs, they have other symptoms and findings that strongly suggest the correct diagnosis.",
"   </p>",
"   <p>",
"    It is exceedingly rare for bacterial meningitis to be detected on the basis of doing a \"routine\" evaluation of the CSF after a febrile seizure. When the only indication for performing a lumbar puncture is the seizure, meningitis will be found in less than 1 percent of patients and less than one-half of these will have bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with status epilepticus (SE) and fever are more likely to have bacterial meningitis than those with a short seizure. Meningitis must be considered as a diagnostic possibility in children with SE and fever (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Febrile status epilepticus'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The emergent evaluation and management of the child with suspected meningitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing is unnecessary in most patients with simple febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3416911\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for a lumbar puncture (LP) with CSF examination to exclude meningitis or encephalitis in children with a febrile seizure is uncertain. A retrospective cohort review of 704 patients aged 6 to 18 months who presented with a first simple febrile seizure revealed that 38 percent underwent LP [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/53\">",
"     53",
"    </a>",
"    ]. There were no diagnoses of bacterial meningitis made in children in whom this was not otherwise suspected clinically; leukocytosis was present in 3.8 percent. CSF cultures revealed no pathogens, but in 10 cases (3.8 percent) a contaminant grew. A separate study in children with complex febrile seizures revealed similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While routine performance of LP in all children with febrile convulsions does not seem warranted, the American Academy of Pediatrics (AAP) recommendations regarding the performance of LP in the setting of febrile seizures are the following [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LP should be performed when there are meningeal signs or symptoms or other clinical features that suggest a possible meningitis or intracranial infection.",
"     </li>",
"     <li>",
"      LP should be considered in infants between 6 and 12 months if the immunization status for Haemophilus influenzae type B or Streptococcus pneumoniae is deficient or undetermined.",
"     </li>",
"     <li>",
"      LP should be considered when the patient is on antibiotics because antibiotic treatment can mask the signs and symptoms of meningitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a decision to perform an LP has been made, blood culture and serum glucose testing should be performed concurrently.",
"   </p>",
"   <p>",
"    LP should also be considered when febrile seizures occur after the second day of illness, or when, based on history or examination, the clinician remains concerned about possible central nervous system infection. Based on case series, but not included in the AAP guidelines, febrile status epilepticus may be another possible indication for lumbar puncture (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Febrile status epilepticus'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A finding of pleocytosis in the CSF in a patient with a febrile seizure should be considered a sign of infection until proven otherwise, indicating further evaluation with cultures and in certain cases empiric antimicrobial therapy. While pleocytosis in the CSF has been attributed to an epileptic seizure in some cases, this is rare in the setting of febrile seizure and should be considered a diagnosis of exclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3416918\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete blood count and measurement of serum electrolytes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/60\">",
"     60",
"    </a>",
"    ], blood sugar, calcium, and urea nitrogen is of very low yield; these parameters should be measured only when the patient has a history of vomiting, diarrhea, and abnormal fluid intake, or when physical findings of dehydration or edema exist [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuroimaging with computed tomography (CT) or MRI is not required for children with simple febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/55,58,61\">",
"     55,58,61",
"    </a>",
"    ]. The incidence of intracranial pathology in children presenting with complex febrile seizures also appears to be very low [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Urgent neuroimaging (CT with contrast or MRI) should be done in children with abnormally large heads, a persistently abnormal neurologic examination, particularly with focal features, or signs and symptoms of increased intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/58,61,62\">",
"     58,61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine electroencephalography (EEG) is not warranted, particularly in the setting of a neurologically healthy child with a simple partial febrile seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/55\">",
"     55",
"    </a>",
"    ]. Abnormalities are more likely to be found when the test is performed shortly after the seizure and when convulsions are of long duration and have focal features. While some studies suggest that certain abnormal EEG findings may be associated with the risk of epilepsy, it should not be used as a basis for treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/64\">",
"     64",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Febrile seizures that continue for more than five minutes should be treated. Airway, respiratory status, and circulatory status are continuously assessed in patients with active seizures. Blood should be obtained for electrolytes and glucose determination, if indicated. Antiepileptic drugs should be administered intravenously, if possible, starting with a short-acting benzodiazepine such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    (0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    If the seizure persists, an additional dose may be given. The child's respiratory status needs to be monitored carefully and intubation undertaken if the ventilatory status becomes inadequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistence of the seizure is rare. When it does, the child can be treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23258?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Febrile status epilepticus'",
"    </a>",
"    below). If intravenous access is not possible or if the child is being treated at home,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    rectal gel may be used (0.5",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Recurrent febrile seizures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The fever should be treated as the seizures are controlled. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Management of fever'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recurrent febrile seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;One strategy for the treatment of a recurrent febrile seizure is the use of rectal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    gel if the episode lasts longer than five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/65\">",
"     65",
"    </a>",
"    ]. Parents can be taught to safely give the medication at home, and one dose administered rectally will not lead to respiratory depression.",
"   </p>",
"   <p>",
"    One factor helpful in predicting a prolonged febrile seizure is focality. A strong correlation appears to exist between focality and a prolonged duration of both first and recurrent febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/66\">",
"     66",
"    </a>",
"    ]. In children with recurrent febrile seizures, those with long duration, defined as lasting longer than 10 minutes, tend to have similar features in repeat episodes. Similarly, children who have multiple risk factors for recurrent febrile seizures (focal onset, multiple seizures during the episode) and have a prolonged febrile seizure often have prolonged recurrent febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/66\">",
"     66",
"    </a>",
"    ]. This may be a group of children for whom rectal therapy at the time of occurrence should be strongly considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for children with febrile seizures is favorable. While early reports had suggested that febrile seizures were associated with sudden death, the results from a large population-based study indicate that the small excess in mortality among children with febrile seizures is restricted to those with complex febrile seizures. Furthermore, the increased risk in those patients is explained, at least in part, by pre-existing neurologic abnormalities and subsequent epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Recurrent febrile seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with febrile seizures are at risk for developing recurrent febrile seizures. The overall recurrence rate is approximately 30 to 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, the values vary with age from as high as 50 to 65 percent in children who are younger than one year of age at the time of the first seizure to as low as 20 percent in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/70\">",
"     70",
"    </a>",
"    ]. A major factor influencing the recurrence rate is the age of the infant at the time of the first seizure.",
"   </p>",
"   <p>",
"    A prospective cohort study of 428 children with a first febrile seizure defined other features and factors influencing recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/68\">",
"     68",
"    </a>",
"    ]. Approximately one-third of the children had at least one recurrence, 17 percent had one recurrence, 9 percent had two recurrences, and approximately 6 percent had three or more recurrences. The majority of recurrences (50 to 75 percent) took place within one year of the initial seizure and almost all occurred within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/71\">",
"     71",
"    </a>",
"    ]. Four factors in the prospective cohort study increased the recurrence risk [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Young age at onset",
"     </li>",
"     <li>",
"      History of febrile seizures in a first-degree relative",
"     </li>",
"     <li>",
"      Low degree of fever while in the emergency department",
"     </li>",
"     <li>",
"      Brief duration between the onset of fever and the initial seizure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who had all four factors were much more likely to have a recurrent febrile seizure than were those with none (&ge;70 versus &le;20 percent). Complex features were not associated with the risk of recurrence. These findings were confirmed in another prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors identified in different studies have been abnormal development before the first febrile seizure, a history of afebrile seizures in parents and siblings, recurrence of seizures within the same illness, and the number of subsequent febrile illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/69,71-73\">",
"     69,71-73",
"    </a>",
"    ]. Among children who have had one recurrence, younger age at the time of the first recurrence and a family history of epilepsy are predictors of subsequent recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/68,72\">",
"     68,72",
"    </a>",
"    ]. Another risk factor is an unprovoked seizure after a febrile seizure; such children are at substantial risk for further seizures with fever (rate ratio 3.47 after adjusting for the above risk factors, p = 0.0015) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neurologic sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic sequelae, including new neurologic deficits, intellectual impairment, and behavioral disorder, are rare following febrile convulsions.",
"   </p>",
"   <p>",
"    Most reports documenting neurologic complications have been anecdotal and derived from biased populations consisting of children assessed in hospitals or clinics; in some cases, they may reflect preexisting abnormalities. When new deficits were reported, they occurred only after complex or prolonged febrile seizures.",
"   </p>",
"   <p>",
"    In general, population-based studies do not corroborate anecdotal reports of neurologic complications. In the National Collaborative Perinatal Project, approximately 5 percent of children had febrile seizures lasting longer than 30 minutes. None of these children sustained permanent motor deficits and none had impaired mental development unless they developed afebrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/73\">",
"     73",
"    </a>",
"    ]. Similar findings were noted in a population-based study of 381 children with febrile convulsions in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/75\">",
"     75",
"    </a>",
"    ]. The children were assessed when they were ten years old, and children who had neurologic and developmental problems prior to the first febrile seizure were excluded. No difference was found in measurements of academic progress in children with febrile convulsions, whether simple, complex, or recurrent, compared to a controlled cohort. There was also no difference in behavior between the two groups. Finally, among 18 thousand Danish conscripts aged 18 to 20 years, there was no association found between febrile seizures and cognitive function [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Subsequent epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy occurs more frequently in children who have had febrile seizures than in the general population. In a normal child with a simple febrile seizure, the risk is only slightly above that of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/77\">",
"     77",
"    </a>",
"    ]. Epidemiologic studies have identified risk factors for epilepsy among children with febrile seizures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the National Collaborative Perinatal Project, children with abnormal neurologic development and whose first seizure was complex (focal, multiple, or longer than 15 minutes) had a 9.2 percent incidence of afebrile seizures by seven years of age; a risk 18 times higher than that in children with no history of febrile seizures (0.5 percent) and more than eight times higher than that in normal children with a noncomplex first febrile seizure (1.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Rochester, Minnesota, 687 children with a history of febrile seizures were observed into adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/78\">",
"       78",
"      </a>",
"      ]. Three risk factors for developing epilepsy were identified: focal seizures, prolonged seizures, and repeated episodes within 24 hours during the same illness. The risk of developing epilepsy was 2.4, 6 to 8, 17 to 22, and 49 percent in children with no, one, two, or three of these risk factors, respectively.",
"     </li>",
"     <li>",
"      A population-based study in Denmark also followed children with febrile seizures into adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/79\">",
"       79",
"      </a>",
"      ]. The cumulative incidence of epilepsy was 6.9 percent at 23 years, and the relative risk associated with febrile seizures was 5.4. The risk of epilepsy was higher in those with a family history of epilepsy, cerebral palsy, or low Apgar scores at five minutes.",
"     </li>",
"     <li>",
"      Another cohort study of 181 children with febrile seizure found that the risk of epilepsy was highest in the first five years and appeared to decrease over time [",
"      <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/80\">",
"       80",
"      </a>",
"      ]. Overall, individuals aged 15 to 19 years with a history of febrile seizure appeared to have a similar risk of epilepsy compared with controls, however subgroups of children with febrile seizures who might be at higher risk of epilepsy were not compared.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Subsequent temporal lobe epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a variety of seizure types follow febrile convulsions, whether prolonged febrile convulsions lead to the development of temporal lobe epilepsy is controversial. Reports of patients with refractory temporal lobe epilepsy considered for surgery often find an association with febrile convulsions in infancy, particularly prolonged seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/81\">",
"     81",
"    </a>",
"    ]. In addition, studies assessing hippocampal volume in adults with epilepsy have found an association between a smaller hippocampus and a history of febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Data are conflicting as to whether a correlation exists between the duration of epilepsy and a reduction in hippocampal volume [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/84\">",
"     84",
"    </a>",
"    ]. As noted above, hippocampal abnormalities have also been associated with familial febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hippocampal lesions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The possibility of hippocampal injury induced by febrile seizures was assessed by MRI in infants who had had complex febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/85\">",
"     85",
"    </a>",
"    ]. Abnormalities were found in the children with focal and prolonged complex febrile seizures but not in those with generalized febrile convulsions. In a few children who had significantly longer seizures, MRI suggested acute edema of the hippocampus, a finding noted in other case series as well [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. Follow-up imaging studies in these children may show hippocampal atrophy or abnormal apparent diffusion coefficient measurements. Another study found that hippocampal atrophy and other MRI characteristic of hippocampal sclerosis were more common in adults with a history of febrile seizures in childhood than those without [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/89\">",
"     89",
"    </a>",
"    ]. Although these observations suggest acute injury to the hippocampus during a febrile seizure, the possibility of preexisting lesions leading to susceptibility to injury is not excluded.",
"   </p>",
"   <p>",
"    Studies based mainly upon imaging results and patients being considered for epilepsy surgery suggest an association between febrile seizures and temporal lobe epilepsy. Some clinical studies reached a similar conclusion. In one, patients presenting to an epilepsy clinic because of a previous diagnosis of epilepsy or recent onset of seizures were prospectively questioned about febrile convulsions and their characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/90\">",
"     90",
"    </a>",
"    ]. Febrile convulsions were reported by 13.2 percent of the patients. Temporal lobe epilepsy was more likely to be preceded by febrile convulsions than by other types of epilepsy (25.2 percent versus 5.6 percent, respectively). Prolonged duration was the most common feature of the complex febrile seizure associated with temporal lobe epilepsy, although patients with generalized epilepsy were more likely to have had simple febrile convulsions.",
"   </p>",
"   <p>",
"    However, carefully performed community-based epidemiologic studies have not been able to confirm this association. In one, the characteristics of epilepsy were evaluated in 524 children who were one year of age or older at the onset of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/81\">",
"     81",
"    </a>",
"    ]. Febrile seizures were present in 14 percent of the patients. Complex febrile seizures were associated with a younger age at onset of the epilepsy, but there was no specific association with localization-related forms of epilepsy. No evidence that focal or prolonged febrile seizures were associated with temporal lobe epilepsy was found; three children had hippocampal atrophy demonstrated on their initial MRI, but none had a history of febrile seizures.",
"   </p>",
"   <p>",
"    In summary, febrile seizures do not appear to cause temporal lobe epilepsy. The association may represent an inherent susceptibility in some children who are predisposed to prolonged febrile seizures and epilepsy simultaneously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FEBRILE STATUS EPILEPTICUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged febrile seizure (febrile status epilepticus [FSE]) is a concern for both physicians and parents. A multicenter prospective cohort study described the characteristics of prolonged (&gt;30 minutes) febrile seizures in 119 children, aged one month through five years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/11,91\">",
"     11,91",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The median duration was 68 minutes",
"     </li>",
"     <li>",
"      The seizures were convulsive in all but one child",
"     </li>",
"     <li>",
"      The seizures were continuous in 52 percent and intermittent in 48 percent",
"     </li>",
"     <li>",
"      Two-thirds of seizures were partial",
"     </li>",
"     <li>",
"      This was the first febrile seizure in 76 percent of children",
"     </li>",
"     <li>",
"      Primary or reactivated HHV-6B infection was found in 32 percent of children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chart reviews suggested that status epilepticus was often not recognized by the emergency department staff, perhaps contributing to the long duration of the seizures.",
"   </p>",
"   <p>",
"    The clinical setting in which FSE is not clearly different than shorter febrile seizures. In the multicenter cohort described above, the median peak temperature was 103&ordm;F (39.4&ordm;C), most patients had a defined viral or bacterial illness, and there was a higher than expected family history of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another series, patients with FSE were more likely to have a family history of epilepsy than children who presented with briefer febrile seizures; they also had a higher prevalence of baseline neurologic disease and a personal history of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some reports suggest that children with status epileptics and fever are more likely to have bacterial meningitis than those with a short seizure. A group of 24 children with status epilepticus in the setting of fever were identified over a six month period through a British surveillance study of children with SE [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/56\">",
"     56",
"    </a>",
"    ]. Lumbar puncture was performed in nine patients, four of whom had findings characteristic of bacterial meningitis. The incidence of bacterial meningitis in this report is quite high and may be due, in part, to the small sample size. In another series 11 of 95 children with status epilepticus and fever (11.6 percent) had acute bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/57\">",
"     57",
"    </a>",
"    ]. Thus, meningitis must be considered as a diagnostic possibility in children with presumed FSE.",
"   </p>",
"   <p>",
"    The distribution of seizure durations suggests that the longer a febrile seizure continues the less likely is it to stop without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/91\">",
"     91",
"    </a>",
"    ]. Patients with FSE should be treated with anticonvulsant medication as are other patients with status epilepticus and efforts should be made to lower fever using antipyretics and a cooling blanket. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Management of fever'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long term consequences of FSE have not been defined. Clinical follow-up of the above mentioned cohort is in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/91\">",
"     91",
"    </a>",
"    ]. The significance and predictive value of MRI abnormalities in the hippocampus (abnormal T2 hyperintensity in 11.5 percent, developmental abnormalities in 10.5 percent) found at the time of presentation with FSE are being studied [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/47,91\">",
"     47,91",
"    </a>",
"    ]. Another study followed 44 children with FSE, most of whom were identified prospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/93\">",
"     93",
"    </a>",
"    ]. After a mean follow-up of 28 months, the risk of recurrent seizures (febrile and afebrile) was increased only in those who had prior neurologic abnormalities. This finding is similar to that seen in patients with febrile seizures without status. Other case series have found that EEG studies, performed within one week after FSE, show focal slowing in one-third [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/94\">",
"     94",
"    </a>",
"    ]. While some have found that this is associated with a higher risk of epilepsy, this association has not been consistently reported and requires further study. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Subsequent epilepsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ROLE OF PREVENTIVE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antiepileptic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with febrile seizures are at increased risk for recurrent febrile as well as the development of afebrile seizures, suggesting a role for prophylactic treatment with chronic antiepileptic medications (AEDs). However, given the benign nature of recurrent febrile seizures, there is increasing consensus that risks of AED treatment outweigh potential benefits for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/95-97\">",
"     95-97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of AEDs was evaluated in a meta-analysis of studies for the prevention of recurrent febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/97\">",
"     97",
"    </a>",
"    ]. While treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    , or intermittent oral or rectal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    was associated with reduced risk of recurrent seizures in the short term (six months to two years), this was also associated with a risk of adverse effects in 30 to 40 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/97-101\">",
"     97-101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no available evidence that the use of chronic AEDs or the prevention of recurrent febrile seizures is associated with a reduced risk of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Committee on Quality Improvement, Subcommittee on Febrile Seizures of the AAP concluded that \"Based on the risk and benefits of effective therapies, neither continuous nor intermittent anticonvulsive therapy is recommended for children with one or more simple febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/96\">",
"     96",
"    </a>",
"    ]. The American Academy of Pediatrics recognizes that recurrent episodes of febrile seizures can create anxiety in some parents and their children and as such appropriate educational and emotional support should be provided\".",
"   </p>",
"   <p>",
"    There is no data upon which to base a recommendation regarding AED prophylaxis in children with complex febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/101\">",
"     101",
"    </a>",
"    ]. Treatment in such cases is individualized based upon underlying risk factors, but there is no evidence that supports treatment in any one subset of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antipyresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children who have had febrile seizures, treatment with antipyretics at the time of a febrile illness may be helpful in overall management but does not appear to affect the recurrence rate of febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/96,97,101-103\">",
"     96,97,101-103",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study in which low dose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or a placebo was administered for fever failed to demonstrate a decrease in febrile seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/103\">",
"       103",
"      </a>",
"      ]. However, the fact that the patients also received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"       diazepam",
"      </a>",
"      or a placebo and the fact that all patients apparently received acetaminophen if temperature reached 40 C (104 F) makes the data difficult to interpret.",
"     </li>",
"     <li>",
"      A systematic review of 12 trials (1,509 patients) of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      versus placebo or sponging for treatment of fever concluded that there was insufficient evidence to show whether or not acetaminophen influenced the risk of febrile convulsions [",
"      <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequently published clinical trial randomly assigned 231 children with febrile seizures to receive either rectal",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/59/37808?source=see_link\">",
"       diclofenac",
"      </a>",
"      or placebo at onset of a subsequent febrile episode; patients were simultaneously randomized into one of three subsequent treatment groups (oral placebo versus",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"       acetaminophen",
"      </a>",
"      versus",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ) to begin eight hours after initial treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?3/9/3226/abstract/104\">",
"       104",
"      </a>",
"      ]. In this study, antipyretics were not effective at lowering body temperature or preventing the recurrence of febrile seizures (overall incidence 23 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and management of fever in infants and children\", section on 'Management of fever'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/20/11586?source=see_link\">",
"       \"Patient information: Febrile seizures (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=see_link\">",
"       \"Patient information: Febrile seizures (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28752460\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Febrile seizures occur in children with fever, usually in the setting of systemic bacterial or viral infection. Affected patients are typically between the ages of six months and six years of age and do not have epilepsy, central nervous system infection or inflammation, or other triggers for seizures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Febrile seizures occur in 2 to 4 percent of children younger than five years of age, typically in the setting of infection or after an immunization. Genetic and familial factors appear to be important in the genesis of febrile seizures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Febrile seizures may be simple or complex: (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Simple febrile seizures are the most common and are characterized by seizures that last less than 15 minutes, have no focal features, and, if they occur in a series, the total duration is less than 30 minutes. These are mainly generalized clonic seizures but may also be atonic or tonic in character.",
"     </li>",
"     <li>",
"      Complex febrile seizures are characterized by episodes that last more than 15 minutes, have focal features or postictal paresis, and occur in a series with a total duration greater than 30 minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Febrile status epilepticus (FSE) lasts 30 minutes or longer, but otherwise shares the characteristics of febrile seizures of shorter duration. The longer the seizure continues, the less likely it is to stop without treatment. Patients with FSE should be treated with antiepileptic medication as are other patients with status epilepticus and efforts should be made to lower fever using antipyretics and a cooling blanket. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"       \"Management of status epilepticus in children\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H19\">",
"       'Febrile status epilepticus'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathophysiology and management of fever in infants and children\", section on 'Management of fever'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The need for a lumbar puncture (LP) with CSF examination to exclude meningitis or encephalitis in children with a febrile seizure is uncertain (See",
"      <a class=\"local\" href=\"#H3416911\">",
"       'Lumbar puncture'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      LP should be performed when there are meningeal signs or symptoms or other clinical features that suggest a possible meningitis or intracranial infection.",
"     </li>",
"     <li>",
"      LP should be considered in infants between 6 and 12 months if the immunization status for Haemophilus influenzae type B or Streptococcus pneumoniae is deficient or undetermined.",
"     </li>",
"     <li>",
"      LP should be considered when the patient is on antibiotics because antibiotic treatment can mask the signs and symptoms of meningitis.",
"     </li>",
"     <li>",
"      Other possible indications for LP include a presentation with febrile status epilepticus, febrile seizures occurring after the second day of illness, or other concerns for possible central nervous system infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other laboratory testing, neuroimaging and electroencephalography are required only in specific circumstances. (See",
"      <a class=\"local\" href=\"#H3416918\">",
"       'Other tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with febrile seizures are at risk for recurrent febrile seizures, particularly if they have a young age of onset, a family history of febrile seizures, brief latency between onset of fever and seizures, and a relatively low fever. Epilepsy occurs somewhat more frequently in children who have had febrile seizures than in the general population. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT treating patients with simple febrile seizures with antiepileptic drug (AED) therapy. While AEDs may decrease the risk of recurrent febrile seizures, the prevention of these benign events and generally not considered worth the potential adverse effects of treatment. There is no available evidence that the use of chronic AEDs is associated with a reduced risk of epilepsy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Role of preventive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of AED prophylaxis in children with complex febrile seizures is individualized based upon underlying risk factors. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Antiepileptic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment to lower fever does not appear to affect the recurrence rate of febrile seizures. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Antipyresis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fishman MA. Febrile seizures. In: Principles and Practice of Pediatrics, 3rd, McMillan JA, et al.  (Eds), JB Lippincott, Philadelphia 1999. p.1949.",
"    </li>",
"    <li>",
"     Febrile Seizures, Nelson KB, Ellenberg JH.  (Eds), Raven Press, New York 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/3\">",
"      Nakayama J. Progress in searching for the febrile seizure susceptibility genes. Brain Dev 2009; 31:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/4\">",
"      Heida JG, Mosh&eacute; SL, Pittman QJ. The role of interleukin-1beta in febrile seizures. Brain Dev 2009; 31:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/5\">",
"      Shibasaki K, Suzuki M, Mizuno A, Tominaga M. Effects of body temperature on neural activity in the hippocampus: regulation of resting membrane potentials by transient receptor potential vanilloid 4. J Neurosci 2007; 27:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/6\">",
"      Thomas EA, Hawkins RJ, Richards KL, et al. Heat opens axon initial segment sodium channels: a febrile seizure mechanism? Ann Neurol 2009; 66:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/7\">",
"      Schuchmann S, Schmitz D, Rivera C, et al. Experimental febrile seizures are precipitated by a hyperthermia-induced respiratory alkalosis. Nat Med 2006; 12:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/8\">",
"      Chung B, Wong V. Relationship between five common viruses and febrile seizure in children. Arch Dis Child 2007; 92:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/9\">",
"      Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994; 331:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/10\">",
"      Suga S, Suzuki K, Ihira M, et al. Clinical characteristics of febrile convulsions during primary HHV-6 infection. Arch Dis Child 2000; 82:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/11\">",
"      Epstein LG, Shinnar S, Hesdorffer DC, et al. Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. Epilepsia 2012; 53:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/12\">",
"      Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/13\">",
"      von Spiczak S, Helbig I, Drechsel-Baeuerle U, et al. A retrospective population-based study on seizures related to childhood vaccination. Epilepsia 2011; 52:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/14\">",
"      L&ouml;scher W, Rating D, Siemes H. GABA in cerebrospinal fluid of children with febrile convulsions. Epilepsia 1981; 22:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/15\">",
"      Knight M, Ebert J, Parish RA, et al. gamma-Aminobutyric acid in CSF of children with febrile seizures. Arch Neurol 1985; 42:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/16\">",
"      Kawakami Y, Fukunaga Y, Kuwabara K, et al. Clinical and immunological significance of neopterin measurement in cerebrospinal fluid in patients with febrile convulsions. Brain Dev 1999; 21:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/17\">",
"      Daoud AS, Batieha A, Abu-Ekteish F, et al. Iron status: a possible risk factor for the first febrile seizure. Epilepsia 2002; 43:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/18\">",
"      Kira R, Ishizaki Y, Torisu H, et al. Genetic susceptibility to febrile seizures: case-control association studies. Brain Dev 2010; 32:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/19\">",
"      Wallace RH, Berkovic SF, Howell RA, et al. Suggestion of a major gene for familial febrile convulsions mapping to 8q13-21. J Med Genet 1996; 33:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/20\">",
"      Johnson EW, Dubovsky J, Rich SS, et al. Evidence for a novel gene for familial febrile convulsions, FEB2, linked to chromosome 19p in an extended family from the Midwest. Hum Mol Genet 1998; 7:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/21\">",
"      Kugler SL, Stenroos ES, Mandelbaum DE, et al. Hereditary febrile seizures: phenotype and evidence for a chromosome 19p locus. Am J Med Genet 1998; 79:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/22\">",
"      Peiffer A, Thompson J, Charlier C, et al. A locus for febrile seizures (FEB3) maps to chromosome 2q23-24. Ann Neurol 1999; 46:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/23\">",
"      Nakayama J, Hamano K, Iwasaki N, et al. Significant evidence for linkage of febrile seizures to chromosome 5q14-q15. Hum Mol Genet 2000; 9:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/24\">",
"      Nakayama J, Fu YH, Clark AM, et al. A nonsense mutation of the MASS1 gene in a family with febrile and afebrile seizures. Ann Neurol 2002; 52:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/25\">",
"      Nabbout R, Prud'homme JF, Herman A, et al. A locus for simple pure febrile seizures maps to chromosome 6q22-q24. Brain 2002; 125:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/26\">",
"      Poduri A, Wang Y, Gordon D, et al. Novel susceptibility locus at chromosome 6q16.3-22.31 in a family with GEFS+. Neurology 2009; 73:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/27\">",
"      Hedera P, Ma S, Blair MA, et al. Identification of a novel locus for febrile seizures and epilepsy on chromosome 21q22. Epilepsia 2006; 47:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/28\">",
"      Nakayama J, Yamamoto N, Hamano K, et al. Linkage and association of febrile seizures to the IMPA2 gene on human chromosome 18. Neurology 2004; 63:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/29\">",
"      Schlachter K, Gruber-Sedlmayr U, Stogmann E, et al. A splice site variant in the sodium channel gene SCN1A confers risk of febrile seizures. Neurology 2009; 72:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/30\">",
"      Petrovski S, Scheffer IE, Sisodiya SM, et al. Lack of replication of association between scn1a SNP and febrile seizures. Neurology 2009; 73:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/31\">",
"      Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain 1997; 120 ( Pt 3):479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/32\">",
"      Singh R, Scheffer IE, Crossland K, Berkovic SF. Generalized epilepsy with febrile seizures plus: a common childhood-onset genetic epilepsy syndrome. Ann Neurol 1999; 45:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/33\">",
"      Thomas RH, Johnston JA, Hammond CL, et al. Genetic epilepsy with febrile seizures plus: definite and borderline phenotypes. J Neurol Neurosurg Psychiatry 2012; 83:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/34\">",
"      Scheffer IE, Harkin LA, Grinton BE, et al. Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain 2007; 130:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/35\">",
"      Escayg A, Goldin AL. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia 2010; 51:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/36\">",
"      Wallace RH, Wang DW, Singh R, et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat Genet 1998; 19:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/37\">",
"      Sugawara T, Mazaki-Miyazaki E, Ito M, et al. Nav1.1 mutations cause febrile seizures associated with afebrile partial seizures. Neurology 2001; 57:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/38\">",
"      Baulac S, Gourfinkel-An I, Picard F, et al. A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21-q33. Am J Hum Genet 1999; 65:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/39\">",
"      Lopes-Cendes I, Scheffer IE, Berkovic SF, et al. A new locus for generalized epilepsy with febrile seizures plus maps to chromosome 2. Am J Hum Genet 2000; 66:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/40\">",
"      Zuberi SM, Brunklaus A, Birch R, et al. Genotype-phenotype associations in SCN1A-related epilepsies. Neurology 2011; 76:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/41\">",
"      Baulac S, Gourfinkel-An I, Couarch P, et al. A novel locus for generalized epilepsy with febrile seizures plus in French families. Arch Neurol 2008; 65:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/42\">",
"      Escayg A, MacDonald BT, Meisler MH, et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 2000; 24:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/43\">",
"      Baulac S, Huberfeld G, Gourfinkel-An I, et al. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat Genet 2001; 28:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/44\">",
"      Audenaert D, Schwartz E, Claeys KG, et al. A novel GABRG2 mutation associated with febrile seizures. Neurology 2006; 67:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/45\">",
"      Wallace RH, Marini C, Petrou S, et al. Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet 2001; 28:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/46\">",
"      Fern&aacute;ndez G, Effenberger O, Vinz B, et al. Hippocampal malformation as a cause of familial febrile convulsions and subsequent hippocampal sclerosis. Neurology 1998; 50:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/47\">",
"      Shinnar S, Bello JA, Chan S, et al. MRI abnormalities following febrile status epilepticus in children: the FEBSTAT study. Neurology 2012; 79:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/48\">",
"      Dube C, Chen K, Eghbal-Ahmadi M, et al. Prolonged febrile seizures in the immature rat model enhance hippocampal excitability long term. Ann Neurol 2000; 47:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/49\">",
"      Kim SH, Lee HY, Kim YH. Subsequent afebrile seizure in children who have a first seizure with fever after 6 years of age. Pediatr Neurol 2010; 43:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/50\">",
"      Hesdorffer DC, Benn EK, Bagiella E, et al. Distribution of febrile seizure duration and associations with development. Ann Neurol 2011; 70:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/51\">",
"      Carroll W, Brookfield D. Lumbar puncture following febrile convulsion. Arch Dis Child 2002; 87:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/52\">",
"      Oluwabusi T, Sood SK. Update on the management of simple febrile seizures: emphasis on minimal intervention. Curr Opin Pediatr 2012; 24:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/53\">",
"      Kimia AA, Capraro AJ, Hummel D, et al. Utility of lumbar puncture for first simple febrile seizure among children 6 to 18 months of age. Pediatrics 2009; 123:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/54\">",
"      Kimia A, Ben-Joseph EP, Rudloe T, et al. Yield of lumbar puncture among children who present with their first complex febrile seizure. Pediatrics 2010; 126:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/55\">",
"      Subcommittee on Febrile Seizures, American Academy of Pediatrics. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics 2011; 127:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/56\">",
"      Chin RF, Neville BG, Scott RC. Meningitis is a common cause of convulsive status epilepticus with fever. Arch Dis Child 2005; 90:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/57\">",
"      Chin RF, Neville BG, Peckham C, et al. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet 2006; 368:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/58\">",
"      Sadleir LG, Scheffer IE. Febrile seizures. BMJ 2007; 334:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/59\">",
"      Haeusler GM, Tebruegge M, Curtis N. Question 1. Do febrile convulsions cause CSF pleocytosis? Arch Dis Child 2012; 97:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/60\">",
"      Thoman JE, Duffner PK, Shucard JL. Do serum sodium levels predict febrile seizure recurrence within 24 hours? Pediatr Neurol 2004; 31:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/61\">",
"      Practice parameter: the neurodiagnostic evaluation of the child with a first simple febrile seizure. American Academy of Pediatrics. Provisional Committee on Quality Improvement, Subcommittee on Febrile Seizures. Pediatrics 1996; 97:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/62\">",
"      Teng D, Dayan P, Tyler S, et al. Risk of intracranial pathologic conditions requiring emergency intervention after a first complex febrile seizure episode among children. Pediatrics 2006; 117:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/63\">",
"      Kimia AA, Ben-Joseph E, Prabhu S, et al. Yield of emergent neuroimaging among children presenting with a first complex febrile seizure. Pediatr Emerg Care 2012; 28:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/64\">",
"      Kanemura H, Mizorogi S, Aoyagi K, et al. EEG characteristics predict subsequent epilepsy in children with febrile seizure. Brain Dev 2012; 34:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/65\">",
"      Knudsen FU. Febrile seizures: treatment and prognosis. Epilepsia 2000; 41:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/66\">",
"      Berg AT, Shinnar S. Complex febrile seizures. Epilepsia 1996; 37:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/67\">",
"      Vestergaard M, Pedersen MG, Ostergaard JR, et al. Death in children with febrile seizures: a population-based cohort study. Lancet 2008; 372:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/68\">",
"      Berg AT, Shinnar S, Darefsky AS, et al. Predictors of recurrent febrile seizures. A prospective cohort study. Arch Pediatr Adolesc Med 1997; 151:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/69\">",
"      Offringa M, Bossuyt PM, Lubsen J, et al. Risk factors for seizure recurrence in children with febrile seizures: a pooled analysis of individual patient data from five studies. J Pediatr 1994; 124:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/70\">",
"      Frantzen E, Lennox-Buchthal M, Nygaard A. Longitudinal EEG and clinical study of children with febrile convulsions. Electroencephalogr Clin Neurophysiol 1968; 24:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/71\">",
"      Berg AT, Shinnar S, Hauser WA, et al. A prospective study of recurrent febrile seizures. N Engl J Med 1992; 327:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/72\">",
"      Pavlidou E, Tzitiridou M, Kontopoulos E, Panteliadis CP. Which factors determine febrile seizure recurrence? A prospective study. Brain Dev 2008; 30:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/73\">",
"      Nelson KB, Ellenberg JH. Prognosis in children with febrile seizures. Pediatrics 1978; 61:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/74\">",
"      Berg AT, Darefsky AS, Holford TR, Shinnar S. Seizures with fever after unprovoked seizures: an analysis in children followed from the time of a first febrile seizure. Epilepsia 1998; 39:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/75\">",
"      Verity CM, Greenwood R, Golding J. Long-term intellectual and behavioral outcomes of children with febrile convulsions. N Engl J Med 1998; 338:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/76\">",
"      N&oslash;rgaard M, Ehrenstein V, Mahon BE, et al. Febrile seizures and cognitive function in young adult life: a prevalence study in Danish conscripts. J Pediatr 2009; 155:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/77\">",
"      Nelson KB, Ellenberg JH. Predictors of epilepsy in children who have experienced febrile seizures. N Engl J Med 1976; 295:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/78\">",
"      Annegers JF, Hauser WA, Shirts SB, Kurland LT. Factors prognostic of unprovoked seizures after febrile convulsions. N Engl J Med 1987; 316:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/79\">",
"      Vestergaard M, Pedersen CB, Sidenius P, et al. The long-term risk of epilepsy after febrile seizures in susceptible subgroups. Am J Epidemiol 2007; 165:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/80\">",
"      Neligan A, Bell GS, Giavasi C, et al. Long-term risk of developing epilepsy after febrile seizures: a prospective cohort study. Neurology 2012; 78:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/81\">",
"      Berg AT, Shinnar S, Levy SR, Testa FM. Childhood-onset epilepsy with and without preceding febrile seizures. Neurology 1999; 53:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/82\">",
"      Barr WB, Ashtari M, Schaul N. Bilateral reductions in hippocampal volume in adults with epilepsy and a history of febrile seizures. J Neurol Neurosurg Psychiatry 1997; 63:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/83\">",
"      Theodore WH, Bhatia S, Hatta J, et al. Hippocampal atrophy, epilepsy duration, and febrile seizures in patients with partial seizures. Neurology 1999; 52:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/84\">",
"      Tanabe T, Hara K, Shimakawa S, et al. Hippocampal damage after prolonged febrile seizure: one case in a consecutive prospective series. Epilepsia 2011; 52:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/85\">",
"      VanLandingham KE, Heinz ER, Cavazos JE, Lewis DV. Magnetic resonance imaging evidence of hippocampal injury after prolonged focal febrile convulsions. Ann Neurol 1998; 43:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/86\">",
"      Scott RC, King MD, Gadian DG, et al. Hippocampal abnormalities after prolonged febrile convulsion: a longitudinal MRI study. Brain 2003; 126:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/87\">",
"      Scott RC, King MD, Gadian DG, et al. Prolonged febrile seizures are associated with hippocampal vasogenic edema and developmental changes. Epilepsia 2006; 47:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/88\">",
"      Provenzale JM, Barboriak DP, VanLandingham K, et al. Hippocampal MRI signal hyperintensity after febrile status epilepticus is predictive of subsequent mesial temporal sclerosis. AJR Am J Roentgenol 2008; 190:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/89\">",
"      Auer T, Barsi P, Bone B, et al. History of simple febrile seizures is associated with hippocampal abnormalities in adults. Epilepsia 2008; 49:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/90\">",
"      Hamati-Haddad A, Abou-Khalil B. Epilepsy diagnosis and localization in patients with antecedent childhood febrile convulsions. Neurology 1998; 50:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/91\">",
"      Shinnar S, Hesdorffer DC, Nordli DR Jr, et al. Phenomenology of prolonged febrile seizures: results of the FEBSTAT study. Neurology 2008; 71:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/92\">",
"      Shinnar S, Pellock JM, Berg AT, et al. Short-term outcomes of children with febrile status epilepticus. Epilepsia 2001; 42:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/93\">",
"      Maytal J, Shinnar S. Febrile status epilepticus. Pediatrics 1990; 86:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/94\">",
"      Nordli DR, Mosh&eacute; SL, Shinnar S. The role of EEG in febrile status epilepticus (FSE). Brain Dev 2010; 32:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/95\">",
"      Practice parameter: long-term treatment of the child with simple febrile seizures. American Academy of Pediatrics. Committee on Quality Improvement, Subcommittee on Febrile Seizures. Pediatrics 1999; 103:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/96\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics 2008; 121:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/97\">",
"      Offringa M, Newton R. Prophylactic drug management for febrile seizures in children. Cochrane Database Syst Rev 2012; 4:CD003031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/98\">",
"      Rosman NP, Colton T, Labazzo J, et al. A controlled trial of diazepam administered during febrile illnesses to prevent recurrence of febrile seizures. N Engl J Med 1993; 329:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/99\">",
"      Hirabayashi Y, Okumura A, Kondo T, et al. Efficacy of a diazepam suppository at preventing febrile seizure recurrence during a single febrile illness. Brain Dev 2009; 31:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/100\">",
"      Verrotti A, Latini G, di Corcia G, et al. Intermittent oral diazepam prophylaxis in febrile convulsions: its effectiveness for febrile seizure recurrence. Eur J Paediatr Neurol 2004; 8:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/101\">",
"      Lux AL. Treatment of febrile seizures: historical perspective, current opinions, and potential future directions. Brain Dev 2010; 32:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/102\">",
"      Meremikwu M, Oyo-Ita A. Paracetamol for treating fever in children. Cochrane Database Syst Rev 2002; :CD003676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/103\">",
"      Uhari M, Rantala H, Vainionp&auml;&auml; L, Kurttila R. Effect of acetaminophen and of low intermittent doses of diazepam on prevention of recurrences of febrile seizures. J Pediatr 1995; 126:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/9/3226/abstract/104\">",
"      Strengell T, Uhari M, Tarkka R, et al. Antipyretic agents for preventing recurrences of febrile seizures: randomized controlled trial. Arch Pediatr Adolesc Med 2009; 163:799.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6183 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3226=[""].join("\n");
var outline_f3_9_3226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28752460\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hippocampal lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3416911\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3416918\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recurrent febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Recurrent febrile seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neurologic sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Subsequent epilepsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Subsequent temporal lobe epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FEBRILE STATUS EPILEPTICUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ROLE OF PREVENTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antiepileptic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antipyresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28752460\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31577?source=related_link\">",
"      Human herpesvirus 6 infection in children: Clinical manifestations; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=related_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39473?source=related_link\">",
"      Patient information: Febrile seizures (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/20/11586?source=related_link\">",
"      Patient information: Febrile seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_9_3227="Symptoms of brain tumors";
var content_f3_9_3227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neurologic presentation of brain tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Generalized",
"       </td>",
"       <td class=\"subtitle1\">",
"        Focal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Headaches",
"       </td>",
"       <td class=\"indent1\">",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seizures",
"       </td>",
"       <td class=\"indent1\">",
"        Weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nausea/vomiting",
"       </td>",
"       <td class=\"indent1\">",
"        Sensory loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depressed level of consciousness",
"       </td>",
"       <td class=\"indent1\">",
"        Aphasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurocognitive dysfunction",
"       </td>",
"       <td class=\"indent1\">",
"        Visual spatial dysfunction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3227=[""].join("\n");
var outline_f3_9_3227=null;
var title_f3_9_3228="Nonskeletal causes LS radiculopathy";
var content_f3_9_3228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonskeletal causes of lumbosacral radiculopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Single or multiple radiculopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute inflammatory demyelinating polyradiculoneuropathy (AIDP; Guillain-Barr&eacute; syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Borrelia burgdorferi (Lyme disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epstein-Barr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human immunodeficiency virus (HIV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycoplasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella zoster virus (Herpes zoster or shingles)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arteriovenous malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation-induced vascular occlusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis (nerve root infarction)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3228=[""].join("\n");
var outline_f3_9_3228=null;
var title_f3_9_3229="Genodermatoses and malignancy";
var content_f3_9_3229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genodermatoses associated with malignancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance/ pathogenesis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Key clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Basal Cell Nevus Syndrome (Nevoid Basal Cell Carcinoma Syndrome, Gorlin Syndrome)",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td rowspan=\"2\">",
"        Multiple basal cell carcinomas. Other features include odontogenic cysts of the jaw, palmoplantar pits, bifid ribs and other skeletal abnormalities. Common CNS abnormalites include calcification of the falx cerebri and bridging of the sella turcica. Extracutaneous tumors, including medulloblastomas, meningiomas, and ovarian fibrosarcomas, are also associated with the syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutation of the tumor suppressor gene patched (PTC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Gardner Syndrome",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td rowspan=\"2\">",
"        Triad of familial adenomatous polyposis, benign osteomas, and skin and soft tissue tumors. Multiple epidermoid cysts are the most characteristic skin finding. Desmoid tumors may also be seen. Congenital hypertrophy of the retinal pigmented epithelium is a reliable and early marker of disease. Colon cancer develops in all affected individuals requiring prophylactic colectomy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutation of tumor suppressor gene APC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Peutz-Jegher Syndrome",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td rowspan=\"2\">",
"        Dark periorificial and acral freckling most markedly on the lips; patients develop hamartomatous polyps of GI tract which may give rise to cancer. Also associated with increased risk of early adenocarcinomas of the breast, cervix, pancreas, uterus and ovaries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutation of tumor suppressor gene STK11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Xeroderma Pigmentosa",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td rowspan=\"2\">",
"        Increased photosensitivity, development of cutaneous malignancies in early childhood. Associated ocular and neurologic abnormalities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Defective excision repair of UV-induced DNA damage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Epidermolysis bullosa (EB) syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Dowling Meara EB simplex",
"       </td>",
"       <td>",
"        Autosomal dominant",
"       </td>",
"       <td rowspan=\"2\">",
"        Presents at birth or in early infancy; bullae occur with mild trauma, but lesions heal without scarring; mild or no mucosal involvement. Increased risk of basal cell carcinoma during mid-adulthood.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutation of keratin 5 or keratin 14 gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Herlitz junctional EB",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Onset at birth with widespread bullae and erosions with nonhealing granulation tissue; absent nails, dysplastic teeth, oral lesions.",
"        </p>",
"        <p>",
"         Increased risk of squamous cell carcinoma beginning in adolescence.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutations in the laminin alpha-3, beta-3, or gamma-2 gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Hallopeau-Siemens recessive dystrophic EB",
"       </td>",
"       <td>",
"        Autosomal recessive",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Onset at birth; generalized bullae that heal with extensive scarring; repeated episodes may lead to contraction flexures at the knees and elbows and fusion of the digits; frequent involvement of the mucous membranes.",
"        </p>",
"        <p>",
"         Increased risk of malignant melanoma beginning in childhood and squamous cell carcinoma beginning in adolescence.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mutation in the collagen type VII alpha-1 gene",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3229=[""].join("\n");
var outline_f3_9_3229=null;
var title_f3_9_3230="Hepatic drug metabolism";
var content_f3_9_3230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic drug metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Phase I reactions are catalyzed by cytochrome P450. Phase II reactions are catalyzed by one of several enzymes, such as UDP-glucuronyltransferase, sulfotransferases, and glutathione S-transferases. Active metabolites can lead to hepatic injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3230=[""].join("\n");
var outline_f3_9_3230=null;
var title_f3_9_3231="Hypertension and AHI";
var content_f3_9_3231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Hypertension (HT) and the apnea hypopnea index (AHI)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 524px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_9_3231=[""].join("\n");
var outline_f3_9_3231=null;
